PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

EASL Congress 2026

27-30 May, Barcelona

N. Poster

Poster title

Applicant name

Status


LBP-1	Primary care liver fibrosis detection pathway in people with type 2 diabetes: results from the PRELUDE1 prospective, pragmatic, electronic health record-embedded, parallel-arm cohort study	William Alazawi	Received

TOP-1	Global pathways linking alcohol exposure, food systems, and alcohol-associated liver disease	Zobair younossi	Received

TOP-2	Clinical and humanistic burden of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in the United States: a system dynamics model	Thomas Padgett	Received

WED-3	Impact of a national hepatocellular carcinoma surveillance program on tumor staging: geographic disparities and temporal trend in post-hcv elimination Egypt	Wael Abdel-Razek	Received

FRI-3	A systematic review of digital health tools and early real-world experience with HepB&Me application in chronic hepatitis B to tackle the unmet clinical need	Almuthana Mohamed	Received

THU-3	Evolving impact of alcohol and abdominal adiposity on liver mortality in Finland over four decades: implications for public health interventions	Fredrik berg	Received

SAT-3	Risk of advanced fibrosis and cancer in a population-based colorectal cancer screening program: implications for EASL case-finding strategies	David Marti-Aguado	Received

THU-4	Rising liver fibrosis rates due to MASLD identified amongst young adults in a general population birth cohort	Kushala Abeysekera	Received

LBP-4	Real-world validation of elafibranor in UDCA non-responders previously treated with OCA or fibrates — results from the ELEVATE-PBC study	Alessandra Bonfichi	Received

SAT-4	An observational study of alcohol related liver disease hospitalisations in Australia before and during the COVID-19 pandemic, using routinely collected national data	Edward Meehan	Received

FRI-4	SIMPLY-B pilot study: assessing hepatitis B treatment uptake in primary care clinics	Jessica Howell	Received

WED-4	Introduction of a hepatitis C testing prompt for primary care LFTs with raised ALT leads to increased testing and diagnosis	Stephen Barclay	Received

FRI-5	Monitoring of the cascade of care in patients with chronic HBV in primary care clinics in Australia	Jessica Howell	Received

LBP-5	Treatment of hepatitis C in pregnancy with Sofosbuvir/Velpatasvir: interim results from the STORC study	Catherine Chappell	Received

WED-5	Symptom burden and health-related quality of life in chronic HBV–HDV infection: real-life evidence from the ANRS HD EP01 HEPDELTA cohort	Camelia Protopopescu	Received

THU-6	Digital technology policy is associated with liver disease mortality: a multinational ecological study	Somaya Albhaisi	Received

WED-6	Implementation of the ReLink-C strategy in hospitals in Spain (ReLink-C Observatory Spain)	Nataly Espinoza-Cámac	Received

FRI-6	Reaching the unreachable: prison mobile outreach as a cornerstone of national HCV micro-elimination efforts in Croatia	Tatjana Reic	Received

THU-7	Impact of United States food and drug administration drug approvals on public and scientific dialogue on metabolic dysfunction-associated steatotic liver disease: a multi-platform digital analysis	Somaya Albhaisi	Received

WED-7	Viral hepatitis in the community of Shenzhen city, China: current status and elimination challenges — a large scale screening study	Jun Chen	Received

FRI-7	Persistence of immune response and memory after infant hepatitis B vaccination: a systematic literature review	Pierre-Paul Prevot	Received

SAT-7	Economic and healthcare resource burden of metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a United States system dynamics model	Thomas Padgett	Received

LBP-7	Comparative study of the efficacy and safety of systemic glucocorticosteroids on liver enzyme activity in patients with autoimmune hepatitis without liver cirrhosis	Volodymyr Cherniavskyi	Received

SAT-8	A pan European observational cohort study describing clinical characteristics, treatment patterns and outcomes in patients diagnosed with hepatocellular carcinoma	Nick Denholm	Received

THU-8	Socioeconomic barriers to initiation of second-line therapy in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid	Lital Aliasi-Sinai	Received

LBP-8	longitudinal multi-omics reveals regenerative programs and predictive plasma signatures in human liver regeneration	martin cornillet	Received

FRI-8	Viral hepatitis B, C, and delta in Greenland: a national cross-sectional study	Carina Naustdal	Received

WED-8	Perspectives of people living with hepatitis B towards long-acting antivirals: a global study	Su Wang	Received

SAT-9	Real-world patient profiles and outcomes of hepatocellular carcinoma patients treated with embolization procedures: a European observational longitudinal study	Nick Denholm	Received

FRI-9	Re-engagement as a hepatitis b elimination strategy: a scoping review	Helen Nde	Received

LBP-9	Synthetic data generation by artificial intellegence predicts clinical outcomes in untreated and Bulevirtide-treated patients with chronic hepatitis Delta	Saverio DAmico	Received

THU-9	Cirrhosis in France: is there disparities to address to improve prognosis?	Aurore Baron	Received

WED-9	Modeling the potential effect of long-acting injectables of DAA treatment to reach HCV elimination among persons who inject drugs	Harel Dahari	Received

THU-10	Unmet needs in palliative care for terminal liver diseases: analysis of a german physician survey	Lena Bartke	Received

LBP-10	Safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726, an oxyntomodulin analogue, in a higher-dose phase 1 cohort with exploratory noninvasive liver assessment	Ji Eun Lee	Received

SAT-10	Interim findings from the KIDS-LIVE study: metabolic phenotypes and burden of MASLD in Indian children and adolescents	Abirami Perumal	Received

WED-10	HCV screening and linkage to care in the 1969-1989 birth-cohort population: the Bergamo experience	Alessandro Loglio	Received

FRI-10	Decentralised HBV, HCV, and HIV screening among migrant and refugee populations in Portugal and Spain: results from VH-COMSAVAC	Aina Nicolàs Olivé	Received

WED-11	Anti-HDV reflex testing among HBsAg positive individuals in the Netherlands	Esmee Fath el Bab	Received

LBP-11	Pharmacological effects of apixaban and edoxaban in patients with liver cirrhosis	Lucas Gautier	Received

THU-12	MASLD in the WHO Africa region: prevalence and development of a simple score to detect advanced fibrosis in dysmetabolic patients	Isabelle Bough	Received

LBP-12	High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study	Jinlin Hou	Received

FRI-12	Low treatment rates observed in an analysis of the chronic hepatitis B care cascade at a tertiary medical center in a major metropolitan area in the US	Kevin Pak	Received

WED-12	Advancing elimination targets for viral hepatitis and human immunodeficiency virus in Poland: estimating the cost-effectiveness of emergency department opt-out testing for blood-borne viruses	Laurel Bates	Received

SAT-12	Patient pathways for rare liver diseases: development of a European template	Sarah Raevens	Received

LBP-13	A phase Ib multiple dose ascending study of HH-006 in treatment-naïve participants with chronic hepatitis B virus infection	Ying Zhuang	Received

SAT-13	Marginal structural models to evaluate the prognostic utility of steatotic liver disease subclasses in association with all-cause mortality	Carmela Rapino	Received

WED-13	Addiction medicine involvement is associated with improved hepatitis C and viral hepatitis screening among hospitalised incarcerated patients who inject drugs	Ezaam Fraz	Received

FRI-13	Prevalence and socioeconomics of hepatitis D virus coinfection in two Southern California counties	Kevin Pak	Received

THU-13	Mapping receptivity and susceptibility to new models of care for metabolic dysfunction-associated steatotic liver disease (MASLD) across Europe: a mixed-methods, landscaping study	Leonard Broekman	Received

SAT-14	Income and sex disparities in prognosis among individuals with MASLD: a survival analysis from the Canadian longitudinal study on aging	Carmela Rapino	Received

LBP-14	Safety, tolerability, pharmacokinetics and pharmacodynamics of an orally innovative GalNAc-conjugated thyroid hormone receptor-beta agonist (Kylo-0603) in healthy volunteers: a multiple ascending dose study	Xingjiang Hu	Received

THU-14	Evaluating the impact of implementing criteria for initial fibrosis assessment in people at risk of MASLD: a national level analysis using the health survey for England	Ryan Buchanan	Received

WED-14	A multivariable model of spontaneous hepatitis C virus clearance: increasing realism of simulated data	Keshav Gandhi	Received

LBP-15	Thybetador, a potent and selective THR-ß agonist: results from a phase 1 first-in-human study in healthy volunteers and participants with elevated LDL-C	Xiangwei Hua	Received

WED-15	Assessing the economic value of bulevirtide for chronic hepatitis delta in Romania: combining real-world patient data with a markov state-transition model	Speranta Iacob	Received

THU-15	Gender differences in stigma and care avoidance among people living with metabolic dysfunction–associated steatotic liver disease (MASLD): an international survey	Patrizia Carrieri	Received

FRI-15	Predictors of hepatitis B infection and vaccination coverage in sub-Saharan Africa: case studies from Gabon and Mauritania using Demographic and health Survey data	Jodi Palmer	Received

SAT-15	Multidisciplinary assessment of unemployment risk factors in liver transplant recipients: final results of the RICReaTI project	Margherita Saracco	Received

TOP-16	Socio-demographic inequalities on the UK liver transplant waiting list over time: the impact of prognostic scores and candidate selection schemes	Ji Jade King	Received

LBP-16	Immunogenetic predictors of hepatitis D virus infection progression in Uzbekistan: implications for a national screening strategy	Zebiniso Ismailova	Received

LBP-17	Longitudinal analysis of routine laboratory data prospectively identifies clinically significant hepatic fibrosis from the general population, outperforming standard fibrosis scores: validation from the LiveWell multi-modal screening study	Timothy Jobson	Received

TOP-17	Feasibility and outcomes of liver health checks in community alcohol services	Daniel Gutmann	Received

LBP-18	Improvements in fatigue in patients with primary biliary cholangitis treated with elafibranor: patient-reported outcome measurement information system fatigue short form 7a (PFSF 7a) data from the phase III ELATIVE® trial	Costello Medical	Received

TOP-18	Increased diagnosis and risk stratification for MASLD in primary care over the last 20 years: real-world evidence from over 11.7 million individuals in the UK	Huei-Tyng (Philippe) Huang	Received

LBP-19	Real-World HCV Epidemiology Data to Drive Elimination Strategies in South Africa	Bongani Khanyi	Received

WED-19	Multicenter automated strategy for opportunistic screening of viral hepatitis in primary care based on hypertransaminasemia and the FIB-4 index (ProHCYL study)	Jesús M. González-Santiago	Received

FRI-19	Real-world results of Opti-Hep-D: a multicenter, multidisciplinary program for hepatitis D detection and linkage to care in Catalonia	Adriana Palom	Received

THU-19	Sexual function in chronic liver disease: a case-control study	Yooyun Chung	Received

LBP-20	A global Delphi consensus to define chronic liver disease severity: replacing cirrhosis with a stage-based model	Aleksander Krag	Received

SAT-20	Patient characteristics and functional impairment in MASLD: a remote prospective cross-sectional real-world study in Germany	Anja Schulz-Kuhnt	Received

WED-20	Evaluation of sex-based differences on hepatitis B, C and D viruses´ disease burden and cascade of care in Italy	Samantha Hall	Received

THU-20	An interpretable artificial intelligence framework for cardiovascular risk prediction in metabolic dysfunction-associated steatotic liver disease: LiverCARD	antonio cirella	Received

SAT-21	Transparent and dynamic network-based risk assessment for development of hepatic encephalopathy	Yuxi Shi	Received

LBP-21	24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1	Dheepika Weerasinghe	Received

WED-21	Hepatitis D testing patterns and prevalence in Australia: a retrospective statewide cohort study	Jessica Howell	Received

FRI-21	An optimized in-hospital management model enhances linkage to care for non-hepatology HBV-infected patients: interim analysis of Hot Wave Project 2.0	Liang Peng	Received

THU-21	The global academic hepatology capacity index (IGCAH): a multi-source assessment reveals profound inequities across Latin America	PABLO ANDRES COSTE MURILLO	Received

LBP-22	Single-dose of a novel monoclonal anti-HBV antibody (HepB mAb19) demonstrates sustained HBsAg suppression beyond 48 weeks: interim results from first-in-human phase I RUHBV1 and SAMBA trials	Han Ngoc Le	Received

WED-22	What Drives Viral Hepatitis Screening? Evidence from Bangladeshi Immigrants in Calgary, Canada	Md Irfan Hyder	Received

FRI-22	The impact of disability weights on the projected burden and prioritization of HBV in global health	Devin Razavi-Shearer	Received

THU-22	Trends in hospitalizations and in-hospital mortality due to primary biliary cholangitis in Brazil (2015–2024): a decade of real-world evidence from the public unified health system	Cláudia Couto	Received

SAT-22	Trends in mortality due to liver neoplasms in Portugal (2013-2022): a decade of rising challenges	Mario Jorge Silva	Received

LBP-23	Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1× to 1.67× the upper limit of normal	Costello Medical	Received

SAT-23	From guidelines to practice : Expert advisory board insights on nutritional intervention in patients with liver cirrhosis in India	Sourabh Sonawale	Received

FRI-23	Artificial intelligence-based hepatitis C screening: a real-world evidence analysis on Andalusian health database	Manuel Romero-Gómez	Received

WED-23	Hepatitis B and C viruses drive the burden of transfusion-transmissible infections in Karamoja Uganda	Francesco Paolo Russo	Received

THU-23	Reduced physician confidence in the acute management of decompensated liver disease: Implications for targeted hepatology education	Rachel Edwards	Received

SAT-24	Contacts to general practice by patients with liver cirrhosis: a Danish nationwide cohort study	Marie Storgaard	Received

THU-24	Poorer social deprivation exacerbates clinical outcomes in alcohol related liver disease admissions in Ireland	Clare Foley	Received

FRI-24	Prevalence of hepatitis B, and C in a cohort of transgender women living with HIV or on PrEP	Pablo Ryan	Received

THU-25	Impact of social deprivation on liver disease admissions in Ireland	Clare Foley	Received

WED-25	Changing epidemiology of hepatitis A in India: trends converging with Europe	Ayush Jasrotia	Received

LBP-25	Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial	Sarah Case	Received

SAT-25	Sociodemographic associations between increasing alcohol sales and new hospitalizations for alcohol-related cirrhosis in Alberta, Canada	Liam Swain	Received

FRI-26	Women´s perspectives on care barriers in the setting of untreated HCV	MAI SEDKI	Received

THU-26	Implementation of a health navigator program post-liver transplantation, utilization and outcomes	R. Todd Frederick	Received

LBP-26	Hepatic recompensation is associated with sustained transplant-free survival in primary biliary cholangitis decompensated cirrhosis: an international multicenter study from the Global-PBC study group	Adrielly Martins	Received

SAT-26	Sociodemographic associations between increasing alcohol sales and new hospitalizations for alcohol-related hepatitis in Alberta, Canada	Liam Swain	Received

WED-26	Mother-to-child is the dominating route of HBV transmission in the post vaccination era: a community based study in Ethiopia	Asgeir Johannessen	Received

WED-27	National hepatitis B virus (HBV) screening pilot using rapid HBV antibody tests in Kazakhstan	KULPASH KALIASKAROVA	Received

LBP-27	ARO-INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity	Grigoriy Shekhtman	Received

SAT-27	Temporal and seasonal trends in alcohol sales and alcohol-related liver disease hospitalizations in Alberta, Canada	Liam Swain	Received

FRI-27	Gaps between guidelines and clinical practice in hepatitis B virus reactivation prevention in non-hepatology immunosuppressive care	Hiroko Setoyama	Received

THU-27	Stable alcohol consumption over time in older adults, assessed by PEth	Marie Fredriksson	Received

LBP-28	Preventing vertical transmission of hepatitis B virus in Democratic Republic of Congo (DRC) by combining birth-dose vaccine and tenofovir: The COMBAT RCT	Nefer Batsuli	Received

WED-28	Experience from the first two years of a peer support programme for people living with hepatitis B in north central London	Shun King KO	Received

FRI-28	Real-world implementation of hepatocellular carcinoma surveillance after hepatitis C virus cure in Japan: a comparative analysis of performance indicators and a nationwide hospital-based database	Hiroko Setoyama	Received

SAT-28	Geographic variation in primary biliary cholangitis across Alberta: Validated incidence and prevalence estimates with Joinpoint trends	Bryce Tkachuk	Received

FRI-29	Long term health and economic impact of a successful national hepatitis C elimination program: a model-based evaluation using real-world post-SVR outcomes	Gamal shiha	Received

THU-29	Public health implications of metabolic dysfunction-associated steatotic liver disease based on global stepwise approach to surveillance data	Taras Griadil	Received

SAT-29	Socio-economic deprivation is overrepresented in Australian cirrhosis patients seeking acute hospital-based care, suggesting disparities in utilisation of structured outpatient services	Patricia C Valery	Received

WED-29	Population-based hepatitis C screening and elimination program in Lithuania: may it affect the incidence of hepatocellular carcinoma?	Limas Kupcinskas	Received

THU-30	Impact of alternative VCTE diagnostic criteria on yearly prevalence estimates of MASLD and significant fibrosis	Luis Gutierrez-Rosas	Received

FRI-30	Synergistic effect of diabetes and hypertension on the risk of liver disease progression in hepatitis B virus infection	Laura E Telep	Received

SAT-30	Improving patient knowledge — A feasible target to enhance motivation for lifestyle change in patients with MASLD in Australia	Patricia Valery	Received

WED-30	Epidemiological landscape of hepatitis E in South Korea: analysis of national surveillance data (2020–2023)	Chang Hun Lee	Received

FRI-31	Predictors of advanced liver disease events among individuals with hepatitis delta infection in a large United States administrative claims dataset: a machine learning analysis	Laura Telep	Received

WED-31	Global prevalence of HIV-HBV co-infection in pregnancy: a systematic review to inform elimination of mother-to-child transmission	Leona Leipold	Received

SAT-31	Validated early detection metrics reduces the population requiring liver fibrosis screening	Laurens Van Kleef	Received

LBP-32	Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial	Wen-Wei Tsai	Received

TOP-32	Real-world data highlight gaps in hospital care and access to gastroenterologists or hepatologists in patients with acutely decompensated cirrhosis	Yacine Hajji	Received

LBP-33	Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis	Costello Medical	Received

TOP-33	Non-genetic determinants of hepatitis B surface antibody disappearance in Taiwan´s vaccinated generations	CHUN-YI CHANG	Received

TOP-34	Impact of an EASL-guided screen-and-treat intervention for hepatitis B on HCC incidence in West Africa: results of a large-scale population-based study in The Gambia	Ousman Bah	Received

LBP-34	Real-world experience with seladelpar in primary biliary cholangitis: first results from the Italian RESTART-PBC study	Francesca Terracciani	Received

LBP-35	Scalable bioreactor production of functional iPSC-derived hepatic microtissues demonstrates unprecedented therapeutic efficacy in a preclinical model of acute liver failure	Dilyana TODOROVA	Received

THU-35	Factors associated with engagement in hepatocellular carcinoma surveillance in a diverse urban population	Apoorva Hegde	Received

FRI-35	Community-based dried blood spot testing reveals substantial progress towards hepatitis C virus elimination in people who inject drugs in Catalonia	Ona Torrejón-Llorens	Received

WED-35	Global drug utilization and expenditure of essential medicines forecasting future viral hepatitis elimination: a multinational drug use study	Lung-Yi Loey Mak	Received

SAT-35	Impact of fibrotic MASH as a new indication on semaglutide eligibility in the U.S. adult population	Laurens Van Kleef	Received

THU-36	Cost-effectiveness of sequential non-invasive testing strategies to optimise hepatology referrals in MASLD: implications for primary care pathways	Marta Hernandez Conde	Received

FRI-36	Identifying and re-engaging hidden hepatitis C cases through registry linkage in primary care: a population-based intervention in Barcelona	Elena Torrell-Pedreira	Received

LBP-36	Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial	Shaheen Tomah	Received

SAT-36	Artificial intelligence in scientific abstract review: complement or contradiction to human judgment? Insights from a Latin American hepatology cohort	Maria Lynch-Mejia	Received

WED-36	Incidence of HIV among people living with chronic hepatitis B: 10-year results from a large cohort in Ethiopia	Kristian Braathen Malme	Received

FRI-37	Cross-sectional testing for diagnosing asymptomatic BBV (Blood Borne Virus: HIV, HBV, HCV) infection; HBV infection is being eliminated in Japan	Haruka Uemura	Received

LBP-37	Seladelpar leads to decreases in serum proteins associated with PBC disease severity: proteomic analysis from the pivotal RESPONSE trial	Allison Yankey	Received

THU-37	Global variation in standard drink definitions compared to the World Health Organization 10-gram benchmark: a 185-country analysis	Adelina Horhat	Received

SAT-37	Excess mortality from cirrhosis by neighbourhood deprivation, aetiology, and clinical presentation: a Swedish register-based cohort study	Juan Vaz	Received

LBP-38	A novel trientine tetrahydrochloride formulation administered once-a-day for people living with Wilson disease: results from a phase 2 study	Omar Kamlin	Received

SAT-38	Socioeconomic disparities in access to curative treatment among individuals with surveillance-detected hepatocellular carcinoma in Sweden: a nationwide cohort study	Juan Vaz	Received

THU-38	Real-world epidemiology and clinical outcomes in MASLD: A 20-year nationwide analysis of over 23 million individuals in Taiwan´s national health insurance research database	Huei-Tyng (Philippe) Huang	Received

FRI-38	European emergency department screening shows progress toward HCV elimination	Elena Vargas-Accarino	Received

WED-38	From control to elimination of HCV infection: the experience in prisons of Catalonia, Spain	Andrés Marco	Received

SAT-39	Burden, trends and projections of liver cancer in China and G20 countries: a comparative study based on the global burden of disease database 2023	Yikai Wang	Received

FRI-39	Why screen hepatitis C alone? Integrated hepatitis B and hepatitis C screening reduces liver related complication and is cost effective: a model-based cost effectiveness analysis	William WL Wong	Received

LBP-39	Survodutide reduces steatosis and fibrosis in a MASH human liver spheroid model through direct glucagon receptor agonism	Francisco Verdeguer	Received

WED-39	´Hep-MoLo´: integrating community co-design and multidisciplinary approach to deliver decentralised liver health screening for Mongolians in London	Emily Martyn	Received

THU-39	Outcomes and all-cause mortality in people with MASLD in UK primary care: a real-world matched cohort study of 1.8 million individuals	Huei-Tyng (Philippe) Huang	Received

SAT-40	Burden, trends and projections of cirrhosis in China and G20 countries: a comparative study based on the global burden of disease database 2023	Yikai Wang	Received

LBP-40	Functional cure rate in chronic hepatitis B virus infected participants receiving elebsiran and pegylated interferon alfa: final results from the phase 2 ENSURE study	Grace Lai-Hung Wong	Received

FRI-40	Adaptive and simplified model of relinking HCV-Ab positive patients to care in China: a real-world study from Yunnan province	Changhui Wu	Received

WED-40	Burden of liver fibrosis and steatosis associated with hepatitis B or C infection in China: a population-based study from the 2020 national serological survey	Tongtong Meng	Received

THU-40	Healthcare provider perspectives on mental health in metabolic dysfunction-associated steatotic liver disease and steatohepatitis: the role of multidisciplinary teams and sex differences	Dana Ivancovsky-Wajcman	Received

WED-41	Normal ALT values in patients with MASLD: long-term outcomes and Fib-4 performance	Ali Abdul Hussein	Received

FRI-41	Increasing phosphatidylethanol correlates with increasing liver stiffness – a prospective longitudinal analysis of 1397 individuals at risk of steatotic liver disease	Katrine Tholstrup Bech	Received

THU-41	Factors influencing mental health care provision for people with metabolic dysfunction-associated steatotic liver disease and steatohepatitis	Dana Ivancovsky-Wajcman	Received

LBP-41	HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH and F2–F3 fibrosis: a 52-week phase 2b randomized, double-blind, placebo-controlled trial	Feng Xue	Received

SAT-41	Inefficiency of risk-based screening for steatotic liver disease in primary care: a multi-cohort analysis of more than 15,000 individuals	Bernhard Wernly	Received

WED-42	Use of the ANTICIPATE NASH risk score to stratify patients with compensated MASH cirrhosis: data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-cirrhosis)	Juan G Abraldes	Received

FRI-42	Current management of acute alcoholic hepatitis in France: results from a prospective cohort of 466 patients	MIKE HABIB	Received

LBP-42	Safety, tolerability, sustained hepatitis B surface antigen reduction and HBsAg clearance ratio in chronic hepatitis B patients treated with long-term BW-20507	Zhuo Chang	Received

SAT-42	Estimation of liver fibrosis risk using non-invasive biomarker tests in people living with HIV and pre-diabetes in Tanzania	Trenton White	Received

THU-42	Mental distress and social support in adult offspring of parents with alcohol-related liver disease compared to offspring of parents with a cancer diagnosis: a national health survey	Pernille Jessen	Received

THU-43	Neighborhood deprivation and survival in hospitalized alcoholic hepatitis: a ZIP-code based area deprivation index analysis	Samuel Ji	Received

FRI-43	Sequential day-4 and day-7 Lille model to minimize unnecessary corticosteroid exposure in non-responders with severe alcohol-related hepatitis	Clemence CANIVET	Received

WED-43	Combining vibration controlled transient elastography and enhanced liver fibrosis score lowers the false positive rate for identifying MASLD with significant fibrosis in patients with class 2 or higher obesity	Cyrielle Caussy	Received

LBP-44	Integrated serum proteomics and N-glycoproteomics for non-invasive biomarkers in primary biliary cholangitis	Dong Zhao	Received

WED-44	Anthropometric indices and body composition as predictors of liver fibrosis in young adults with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis	Arash Akhavan Rezayat	Received

FRI-44	Hot & cold fibrosis biomarkers as prognostic tools for assessment of cardiovascular and liver-related events in patients with alcohol-related liver disease	Andressa de Zawadzki	Received

SAT-44	Health literacy and associated factors in patients with cirrhosis in Latin America: the PHAROS study	Ismael de Jesus Yepes Barreto	Received

THU-44	Evaluation of metabolic dysfunction-associated steatotic liver disease in agricultural workers exposed and unexposed to Mancozeb	Hidayat Kassim	Received

WED-45	Metabolic dysfunction, biochemical markers, and lifestyle factors in liver fibrosis development among young adults with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis	Arash Akhavan Rezayat	Received

SAT-45	Global trends and disparities in preventable premature liver deaths due to metabolic dysfunction-associated steatotic liver disease (MASLD): a 20-year study in 204 countries	Zobair M. Younossi	Received

THU-46	Association between neck circumference and steatotic liver disease: a systematic review and meta-analysis	Cecilia Katzenstein	Received

WED-46	Budget impact analysis of the GeneXpert® system for hepatitis C virus infections screening in addiction care and prevention centers and prisons in France	Ines Messai	Received

FRI-46	RE-LIVE study (Re-Linkage to Pan-Viral hepatitis): Interim Results from a Multicenter Observational Study on Care Engagement in Chronic Viral Hepatitis	Jae Hyun Yoon	Received

SAT-46	Ultra-processed food intake is associated with obesity and advanced fibrosis in metabolic dysfunction associated steatotic liver disease: a multinational analysis from the global NASH/MASH registry™	Zobair Younossi	Received

FRI-47	Data for action - Informing viral hepatitis and HIV public health interventions through high resolution geo-mapping of migrant populations	Murad Ruf	Received

WED-47	Progress towards hepatitis C virus elimination in English prisons – 7 year outcomes on a multi-stakeholder project	Louise Missen	Received

SAT-47	How food-system conditions shape burden of metabolic dysfunction associated steatotic liver disease (MASLD) in low- and high-sdi countries	Zobair M. Younossi	Received

THU-47	Effectiveness of a smartphone-assisted lifestyle intervention program on weight reduction: a retrospective study	Stanislav Kravchuk	Received

TOP-48	A low-cost tool to assess HBV treatment eligibility: time to positivity of a point-of-care HBsAg test	Judit Romero	Received

TOP-49	Pooling strategies for age-based hepatitis C screening in Spain: population impact and cost-effectiveness to inform national policy	Federico Garcia	Received

FRI-50	Dynamics of steatotic liver disease subtype classification and predictors of significant fibrosis in Latin America: the STELLA study	Luis Antonio Diaz Piga	Received

THU-50	Assessing Europe´s policy readiness to confront the MASLD/MASH public health threat	Jeffrey Lazarus	Received

SAT-50	Type 2 diabetes (T2D) is the major driver of advanced metabolic dysfunction–associated steatohepatitis (MASH) and associated liver-related mortality in Europe	Zobair M. Younossi	Received

FRI-51	Medications for alcohol use disorder after liver transplantation in the US: patterns, timing, and survival	Luis Antonio Diaz Piga	Received

SAT-51	Central obesity is a key determinant of advanced fibrosis across the spectrum of steatotic liver disease (SLD): a population-based analysis	Zobair M. Younossi	Received

THU-51	Extremes and persistence of body mass index increase risks of HCC and mortality regardless of MASLD status	Mei-Hsuan Lee	Received

WED-51	Clinical characteristics of patients with low liver stiffness measurement (LSM) on VCTE and biopsy-proven at-risk MASH on biopsy	Elizabeth Brombosz	Received

FRI-52	The impact of early alcohol abstinence on further decompensation in alcohol-associated liver disease	Diego Drumond Westgeest e Sousa	Received

WED-52	Metabolic dysfunction–associated fibrosis-5 outperforms fibrosis-4 index for detecting liver fibrosis in a population-based cohort	Saleh A. Alqahtani	Received

SAT-52	Mapping the risk of liver cirrhosis by occupational groups in Sweden: a population-based case-control study	Marie Zalesiak	Received

FRI-53	Alcohol-related hepatitis modifies the prognostic value of laboratory dynamics after abstinence in decompensated alcohol-related cirrhosis	Jan Embacher	Received

WED-53	High burden of MASLD and fibrosis risk in type 1 diabetes: a FibroScan-based screening study	Khalid Alswat	Received

SAT-53	Clinical obesity is strongly associated with steatotic liver disease and advanced fibrosis: evidence from NHANES 2017–2018	Zobair Younossi	Received

WED-54	Clinical significance of patients with significant fibrosis missed by the EASL algorithm in metabolic-associated steatotic liver disease: findings from the HEPAMET registry	Douglas Maya-Miles	Received

THU-54	Analysis and 15-year projection of the disease burden of cirrhosis attributable to metabolic dysfunction-associated steatotic liver disease in China, 1990–2021	Ge Liu	Received

FRI-54	Community-based alcohol-related liver disease early recognition and assessment (CALDERA): effect on drinking behaviour, markers of liver injury and emergency hospital attendance	Ewan Forrest	Received

WED-55	AI-based fibrosis detection in MASLD: evaluating swallow deep neural networks, large language models and foundation models vs. FIB-4	Athanasios Angelakis	Received

FRI-55	Alcohol-metabolite associations differ by liver steatosis status: a metabolomics study in finnish men	Konsta Hakkarainen	Received

SAT-55	The burden of hepatocellular carcinoma in Oceania: an under-represented but high-risk population	Angela Zhu	Received

THU-56	Isoniazid exposure triggers hepatocyte exosome driven Rac 1 mediated engulfment of non-viable hepatocytes and activation of hepatic stellate cells	Debasree Bishnu	Received

FRI-56	The evaluation of a novel multidisciplinary hepatology clinic	Gideon Hanibal	Received

SAT-56	Active pharmacovigilance and performance of K18, M-CSFR, and GLDH as DILI biomarkers for diagnosis and prognosis in a complex hospitalized population in Brazil	Raquel Boff	Received

WED-56	NAFLD liver fat score outperforms controlled attenuation parameter for diagnosing hepatic steatosis in type 2 diabetes: an explainable artificial intelligence study	Athanasios Angelakis	Received

THU-57	Targeting impaired efferocytosis in acute-on-chronic liver failure: human mechanistic insights and murine macrophage therapeutic efficacy	Sunidhi Diwakar	Received

WED-57	Prognostic Performance of Non‑invasive Risk Models for Major Adverse Liver Outcomes in MASLD: An Individual Participant Data Meta‑analysis	Erica Appiah	Received

FRI-57	Postbiotic-driven enhancement of the gut barrier reduces systemic inflammation in patients with alcohol-related liver disease	Johanne Kragh Hansen	Received

SAT-57	Drug-induced liver injury: a survey among members of the society of liver disease in Africa	Maurizio Bonacini	Received

WED-58	Primary care MASLD fibrosis risk stratification: real-world comparison of FIB-4–VCTE and SAFE–VCTE pathways	Afreen Ashraf	Received

THU-58	Sex-dependent modulation of acetaminophen-induced liver injury in diet-induced metabolic steatohepatitis	Laura Fàbrega Jiménez	Received

FRI-58	Prevalence and timing of comorbidities among patients with alcohol-related liver cirrhosis: a nationwide study of 11,989 patients with cirrhosis	gustav jakobsson	Received

SAT-58	Our experience of immune-mediated hepatotoxicity: five-year data from a London cancer centre	Annabelle Chung	Received

THU-59	Estrogen deficiency-induced hepatic steatosis confers protection against drug-induced liver injury via NRF2 activation: implications for postmenopausal liver health	José García Consuegra Martínez	Received

FRI-59	Limited overlap between high phosphatidylethanol, alcohol use disorder, and liver fibrosis in 6,231 individuals screened for steatotic liver disease	Stine Johansen	Received

SAT-59	Trastuzumab is associated with acute hepatitis and chronic porto-sinusoidal vascular disease in the french-speaking network for the study of the hepatotoxicity of health products (REFHEPS)	Bénédicte Delire	Received

WED-59	Re-thinking MASH recruitment: LiverPRO turns routine data into trial candidates	Julie Astono	Received

SAT-60	Hepatotoxicity patterns associated with antibody-drug conjugates in clinical trials: a systematic review and meta-analysis	Yinuo DONG	Received

WED-60	Lower predictive performance of FIB-4 with lower eGFR categories: a cohort study of 63,587 persons	Hanne Åström	Received

THU-60	Neutrophil calcium dynamics and recruitment in acetaminophen induced liver injury	Guilherme Gomes	Received

FRI-60	Presence of cardiometabolic risk factors is not associated with lower lifetime alcohol consumption in newly diagnosed patients with alcohol-related liver disease: A clinical cohort study	Linnea Juhl Vestergaard	Received

WED-61	Routine testing of PNPLA3 and TM6SF2 genetic variants in MASLD: experience from outpatient hepatology clinics in southern Switzerland	Beatrice Barda	Received

SAT-61	Acute liver failure: a 10-year analysis emphasizing the critical role of multidisciplinary approach	Michela Helga Falzone	Received

FRI-61	Hazardous alcohol use amongst persons with compensated cirrhosis from different etiologies: a liver cirrhosis network study	Mandana Khalili	Received

SAT-62	Rechallenge after a DILI episode: importance of the pattern and the medication class	MAR RIVEIRO-BARCIELA	Received

THU-62	A preclinical model of acute alcoholic hepatitis (AAH) in humanized liver mice	Eleanna Kaffe	Received

WED-62	Definite fibrotic metabolic-dysfunction associated steatohepatitis in referrals at center in Denmark	Mark Berner Hansen	Received

FRI-62	Impact of on-demand nalmefene–mediated alcohol reduction on liver function and noninvasive fibrosis and steatosis measures in patients with alcohol use disorder and metabolic dysfunction–associated alcohol-related liver disease	Yohei Koizumi	Received

TOP-63	Prognostic performance of liver stiffness changes in patients with biopsy-proven cirrhosis secondary to metabolic dysfunction-associated steatohepatitis	Jimmy Che-To Lai	Received

TOP-64	Development and validation of a highly accurate noninvasive-based model to predict cirrhosis due to MASH (cirrhosis-7 score)	Elizabeth Brombosz	Received

TOP-65	Universal FIB4 screening, automated secondary care referral, new cACLD & HCC identified; benefits of integrated MASLD screening within the precision iDiabetes platform	Damien Leith	Received

TOP-66	Machine learning–based models with and without VCTE improve prescreening for at-risk MASH compared with FAST in the largest clinical trial validation cohort	Winston Dunn	Received

SAT-67	Multicenter evaluation of large language models versus hepatologists for prognostic prediction in drug-induced liver injury	Haoshuang Fu	Received

FRI-67	Recompensation in alcohol related liver disease is infrequent and should not delay transplantation assessment	Arushi Kumar	Received

WED-67	ActiMASH: a novel blood-based score to measure liver activity in patients with MASLD	Louise Biquard	Received

FRI-68	Beyond maddrey and MELD: machine learning transforms mortality prediction in critically ill alcohol-associated hepatitis	Jeril Lasington	Received

SAT-68	Long-term outcomes following checkpoint inhibitor-induced liver injury	Lina Hountondji	Received

THU-68	Alarmin interleukin-33 protects against liver injury and promotes hepatocyte proliferation in acute liver failure	Mengqi Li	Received

SAT-69	Significant liver fibrosis in patients with steatotic liver disease treated with Tamoxifen or Aromatase inhibitors: a cardiometabolic risk–driven phenomenon	Jae Yoon Jeong	Received

FRI-69	Mortality prediction in alcohol-associated hepatitis	Jeril Lasington	Received

WED-69	Optimizing hepatocellular cancer surveillance in metabolic dysfunction–associated steatotic liver disease based on liver stiffness measurement	Luis Calzadilla Bertot	Received

FRI-70	Metabolic comorbidities are associated with lower in-hospital mortality in alcoholic liver disease hospitalizations: a nationwide analysis (NIS 2019–2022)	Jeril Lasington	Received

WED-70	MASH-iScan: a non-invasive method for diagnosing MASH using ultrasound and artificial intelligence	Ruairi Lynch	Received

THU-70	Construction of engineered biliary trees with P-glycoprotein efflux function and enhanced resistance to drug-induced injury	Shiwen Ma	Received

SAT-70	Clinical relevance of albumin binding kinetics in patients undergoing extracorporeal albumin detoxification	Stine Koball	Received

SAT-71	The dosage effect of polyene phosphatidylcholine injection for treating patients with acute drug-induced liver injury: a cohort trial	Haisong Yang	Received

THU-71	Bacteroides intestinalis AM1 remodels liver microbiome and toxic metabolites, highlighting a novel therapeutic strategy in acute liver failure	SUSHMITA PANDEY	Received

FRI-71	Restoration of ethanol-induced Bifidobacterium bifidum depletion ameliorates alcohol-related liver disease	Yating Li	Received

WED-71	Clinical relevance of repeating FIB-4 in the screening strategy for identifying metabolic dysfunction–associated liver disease-related advanced fibrosis	Cyrielle Caussy	Received

THU-72	Uncovering immune related mechanisms in drug-induced liver toxicity of sitaxsentan using human ex vivo precision-cut liver slices	Kevin Schmidt	Received

FRI-73	Digital pathology and multi-omic profiling in abstinent patients with alcohol-related decompensated cirrhosis shows significant degrees of fibrosis regression associated to clinical improvement	Lisa Longato	Received

THU-73	Plasma bacteriophage diversity correlates with microbiome diversity and contributes todiseases severity and poor outcome in acute liver failure	Neha Sharma	Received

WED-73	Metabolic and cognitive effects of a 6-month dietary intervention in patients with MASLD: a prospective study	Gian Paolo Caviglia	Received

THU-74	Biomolecular mapping of circulating extracellular vesicles to develop AI driven prognostic panels for stratifying acute liver failure patients at risk of early mortality	Neha Sharma	Received

WED-74	C-reactive protein-triglyceride glucose index and fasting C-peptide to high-density lipoprotein cholesterol ratio as predictors for advanced fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease	Georgiana-Diana Cazac-Panaite	Received

THU-75	Assessing drug-mediated inhibition of liver transporter function with functional MRI: proof of concept	Steven Sourbron	Received

SAT-75	Predicting the unpredictable: machine learning outperforms MELD for ICU mortality in acute liver failure	Lawin Steve Mathew Lasington	Received

WED-75	Comparison of clinical care pathways for metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes (T2D) in the dawn of effective pharmacological therapy	Wah Kheong Chan	Received

FRI-75	Association of Protein-Calorie Malnutrition with In-Hospital Complications in Patients with Alcohol-Associated Cirrhosis	Jazmin Mexia Cabrales	Received

FRI-76	Alcohol-associated amino acid signature linked to zonal glutamine synthetase serves as a biomarker of metabolic adaptation in steatotic liver disease	Masaaki Mino	Received

WED-76	Mapping somatic evolution in steatotic liver disease through integrated tissue and organoid genomics	Alessandro Cherubini	Received

THU-76	Variation of CD39-positive tregs in idiosyncratic drug-induced liver injury	Maria Vargas	Received

WED-77	External validation of a parsimonious machine learning model for detecting significant fibrosis in obese patients with metabolic dysfunction–associated steatotic liver disease (MASLD)	Ahmed Cordie	Received

SAT-77	Lipopolysaccharide binding protein as a predictive biomarker for the onset of acute kidney injury in cirrhosis	Namisaki Namisaki	Received

WED-78	Is the fatty liver index just measuring BMI? Evidence from NHANES and an HIV cohort	Ahmed Cordie	Received

SAT-78	Association between biochemical patterns of DILI and histological findings in liver biopsies	tayna domingos	Received

THU-78	Characterisation and applicability of a 3D coculture spheroid model for drug-induced liver injury	Neele Wewer	Received

FRI-78	Long-term mortality under the new steatotic liver disease classification	Sakkarin Chirapongsathorn	Received

SAT-79	Plasma exchange improves transplant-free survival in acute liver failure: a patient-level meta-analysis	Miguel Sogbe	Received

FRI-79	Higher socioeconomic position is associated with alcohol under-reporting relative to PEth	Helle Schnefeld	Received

WED-79	Evaluation of metabolic dysfunction-associated steatohepatitis in adults and children using ultrasound derived fat fraction and elastography with MRI proton density fat fraction and elastography as reference standard	Yassin Labyed	Received

TOP-82	Machine learning–based models with and without VCTE improve cirrhosis prescreening compared with Agile4 and VCTE in the largest clinical trial validation cohort	Winston Dunn	Received

WED-83	Prevalence of elevated fibrosis-4 index in adults from primary care and associated clinical factors	Gianluca Svegliati Baroni	Received

THU-83	IPA ameliorates acute-on-chronic liver failure by suppressing neutrophil extracellular trap formation	You hang	Received

FRI-83	Type 2 diabetes mellitus and alcohol use disorder amplify both cardio-renal-metabolic and liver related outcomes and mortality risk compared to either disorder alone	Neha Shah	Received

SAT-83	Concomitant medications associated with acute liver injury risk following amoxicillin/clavulanate exposure unexplained by other causes: signal detection analyses using electronic health record data	Ayako Suzuki	Received

SAT-84	Development and external validation of the RE-AD score: a clinical-based machine learning tool for acute decompensation prediction in compensated advanced chronic liver disease	Marco Vicardi	Received

WED-84	GRIPonMASH preliminary results: comparison of FIB-4 and MAF-5 as first-line tests to rule out advanced fibrosis in primary care	Vivian de Jong	Received

FRI-84	Triangulated alcohol assessment substantially increases identification of MetALD and ALD in a population-based study of steatotic liver disease	Juho Siltanen	Received

THU-85	Metabolic dysfunction-associated steatotic liver disease in Europe: latest insight into disease incidence and burden	Ahmed Abdulelah	Received

FRI-85	Biological impact of anemia on phosphatidylethanol concentrations in advanced liver disease: analysis of the RH7 cohort	Svetlana Adamcova Selcanova	Received

WED-85	Deep learning integration of nuclear magnetic resonance metabolomics and NASH-FibroTest biomarkers improves blood-based prediction of liver fat measured by magnetic resonance imaging	Olivier Deckmyn	Received

WED-86	Low vitamin D levels are independently associated with increased fibrosis risk in metabolic dysfunction-associated steatotic liver disease	YOUNESS DENDANE	Received

FRI-87	Episodic heavy drinking and implications for steatotic liver disease nomenclature: a national USA study	Yinan Su	Received

WED-87	AI-derived macrophage density reveals hot and cold fibrosis endotypes with distinct biomarker profiles in metabolic dysfunction–associated steatohepatitis	Zoltan Derdak	Received

THU-87	Liver metabolic stress and fibrosis modify APOE e4–associated cognitive vulnerability and amyloid burden	Young Hyeon Ahn	Received

SAT-87	Individualised treatment benefit of double plasma molecular adsorption system in patients with liver failure	Yee Hui Yeo	Received

WED-88	A simple PNPLA3–HSD17B13 genetic risk score predicts major adverse liver-related outcomes in high-risk MASLD	Luis Antonio Diaz Piga	Received

FRI-88	Triglycerides identify a lower-risk phenotype and predict mortality in clinically suspected alcohol-associated hepatitis	Ana Suárez-Saro Fernández	Received

FRI-89	Use of biopsy to diagnose alcoholic hepatitis in a setting a high prevalence of alcohol consumption	Vanessa Trentzsch	Received

WED-89	Optimizing prescreening for VCTE-LSM =8 kPa to support treatment eligibility in metabolic dysfunction–associated steatohepatitis	Winston Dunn	Received

SAT-89	Clinical characteristics, risk factors, and outcomes of immunotherapy-related hepatotoxicity: experience from a large retrospective cohort	Yang Zhi	Received

WED-90	Imaging of liver fibrogenesis in MASH by PDGFR-beta position emission tomography	Olof Eriksson	Received

FRI-90	AI-based quantitative histologic comparison of disease architecture across steatotic liver disease subclassifications	Ida Falk Villesen	Received

SAT-90	Liver-specific somatic beta-klotho knockout dysregulates hepatic lipid metabolism and increases bile acid synthesis	Alexandra Aaldijk	Received

THU-90	Missed opportunities to diagnose metabolic dysfunction associated and alcohol associated steatotic liver disease after incidental detection in the emergency department	Qusai Al Zureikat	Received

FRI-91	The gender equity model for liver allocation accurately predicts 90-day mortality and acute kidney injury in alcohol-associated hepatitis	James Vu	Received

WED-91	A new definition of burning-out MASLD using albumin and amino acid imbalance	Hideki Fujii	Received

THU-91	Epicardial adipose tissue as a marker of divergent hepatic and cardiovascular trajectories in MASLD: a prospective study	Francesca Alletto	Received

THU-92	Prevalence and clinical profile of metabolic dysfunction-associated steatotic liver disease in Saudi adults: the GENESIS study	Saleh A. Alqahtani	Received

WED-92	Implementation of enhanced liver fibrosis testing in type 2 diabetes to improve detection of at-risk metabolic dysfunction-associated steatohepatitis to optimize hepatology referrals: a duke health analysis	Maison Furley	Received

FRI-92	Integration of polygenic risk score with metabolomics (MetPRS) identifies a protective sphingolipid signature that predicts survival in alcohol-related liver disease	Vaishali Yadav	Received

SAT-92	The single-cell landscape of MASLD-enriched liver sinusoidal endothelial	DAE WON JUN	Received

FRI-93	Recompensation criteria and clinical outcomes in decompensated alcohol-associated liver disease: a population-based study in Olmsted county	Alberto Calleri	Received

WED-93	Cardiometabolic risk factor burden predicts longitudinal liver stiffness trajectories in metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease	Zouhir Gadi	Received

SAT-93	Genetic and pharmacologic inhibition of miR-92a attenuates MASLD progression and decreases portal Hypertension	Philipp Stephan Althaus	Received

THU-93	From irregular cycles to menopause: reproductive transitions associated with metabolic dysfunction-associated steatotic liver disease severity in women	Saleh A. Alqahtani	Received

THU-94	Impact of obesity on symptom burden and health-related quality of life in patients with metabolic dysfunction-associated steatotic liver disease	Saleh A. Alqahtani	Received

WED-94	Contrast-enhanced ultrasound in metabolic dysfunction-associated steatotic liver disease: towards a non-invasive marker of histological disease activity	Zouhir Gadi	Received

SAT-94	Semaglutide prevents cognitive dysfunction in experimental metabolic dysfunction-associated steatohepatitis through anti-inflammatory and neuroprotective effects	Kristoffer Kjrgaard Amby	Received

FRI-94	Trends in transplant outcomes for alcohol-related cirrhosis and alcohol-related hepatitis in the United States over 15 years	Zobair Younossi	Received

THU-95	Socioeconomic, clinical, and quality of life differences by physical activity status among patients with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis in Saudi Arabia	Saleh A. Alqahtani	Received

FRI-95	Clinician and patient perspectives on stigma, knowledge, and care gaps in alcohol-related liver disease (ALD)	Zobair Younossi	Received

SAT-95	Dysregulation of the E2F2-PCSK9 axis promotes MASLD progression and related cardiovascular disease	Maider Apodaka-Biguri	Received

TOP-96	Can reliably measured transient elastography be trusted in obesity? Comparing the modifying effects of general and central adiposity in MASLD	Fredrik berg	Received

TOP-97	Assessment of cardiometabolic comorbidities and the impact of glycemic and weight control on liver stiffness in advanced metabolic dysfunction-associated steatotic liver disease	Cautar El Maimouni	Received

TOP-98	Prevalence of MASLD, MetALD, ALD and liver fibrosis in patients with type 2 diabetes in 30,199 subjects in the general population: insights from the LiverScreen cohort	Laurent Castera	Received

THU-99	Clinical and metabolic characteristics of lean compared with overweight/obese metabolic dysfunction-associated steatotic liver disease	Saleh A. Alqahtani	Received

SAT-99	Transcriptomic analysis of paired biopsies of liver and adipose tissue before and after bariatric surgery reveals distinct signaling pathways associated with persistence of MASLD despite significant weight loss	Anouar Aznou	Received

FRI-99	Development and validation of a disease-specific health-related quality of life questionnaire (HRQL) for alcohol-related liver disease (CLDQ-ALD)	Zobair Younossi	Received

WED-99	Parallel combination of FIB-4 and enhanced liver fibrosis test improves prognostication in metabolic dysfunction-associated steatohepatitis	Matthew Gee	Received

THU-100	Demographic and metabolic predictors of MASLD progression in Saudi Arabia: a retrospective cross-sectional analysis	Amani Alsadoon	Received

SAT-100	Enhancing effects of combining resmetirom and semaglutide in a modified AMLN diet-induced mouse model for metabolic dysfunction-associated steatohepatitis (MASH)	Jian-Xin (Jimmy) Bao	Received

WED-100	A novel machine learning-based algorithm improves risk stratification of patients with MASLD compared to FIB-4	Kamela Gjini	Received

FRI-100	Cell-free DNA as a biomarker of liver fibrosis in alcohol-related liver disease	Paola Zuluaga Blanco	Received

SAT-101	Nutritional distress–dependent regulation of cyclin M1 modulates insulin sensitivity via an FGF21-mediated mechanism	Jon Ander Barrenechea-Barrenechea	Received

WED-101	Population-based assessment of metabolic dysfunction–associated steatotic liver disease using CAP: results in the european population from the LiverScreen project	Isabel Graupera Garcia-Milà	Received

FRI-102	Hepatic stellate cell-derived Follistatin-like 3 ameliorates alcohol-induced liver injury via inhibition of Activin type II receptor signaling pathway	Gloria Alvarez-Sola	Received

THU-102	Glucagon-like peptide-1 receptor localization in lipid droplets and M2-like macrophages in MASH	Wataru Ando	Received

WED-102	Artificial intelligence-guided approaches to define biochemical and epigenetic markers that may reflect the metabolic dysfunction-associated steatohepatitis phenotype in children and adults	Flavia Grignaffini	Received

SAT-102	Prime editing models the MTARC1 A165T variant in human liver organoids, demonstrating reduced steatosis, inflammation, and fibrosis	Amel Ben Saad	Received

WED-103	Validation of a multimodal ultrasound and artificial intelligence approach for identifying advanced fibrosis in metabolic dysfunction-associated steatotic liver disease	Yassin Labyed	Received

FRI-103	Impact of fecal microbiota transplant from select human donors on alcohol intake in an immunocompetent alcohol use disorder model is sex-selective	Jasmohan Bajaj	Received

THU-103	Long-term liver-related outcomes in asian and caucasian patients with MASLD: evidence from a large multicentric observational study	Angelo Armandi	Received

SAT-103	Epigenetic programming of metabolic liver disease by early-life nutritional overload	claudia bigas	Received

FRI-104	Thermoneutral housing alters ethanol metabolism in a mouse model of Alcohol-associated Liver Disease	Monica Barrios	Received

THU-104	Assessing the impact of demographic, metabolic and liver disease severity factors on physical and mental health component scores among a large Canadian MASLD cohort	Elizabeth Baguley	Received

WED-104	Changes in non-invasive tests PRO-C3, ADAPT, LiverRisk and FIB-4 can be used to predict changes in liver stiffness in patients with MASLD	Hannes Hegmar	Received

SAT-104	Global analysis of protein post-translational modifications reveals novel regulatory mechanisms in steatotic liver disease	Virginia Aranda	Received

WED-105	Optimization of non-invasive screening algorithms for referral to liver elastography in the general population	Marta Hernandez Conde	Received

FRI-105	Exhaled breath condensate bile acid profile correlates with plasma bile acid profile in alcohol related liver diseases	SUSHMITA PANDEY	Received

SAT-106	Surfaceome mapping of human hepatocytes uncovers proteome dynamics in steatotic hepatocytes	Daniel Zaldumbide	Received

WED-106	External validation of a standardized FLI without anthropometric data for the screening of significant liver fibrosis	Marta Hernandez Conde	Received

THU-106	Sex differences in improvement of metabolic dysfunction-associated steatotic liver disease and cardiorespiratory fitness in a residential lifestyle intervention for youth living with obesity	Maarten Buytaert	Received

WED-107	Biogenic amines as possible biomarkers of liver fibrosis severity in metabolic dysfunction-associated steatotic liver disease	Zdenka Hertelyová	Received

FRI-107	Gut-derived immunoglobulin A activates hepatic macrophages and exacerbates inflammation in alcohol-related liver disease	Min Su Cha	Received

SAT-107	Protease driven phenotypical changes in lipid associated macrophages attenuates metabolic dysfunction associated steatohepatitis progression	Júlia Cacho-Pujol	Received

THU-107	Stronger association and causal link between visceral adipose tissue and metabolic dysfunction-associated steatotic liver disease in women, particularly after menopause	Yutian Cao	Received

THU-108	Supervised physical activity improves muscle quality and function in MASLD: insights from the EHMet-DIA study	Paloma Carrillo-Fernández	Received

SAT-108	Hepatocyte succinate dehydrogenase/complex II promotes metabolic dysfunction–associated steatotic liver disease progression and represents a therapeutic target	David Carneros Trujillo	Received

WED-108	Diagnostic accuracy of non-invasive serum biomarkers for liver fibrosis in hepatocellular carcinoma patients with and without concurrent metabolic dysfunction–associated steatotic liver disease	CHUN-TING HO	Received

FRI-108	Methyl group donor supplementation modulates gut microbiota and methylome in a metabolic and alcohol-related liver disease murine model	Carolina Diaz Canul	Received

FRI-109	Lifestyle and microbiome modification for the management of MetALD in the preclinical DUAL model	Olga Estévez Vázquez	Received

WED-109	Unsupervised biomarker clustering reveals clinically relevant phenotypes in metabolic dysfunction–associated steatotic liver disease	Frederik Hbjerg Svejsø	Received

SAT-109	PNPLA3 p.I148M variant affects lipid droplets number and size in patient-derived liver organoids	Elia Casirati	Received

THU-109	Metabolic dysfunction–associated steatotic liver disease predicts hepatic and cardiovascular complications after kidney transplantation	Lourianne Cavalcante	Received

THU-110	Etiology specific risk of hepatic and extrahepatic complications in MASLD patients with alcohol or viral co-etiologies: a retrospective multicentre cohort study	Talia Yi Hui Chan	Received

WED-110	External validation of the LiverPRO algorithm for liver fibrosis risk assessment in U.S. representative adults	He Huang	Received

SAT-110	Exploring the complexity of MASLD: sex-dependent genetic effect on body composition	Annalisa Cespiati	Received

FRI-110	Aldehyde dehydrogenase 2 deficiency promotes alcohol-associated liver fibrosis via AMPK/DRP1-dependent oxidized mtDNA	Yanhang Gao	Received

SAT-111	Therapeutic targeting of fibrosis-associated microRNAs attenuates steatohepatitis-related liver fibrosis	Young Chang	Received

WED-111	Self-assessed health and healthcare utilisation identify individuals with increased liver stiffness in the general population	He Huang	Received

THU-111	Impact of metabolic dysfunction associated steatotic liver disease on hepatocellular carcinoma risk in patients with chronic hepatitis B or chronic hepatitis C: a nationwide cohort study	Young Chang	Received

FRI-111	Therapeutic potential of mesenchymal stem cells in severe alcoholic hepatitis: integrative analysis of transcriptomic signatures and in vivo validation	Seul Ki Han	Received

TOP-112	Comparative incidence of end-stage complications in type 2 diabetes reveals a high liver disease burden: nationwide cohort study of 539,914 persons	Ying Shang	Received

TOP-113	Clinical profile, histologic features, non-invasive test accuracy, and long-term outcomes of lean metabolic dysfunction associated steatotic liver disease (MASLD): insights from the global masld project	Zobair Younossi	Received

TOP-114	Application of fibrosis tests and hepatocellular carcinoma prediction scores in metabolic dysfunction-associated steatotic liver disease	Huapeng LIN	Received

FRI-115	Ethanol reprograms hepatic lymphatic endothelial cells to promote proinflammatory immune trafficking in alcohol-associated hepatitis	Yasuko Iwakiri	Received

THU-115	Metabolic dysfunction-associated steatotic liver disease (MASLD) as predominant aetiology and poorest prognosis in multi-ethnic Singapore cirrhosis cohort	Jarvis Chia Kai An	Received

WED-115	Prediabetes identifies a high-risk subgroup for advanced liver fibrosis in non-diabetic MASLD: a non-invasive risk stratification study	Trung Huynh	Received

THU-116	Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with impaired health-related quality of life in people with HIV	Felice Cinque	Received

FRI-116	Performance of MAF-5 versus FIB-4 for predicting liver fibrosis across alcohol intake levels: NHANES 2017-2023	Nikhil Kalita	Received

WED-116	Superiority of the FAST score compared to traditional non-invasive indices in detecting liver fibrosis in asymptomatic patients with type 2 diabetes mellitus	Ramazan Idilman	Received

SAT-116	MicroRNA-146a in extracellular vesicles from obese adipocytes trigger hepatic inflammation	Qiuyang Chen	Received

SAT-117	Ultrastructural assessment of liver sinusoidal endothelial cell capillarisation in metabolic dysfunction-associated steatotic liver disease and its modulation by lanifibranor	Shivani Chotkoe	Received

FRI-117	Fibroblast Growth Factor 19 as a diagnostic biomarker for alcohol-related hepatitis	Patrycja Kiczynska	Received

WED-117	Optimizing drug development in populations with compensated MASH cirrhosis by integration of the Disease Severity Index from the HepQuant DuO test in trial design	Michael McRae	Received

SAT-118	Activation of SIRT5 drives mitochondrial dysfunction, impaired hepatic differentiation and steatotic injury in human liver organoids	maura cimino	Received

THU-118	Influence of coexistent steatotic liver disease on outcomes and treatment responses in autoimmune hepatitis or primary biliary cholangitis	Oscar Danielsson	Received

WED-118	Prognostic significance of a 5 kPa absolute change in liver stiffness measurements (LSM) to predict liver-related events in patients with compensated advanced metabolic dysfunction-associated steatotic liver disease (MASLD)	Xinrui Jin	Received

WED-119	Steatotic liver disease phenotypes in inflammatory bowel disease: a screening study identifying masld as the primary driver of liver fibrosis	Dana Kablawi	Received

FRI-119	C-X-C chemokine receptor type 4 and C-X-C motif chemokine 12 mediate liver injury by cytotoxic CD8 T-cells in alcohol-associated liver disease	Gil Won Lee	Received

THU-119	Association between sex and long-term clinical outcomes in metabolic dysfunction-associated steatotic liver disease	Pojsakorn Danpanichkul	Received

SAT-119	NLT-101, a selective estrogen receptor alpha agonist, protects hepatocytes against nuclear envelope alterations associated with lipotoxic metabolic stress	Michael Cooreman	Received

THU-120	MASLD and mental health: association of the liver disease with anxiety, depression and binge eating	Stella De Nicola	Received

WED-120	Utility of ELF compared with VCTE in guideline-based fibrosis assessment pathways using MRE as reference	Cecilia Katzenstein	Received

SAT-120	Diet and sex dictate CD1d-mediated immune alterations in MASLD and HCC	Carlos Cuño-Gómiz	Received

FRI-120	Unraveling the progressive remodeling and functional exhaustion of peripheral NK cells in alcohol-related liver disease progression	Young-Sun Lee	Received

WED-121	AI-based non-invasive prediction of liver fibrosis in a multicenter biopsy-proven MASLD cohort in Korea	Soon Sun Kim	Received

FRI-121	Alcohol-induced oxidative stress triggers mitochondrial calcium release through permeability transition pore opening in alcohol-associated steatohepatitis	Kwangwoo LEE	Received

THU-121	Medical education on MASH delivered through a social media series had strong clinician engagement	Shari Dermer	Received

SAT-121	The chronic environmental exposure to Bisphenol A influences trained immunity-related pathways and induces immunometabolic innate cells reprogramming, promoting the metabolic dysfunction associated steatotic liver disease (MASLD) progression	Marcello Dallio	Received

THU-122	clinical outcomes in compensated cirrhosis due to MASH: results from a population-based indiana cirrhosis cohort	Naga Chalasani	Received

WED-122	Optimal cut-off of 2D shear wave elastography for ruling out significant hepatic fibrosis in MASLD: a meta-analysis and machine learning	DAE WON JUN	Received

FRI-122	A Novel murine model of metabolic dysfunction-associated alcoholic liver disease (MetALD) for therapeutic drug evaluation	Hui Li	Received

SAT-122	Hepatic estrogen receptor alpha shapes sex differences in MASLD development and progression	Sara Della Torre	Received

SAT-123	Multi-organ crosstalk via Exosomal TCA cycle enzymes underlies metabolic benefits of exercise and daytime time-restricted feeding in murine MASH resolution	Xiaoying Dong	Received

WED-123	Data-driven identification of an IgA-enriched high-risk subtype in MASLD	Takefumi Kimura	Received

THU-123	A head-to-head comparison of MAFLD and MASLD diagnostic criteria in estimating the risk of de novo hepatocellular carcinoma (HCC) occurrence in HCV patients achieving direct-acting antiviral-induced sustained virological response	Mario Romeo	Received

FRI-123	Hepatocyte SIRT7 mediated FXR–bile acid homeostasis facilitates PMN-MDSC differentiation and aggravates alcohol-associated liver disease	Gaoshuang Liang	Received

THU-124	Impact of gallstone disease, cholecystectomy and genetic variants on liver steatosis and fibrosis: a prospective, cross-sectional cohort study at a tertiary hepatology centre	Simon Drews	Received

WED-125	Diagnostic performance of the FibroScan-AST (FAST) score for biopsy-proven metabolic dysfunction-associated steatohepatitis	Jaouhara Lahsini	Received

THU-125	Dissecting the alternate mediterranean diet score identifies whole grains and red meat as key determinants of fibrosis risk in MASLD	Nicholas Dunn	Received

SAT-125	The role of Pyroptosis in metabolic dysfunction-associated steatotic liver disease	Lauredana dos Santos Ferreira Grani	Received

FRI-125	Spatial transcriptomics reveals metabolic, immune and regenerative reprogramming during disease resolution in severe alcohol-related hepatitis	Laura Martinez-Gili	Received

WED-126	Unmasking hidden risk: machine learning reveals ethnic-specific predictors of hepatocellular carcinoma in non-cirrhotic MASLD	Jeril Lasington	Received

THU-126	Natural history and predictors of fibrosis progression in metabolic dysfunction-associated steatotic liver disease (MASLD) – Longitudinal cohort study with paired liver biopsies	Fahim Ebrahimi	Received

SAT-126	Unveiling the protein cargo of high-density lipoprotein particles in metabolic dysfunction-associated steatohepatitis: a biomarker study	Aleksandra Dudzik	Received

FRI-126	Binge alcohol exposure induces neutrophil extracellular trap associated injury in the proximal small intestine	Scott Minchenberg	Received

SAT-127	Glucose-dependent insulinotropic polypeptide signaling in adipose tissue macrophages protects against obesity-induced metabolic dysfunction-associated steatotic liver disease by promoting adaptive adipogenesis	Irina Efimova	Received

WED-127	Emerging indices outperform traditional fibrosis scores in young MASLD across divergent screening goals	Ahlim Lee	Received

FRI-127	Urinary markers of complement and chronic kidney disease are associated with occurrence of acute kidney injury in patients with severe alcohol-associated hepatitis	Laura Nagy	Received

THU-127	Non-invasive two-step triage reduces access delays to liver services for people with metabolic dysfunction-associated steatotic liver disease: a tertiary program evaluation	yasamin farbod	Received

TOP-128	An artificial intelligence model to better predict hepatocellular carcinoma risk in patients with metabolic dysfunction-associated steatotic liver disease: a large-scale 20-year cohort study	Ming-Ying Lu	Received

TOP-130	ZDHHC17-mediated of palmoylation-modified D2HGDH nuclear translocating drives progression of metabolic associated steatohepatitis via HDAC1-H3K27ac pathways	Xi-Xuan Wang	Received

SAT-131	Metabolic and alcohol associated liver disease (MetALD): understanding the gut-liver axis-mediated mechanisms of liver cancer	Alisson Quezada Cuadrado	Received

WED-131	The sequential use of LiverPRO and ADAPT enhances fibrosis detection in at-risk populations	Diana Julie Leeming	Received

THU-131	Vitamin D insufficiency is associated with liver fibrosis development in people with HIV	Francesca Farina	Received

SAT-132	Genome-wide shRNA screen identifies Eif4ebp1 as a novel therapeutic target in metabolic dysfunction-associated steatotic liver disease (MASLD)	Ayat Fayez	Received

FRI-132	Disruption of TCA-glutamine metabolism: a-Ketoglutaric acid as a prognostic marker in alcohol-associated liver disease	SUSHMITA PANDEY	Received

THU-132	Impact of Unhealthy Diet Categories on Liver Disease Outcomes Among Different Steatotic Liver Disease Phenotypes Following Patient-Centered Education	Serena Gilmore	Received

WED-132	Evaluating the uptake of fibrosis-4 index as a screening tool for liver fibrosis in patients with type 2 diabetes	Hak-Keith Leung	Received

FRI-133	Morphological differences in mitochondria of patients with and without alcohol related liver disease	Meliz Sahuri Arisoylu	Received

WED-133	The metabolic body risk index (MBRI) based on anthropometric composite and machine learning for non-invasive diagnosis of MASLD	Yingying Lin	Received

SAT-133	Reprogramming lipid-driven immunometabolic dysfunction in metabolic dysfunction-associated steatohepatitis through PLT012 targeting CD36	Laura Fernandez Rodriguez	Received

THU-133	Depression and anxiety levels are higher in obese women than in men in a cohort of MASLD patients	Marta Guariglia	Received

THU-134	Exploring the link between handgrip strength and MASLD	Leen HEYENS	Received

FRI-134	Selective farnesoid X receptor agonist INT-787 inhibits ethanol-induced liver injury in mice	Catherine Donkus	Received

SAT-134	Ultrastructural analysis of transjugular biopsies in metabolic dysfunction-associated steatotic liver disease identifies core hepatocellular stress adaptations	Jose Fortea	Received

SAT-135	Proteomic profiling of steatotic monkey liver organoids as a model of metabolic dysfunction-associated steatotic liver disease	Bowen Gao	Received

WED-135	Metabolic dysfunction-associated steatotic liver disease and the work environment: results of a multicenter nationwide study	Ekaterina Liusina	Received

THU-135	Association of geriatric nutritional risk index with prognosis in hepatocellular carcinoma patients with and without metabolic dysfunction–associated steatotic liver disease	Chia-Jung Ho	Received

SAT-136	Oral administration of low molecular weight heparin polysaccharide alleviated metabolic dysfunction-associated steatotic liver disease by modulating the gut microbiota and metabolites in Mice	Xuelian Gao	Received

THU-136	Comparison of demographics, metabolic risk factors and clinical presentation in lean Vs. non-lean metabolic dysfunction-associated steatotic liver disease (L-MASLD Vs. NL-MASLD) in all of US large cohort in the United States	Ke-Qin Hu	Received

WED-136	Prevalence and characteristics of patients with lean metabolic dysfunction-associated steatotic liver disease: data from a Russian real-world cohort	Ekaterina Liusina	Received

THU-137	The Zone of Injury in MASH Influences Cardiometabolic Biomarkers and Outcomes	Alan Hutchison	Received

WED-137	Real-life evaluation of the FIB-4 two-step fibrosis screening strategy in MASLD: measurement of waist circumference might make the difference	Rosa Lombardi	Received

SAT-137	Extracellular ATP (eATP) and related pathways in the progression of metabolic dysfunction–associated steatotic liver disease (MASLD)	Vanessa García-Fernández	Received

FRI-137	Intestinal GPR119 activation improves alcohol-related liver disease via gut-liver axis and mediates the protective effect of its ligand palmitoleic acid	Mengyao Wang	Received

WED-138	Metabolome analysis revealed red flag signatures for the identification of MASLD risk across patients with dysmetabolic traits	Miriam Longo	Received

SAT-138	Synergy of SOAT2-inhibitor PRD001 with resmetirom in reducing MASH and fibrosis in obese Ldlr-/-.Leiden mice	Eveline Gart	Received

THU-138	Caloric restriction and lifestyle guidance intensity in placebo arms and histologic improvement in metabolic dysfunction–associated steatohepatitis: systematic review and meta-analysis	Feng IJung	Received

FRI-139	Semaglutide provides liver health-related benefits in menopausal women living with MASH: a post hoc analysis of the ESSENCE trial part 1	Manal F. Abdelmalek	Received

WED-139	Machine learning models of non-invasive tests to predict MASH and fibrosis stage based on MAESTRO-NAFLD-1 and MAESTRO-NASH liver biopsies	Rohit Loomba	Received

THU-139	Aberrant neurovascular coupling as an early biomarker of brain involvement in MASLD with high liver stiffness	Zhuoru Jiang	Received

SAT-139	The liver RNF43-Wnt/ß-catenin pathway remotely regulates the intestinal inflammation repair pattern through bile acid reprogramming	Ying Geng	Received

THU-140	Steatotic liver disease as an upstream risk factor for the development of metabolic syndrome–related disorders: a 7-year health checkup cohort study in Japan	Yoshihiro Kamada	Received

FRI-140	Isotemporal associations of sedentary behavior and physical activity with health-related quality of life in patients with metabolic dysfunction-associated steatotic liver disease	Abdullah Alansare	Received

SAT-140	Inhibition of hepatic bile salt uptake using Bulevirtide attenuates pre-existing diet-induced metabolic dysfunction-associated steatohepatitis in mice	Claire Groenen	Received

SAT-141	Succinate alleviates metabolic dysfunction-associated steatotic liver disease through the hepatocyte SUCNR1/PPAR-gamma/PLIN2 axis	Lei Gu	Received

WED-141	Patients with compensated MASH cirrhosis and Fibroscan® VCTE score <15 kPa: baseline data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis)	Rohit Loomba	Received

THU-141	HCV exposure modifies MASLD trajectories in people living with HIV: impaired steatosis and persistently elevated liver stiffness despite sustained virologic response	Ahmed Kamel	Received

FRI-141	Early real-world effectiveness of resmetirom in adults with metabolic dysfunction associated steatohepatitis and moderate-to-advanced fibrosis	Naim Alkhouri	Received

THU-142	Cardiometabolic risk factors and fibrosis in MASLD: comparison between people living with HIV and the general population in Egypt	Ahmed Kamel	Received

SAT-142	Semaglutide improves metabolic and histological outcomes and reverses clinically relevant biomarker alterations in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH	Henrik Hansen	Received

FRI-142	Study design, rationale, and baseline characteristics of the SYNCHRONY real-world trial: a phase 3 trial evaluating efruxifermin in participants with MASLD or MASH	Sonja Billes	Received

TOP-144	Mitochondrial cholesterol transport by stard1 links hepatocyte stress to macrophage inflammasome activation in MASLD	Sandra Torres Núñez	Received

TOP-145	CBS/H2S-Dependent S-Sulfhydration of PREB regulates ApoB-mediated VLDL secretion and hepatic lipid homeostasis	Mingchang Pang	Received

WED-147	Ethnic variation in FibroScan-detected fibrosis and steatosis in a large multi-ethnic cohort: implications for MASLD screening	Jumshaid Qureshi	Received

FRI-147	Efficacy of a therapeutic physical exercise program in patients with metabolic dysfunction–associated steatotic liver disease: a randomized, open-label, bicenter study (SteatoAPA)	Rodolphe Anty	Received

SAT-147	Lack of MASP-3 ameliorates liver injury and fibrosis in diet-induced fatty liver via modulation of apoptosis and inflammatory pathway in mice	Manabu Hayashi	Received

THU-147	Long-term association between Helicobacter pylori serostatus changes and incident metabolic dysfunction–associated steatotic liver disease	HAE YEON KANG	Received

THU-148	Maternal MASLD and timing of early-childhood adiposity: a prospective cohort of over 1,000 mother–child dyads	Cecilia Katzenstein	Received

SAT-148	Fat stiffens! The influence of steatotic progression on liver tissue	Alexander Hayn	Received

FRI-148	Pharmacodynamics, pharmacokinetics, safety, and tolerability of AZD2389, a fibroblast activation protein inhibitor in participants with liver fibrosis and compensated cirrhosis	Vian Azzu	Received

WED-148	Risk stratification by longitudinal FIB-4 biomarker measurements in patients with MASLD/MASH	Suraj Mahida	Received

SAT-149	AxiomerTM mediated RNA editing converts the pathogenic PNPLA3 I148M variant to a wildtype-like form to reduce hepatic steatosis in MASLD/MASH	Werner Helvensteijn	Received

WED-149	Prevalence and risk factors of steatotic liver disease among secondary public-school students in Chattogram, Bangladesh	Abdullah Al Mahmood	Received

THU-149	Impact of endothelial dysfunction on disease progression in patients with MASLD and microalbuminuria	Hijran Khidirova	Received

FRI-150	Adipose tissue insulin resistance is a marker and a major driver of severe metabolic dysfunction associated steatohepatitis	Nateneal Beyene	Received

WED-150	Refining the EASL two-step strategy for referral of patients with MASLD: a prospective multicenter primary care study	David Marti-Aguado	Received

SAT-150	Pharmacological inhibition of transforming growth factor-beta-activated kinase 1 (TAK1) in a murine model of metabolic dysfunction-associated steatotic liver disease	Felix Hempel	Received

SAT-151	Intramuscular fat in steatotic liver disease is linked to muscle function impairment, insulin resistance and specific inflammatory pathways in the liver	Nicolas Lanthier	Received

WED-151	Repeatability of mri biomarkers for monitoring patients with metabolic dysfunction-associated steatotic liver disease	David Marti Aguado	Received

FRI-151	Which comes first: GLP-1 RA vs resmetirom in MASH real world practice	Ana Maria Davila Morales	Received

THU-151	MASLD and coronary calcification: how Bayesian analysis supports the association	Florian Koutny	Received

FRI-152	Online case-based certified medical education improved clinical decision-making in the management of metabolic dysfunction-associated steatohepatitis	Shari Dermer	Received

SAT-152	Dissecting paraoxonase 1 genotype combinations modulating paraoxonase activity and risk of dysglycemia and liver fibrosis	Laura Herrera	Received

WED-152	Improving identification of metabolic dysfunction-associated steatotic liver disease through integration of glycated haemoglobin into established liver assessment pathways	Holly Martin	Received

SAT-153	Combined exposure to alcohol and the PNPLA3 I148M variant drives hepatocytes toward pro-inflammatory, oncogenic, and profibrotic states in a western diet model	Stephen Hoang	Received

WED-153	Accuracy of non-invasive tests for ruling out or in advanced fibrosis in MASLD patients across clinical settings: a systematic review and meta-analysis	Evangelia Mentsiou-Nikolaou	Received

FRI-153	Treatment with naltrexone/bupropion enhances lifestyle-induced improvements in hepatic steatosis in adults with overweight/obesity	Carmen Dietvorst	Received

FRI-154	Timing and concordance of non-invasive treatment responses to Resmetirom in real-world practice	Winston Dunn	Received

THU-154	Impact of liver biopsy on patients´ readiness to participate in metabolic-dysfunction associated steatotic liver disease drug trials	Piotr Krzeski	Received

WED-154	FIB-4 reflex testing in patients with diabetes mellitus at the primary care level allows calculation of referral rates to specialized care and allocation of resources	Eva Katharina Messer	Received

FRI-155	Efficacy of oral semaglutide in overweight- obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD) related compensated advanced chronic liver disease (cACLD) - Results of first randomized controlled trial	Ajay Duseja	Received

THU-155	Association between biomarkers of subclinical cardiovascular disease and metabolic dysfunction-associated steatotic liver disease (MASLD) severity	Morgane LHenaff	Received

WED-155	Non-invasive test-driven modeling of patient eligibility for resmetirom therapy in MASLD: Data from the German SLD-Registry	Yvonne Serfert	Received

THU-156	Clinical predictors of increased liver stiffness over time in metabolic dysfunction-associated steatotic liver disease: a prospective real-life study	Nicolas Lanthier	Received

WED-156	A prospective multicenter study to examine the impact of acquired and genetic predictors on hepatocellular carcinoma risk in patients with advanced metabolic associated steatotic liver disease	Stefania Mira	Received

SAT-156	Endothelial glycogen synthase kinase 3ß promotes dendritic cells maturations and drives liver inflammation and fibrosis in metabolic dysfunction-associated steatohepatitis	Samar Ibrahim	Received

WED-157	Application of EASL guidelines for the assessment of risk for MASLD-related advanced fibrosis in an outreach screening of underserved rural communities in central and northern Romania using hepatoscope	Andreea Mihaela Morariu-Barb	Received

FRI-157	Habitual aspirin use and MRI-derived liver fat and fibroinflammation	Qi Feng	Received

THU-158	Are current MASLD alcohol thresholds appropriate for all patients? The role of metabolic vulnerability	Rosa Lombardi	Received

FRI-158	Additive associations of the mediterranean diet, physical activity, and coffee consumption with reduced risk of liver fibrosis in metabolic dysfunction-associated steatotic liver disease	Meng-Lun Hsieh	Received

WED-158	LIVERFAST outperforms FIB-4, in sequential combination with vibration controlled transient elastography (VCTE) for identifying =F3 Stages in patients with MASLD including patients with type 2 diabetes (T2D)	Mona Munteanu	Received

SAT-158	Epigenetic maintenance by DNMT1 safeguards the liver from inflammatory and fibrotic injury in MASLD/MASH	Lina Jegodzinski	Received

SAT-159	Hepatocellular GALNT15 promotes the development of metabolic dysfunction-associated steatohepatitis	Zhonghao Jiang	Received

WED-159	Positron emission tomography/magnetic resonance imaging with copper-64 DOTATATE identifies metabolic dysfunction-associated steatohepatitis and shows attenuated hepatic signal with glucagon-like peptide-1 receptor agonist treatment	Puria Nabilou	Received

FRI-159	Dose-dependent efficacy and renal safety of pemafibrate in patients with MASLD: a multicenter randomized controlled trial	Michihiro Iwaki	Received

THU-159	Brief alcohol counseling in steatotic liver disease: a single-center observational study of six-month changes in alcohol use, noninvasive liver metrics, and quality of life	Erica Nicola Lynch	Received

TOP-161	Maternal metabolic dysfunction-associated steatotic liver disease rewires placental-fetal selenium crosstalk and mediates fetal liver insulin resistance	Simran Sharma	Received

TOP-162	Glucagon-like peptide-1 receptor agonists and long-term liver outcomes in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes: A large real-world analysis	Arunkumar Krishnan	Received

WED-163	Metabolic dysfunction-associated steatotic liver disease as a risk factor for fibrosis progression in primary biliary cholangitis: a case-control study	Adela Navarro Pueyo	Received

THU-163	The pseudo-normalization trap in metabolic dysfunction-associated steatotic liver disease: hypolipidemia (low density lipoprotein level < 95 mg/dl) predicts all-cause mortality in a real world cohort	Aysel Mammaryadzada	Received

SAT-163	Inflammation-associated gene expression profiles distinguishing significant fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from a Turkish patient cohort	Dilara Turan Gökçe	Received

FRI-163	Cost-effectiveness of resmetirom treatment, aligned with practice guidance, for suspected ´At-Risk MASH´ identified by transient elastography without histologic confirmation	DAE WON JUN	Received

THU-164	The body roundness index as a novel anthropometric marker in metabolic-associated steatotic liver disease: findings from the HEPAMET registry	Douglas Maya-Miles	Received

WED-164	Comparison of transient elastography and shear wave elastography for MASLD screening in a population at risk	André Neves	Received

SAT-164	Imeglimin attenuates liver injury in a nondiabetic mouse model of MASH by restoring mitochondrial function	Kosuke Kaji	Received

FRI-164	Safety and efficacy of Lactobacillus delbrueckii subsp. lactis CKDB001 in patients with metabolic-associated steatotic liver disease: a randomized, double-blind, placebo-controlled phase II clinical trial	Jung Hee Kim	Received

WED-165	Back from the future? The original logistic FIB-4 model outperforms the current simplified FIB-4	Thuy Duyen Nguyen	Received

SAT-165	Multi-compartment dissection of bile acid remodeling reveals mechanistic drivers of MASLD progression	DAE WON JUN	Received

FRI-166	Improvement of liver steatosis after bariatric surgery in severe obesity is associated to weight reduction and type of surgery	Laura Konings	Received

WED-166	Is perfection the enemy of good? A streamlined screening strategy for metabolic dysfunction-associated steatotic liver disease in the community	TD Clara Nguyen	Received

SAT-167	Region-specific transcriptomic reprogramming and inter-compartmental signaling in metabolic dysfunction–associated steatohepatitis	Jisup Kim	Received

FRI-167	First-in-human phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HP515, a selective THR beta agonist, in healthy participants	Fei Lan	Received

THU-167	Weathering due to accelerated biological aging among younger patients with metabolic dysfunction-associated steatotic liver disease (MASLD)	Andrew Moon	Received

WED-167	The influence of stress factors on the state of the intestinal microbiota and intestinal epithelial permeability in patients with metabolic dysfunction-associated steatotic liver disease	Yana Nikiforova	Received

WED-168	Evaluating discordant enhanced liver fibrosis® test and transient elastography results in patients with metabolic dysfunction–associated steatotic liver disease: insights for risk stratification and management	Laura Pagès	Received

SAT-168	Gut-liver axis modulates the development of hepatic tumorigenesis via gut microbiome alteration and immunomodulation	SEONGJOON KO	Received

FRI-169	Single doses of gatuzosiran (GSK4532990) produce sustained HSD17B13 suppression and liver biochemical improvement in patients with metabolic dysfunction-associated steatohepatitis	Eric Lawitz	Received

SAT-169	Potential protective roles of carvedilol and its derivatives in metabolic dysfunction-associated steatotic liver disease - The molecular docking study	Bojan Korica	Received

THU-170	VAT–MASLD–Sarcopenia cascade: metabolic metamorphosis from anabolism to catabolism and its therapeutic implications in liver disease	ASTUSHI NAKAMURA	Received

FRI-171	First-in-class oral, once-monthly IKKalpha/beta inhibitor targeting steatosis, inflammation, and fibrosis in MASH: results from a phase 1 trial	Qisheng Li	Received

SAT-171	Sex as a key modifier of age- and diet-driven MASLD progression in a murine model: histological and transcriptomic insights	Lucia Lameroli Mauriz	Received

WED-171	Assessment of waist-to-height ratio as a predictor of MASLD and advanced fibrosis	Keyur Patel	Received

THU-171	The journey of MASLD: the implementation gap between guidelines and primary care in linkage to care	DAE WON JUN	Received

SAT-172	GPR84 antagonism shifts liver macrophage polarization from M1 to M2, increases liver triiodothyronine, and improves cholesterol levels and hepatic steatosis in a high-fat diet metabolic dysfunction-associated steatohepatitis mouse model	Martin Leduc	Received

THU-172	Eligibility for resmetirom or semaglutide therapy in a real-life Greek cohort of patients with metabolic associated steatotic liver disease	Margarita Papatheodoridi	Received

WED-172	External validation and recalibration of the CORE risk score to predict 10-year risk of liver cirrhosis in patients with type 2 diabetes	Rajan Paudel	Received

FRI-172	Imaging of Fibroblast Activation Protein: AZD2389 demonstrates liver target occupancy in participants with advanced chronic liver disease	Mathias Liljeblad	Received

SAT-173	Hepatoprotective effects of Efruxifermin in the CDAA-HFD mouse model of advanced MASH with?progressive fibrosis	Monika Lewinska	Received

WED-173	The relationship between liver stiffness measurement and all-cause mortality in patients with chronic liver diseases varies over time	Rajan Paudel	Received

THU-173	Estimated glomerular filtration rate and urine albumin-creatinine ratio trajectories in young adulthood and midlife metabolic-dysfunction associated steatotic liver disease: the coronary artery risk development in young adults study	Seong Park	Received

THU-174	Quantitative digital pathology reveals distinct fibrosis zonal patterns among subtypes of steatotic liver disease	Heejoon Jang	Received

FRI-174	Synergistic effects of SGLT2 inhibitors and HCV eradication on long-term MASLD improvement in patients with chronic hepatitis C and type 2 diabetes: a 3-year follow-up study	Ching-Chu Lo	Received

WED-174	Machine learning prediction of liver fibrosis in patients with metabolic dysfunction associated steatotic liver disease (MASLD)	Grazia Pennisi	Received

FRI-175	Effects of combination treatment with semaglutide, cilofexor and firsocostat on liver noninvasive tests in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis: a post hoc analysis of the WAYFIND trial	Rohit Loomba	Received

THU-175	Dynamic transitions in steatotic liver disease subtypes and risk of liver-related events: a nationwide cohort study	Yewan Park	Received

WED-175	The FIB-4 score has a stronger correlation with cardiovascular risk than other adiposity markers in patients living with obesity	Carolina M. Perdomo Zelaya	Received

TOP-176	Concurrent responses in multiple non-invasive tests for hepatic inflammation and fibrosis following pemvidutide treatment: 24-week responder analyses of the phase 2b IMPACT trial in metabolic dysfunction-associated steatohepatitis	M. Scot Roberts	Received

TOP-178	Predicting in-hospital mortality in drug-induced liver injury	Jeril Lasington	Received

THU-179	Ethnic differences in non-invasive tests, disease severity, and liver-related outcomes in a diverse Canadian population with metabolic dysfunction-associated steatotic liver disease	Keyur Patel	Received

SAT-179	Enhancing treatment of metabolic dysfunction-associated steatohepatitis: combination of GLP-1R agonist with others	Hui Li	Received

WED-179	Head-to-head comparison between FibroTest and ELF, for the fibrosis diagnostic in outpatients with type-2 diabetes, using Bayesian latent class models	Valentina Peta	Received

WED-180	Refined indicators substantially reduce the population required for screening: longitudinal validation from the European LiverScreen consortium	Jesse Pustjens	Received

FRI-180	A carbohydrate-reduced high-protein diet with whey protein supplement reduces liver fat content in weight stable patients with MASLD: Results from a randomized controlled trial	Anders Mellemkjr	Received

THU-180	Health related quality of life in steatotic liver disease patients over time: impact of extra-hepatic comorbidities	Katrina Pekarska	Received

SAT-180	Intracellular and non-immune regulatory mechanisms: molecular function of complement C3 in hepatic triglyceride metabolism	Yinling Li	Received

FRI-181	Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the ESSENCE study	Liam Gillies	Received

SAT-181	GIPC1 interacts with GPER1 to promote fatty acid oxidation and ameliorate hepatic steatosis: a novel target in MASLD	Yifang Li	Received

THU-181	Significant hepatic fibrosis identified by serologic scores is associated with a higher risk of advanced colorectal neoplasia: a case-control study	Lucía Pinzón	Received

WED-181	AGILE 3+ enhances non-invasive detection of advanced fibrosis in MASLD: comparison with FIB-4 and liver stiffness measurement	Ismail Qarch	Received

FRI-182	Semaglutide shows favourable safety across subgroups and a reassuring hepatic safety profile: Findings from ESSENCE part 1	Philip N. Newsome	Received

THU-182	The relationship between endothelial dysfunction, insulin resistance, and metabolic associated steatotic liver diseases	Kateryna Pivtorak	Received

SAT-183	Cellular membrane tension regulates liver sinusoidal endothelial cell defenestration in early MASLD	Mian Long	Received

FRI-183	Ontamalimab reduces fibroinflammatory biomarkers and liver injury signals in metabolic dysfunction associated steatohepatitis	Mazen Noureddin	Received

WED-183	High burden of hepatic steatosis, fibrosis, and cardiometabolic risk in HIV-monoinfected adults on antiretroviral therapy: STEAT-HIV results	Giulia Quartini	Received

SAT-184	Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-ß agonist ALG-055009 was administered in combination with incretin receptor agonists	Xuan Luong	Received

FRI-184	Effects of SGLT-2 inhibitors on clinical outcomes in patients with MASLD and type 2 diabetes mellitus: a nested case-control study using LIFE study data	Eiichi Ogawa	Received

WED-184	Referral strategies in intermediate-risk FIB-4 patients: can longitudinal monitoring reduce FibroScan® use without missing advanced fibrosis?	Ilaria Reiso	Received

SAT-185	The UBC13–DOK3 axis drives Kupffer cells activation and promotes metabolic dysfunction-associated steatohepatitis	Yuan-Qiang Ma	Received

THU-185	Heterogeneous vulnerability pathways in metabolic dysfunction-associated steatotic liver disease (MASLD): adiposity vs. genetic susceptibility	Mariana M. Ramírez-Mejía	Received

FRI-185	Roux-en-Y gastric bypass is associated with higher risk of major adverse liver outcomes compared with sleeve gastrectomy	Ilias Papadimopoulos	Received

WED-185	Comparison of MASLD characteristics in patients with type 1 and 2 diabetes mellitus	Donovan Richelle	Received

FRI-186	Twelve-month changes in liver function enzymes and lipids in patients receiving resmetirom	Anthony Martinez	Received

THU-186	Distinct cardiometabolic profiles drive divergent HCC risk trajectories in advanced fibrosis-affected MASLD patients	Carmine Napolitano	Received

WED-186	Combined serological testing to improve efficiency and sustainability in MASLD care	Jesús Rivera Esteban	Received

THU-187	Investigating the role of the IL-17/23 Pathway in MASLD progression	Giuseppe Rusignuolo	Received

WED-187	Routine markers for monitoring liver stiffness in patients with MASLD and low-risk fibrosis	Ying Shang	Received

SAT-188	Improving brain blood flow and reducing microglial activation as the mechanisms behind cognitive improvement following alpha 2A adrenergic receptor antagonism in a mouse model of metabolic dysfunction-associated steatotic liver disease	Anne Catrine Daugaard Mikkelsen	Received

THU-188	Age-related clinical features of metabolic dysfunction associated steatotic liver disease in a real-world cohort	Ryotaro Sakamori	Received

FRI-188	Evaluating non-invasive eligibility criteria for resmetirom in metabolic dysfunction-associated steatotic liver disease (MASLD): real-world data from an italian multicentric cohort	Nicola Pugliese	Received

SAT-189	Preventive effects of milk-derived exosomes on MASH progression through intestinal barrier protection and gut microbiota modulation	TATSUYA NAKATANI	Received

FRI-189	Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and closely associated with adiponectin induction	Mary Rinella	Received

THU-189	Ultrasound-assessed skeletal muscle quality is associated with functional and metabolic impairment in metabolic dysfunction-associated steatotic liver disease	Anna Sheptulina	Received

WED-189	Lysosomal acid lipase activity as a marker of advanced fibrosis in steatotic liver disease: a prospective study	Tarek Saadi	Received

THU-190	Decreased skeletal muscle mass is associated with an adverse metabolic profile in patients with metabolic dysfunction-associated steatotic liver disease	Anna Sheptulina	Received

SAT-190	Long-term intake of bicarbonate-sulfate-calcium-magnesium mineral water improves MASLD-related outcomes by modulating intestinal permeability, systemic inflammation, and oxidative stress	Carmine Napolitano	Received

FRI-190	A self-monitoring mobile health app is superior to lifestyle coaching and minimal intervention in reducing aspartate aminotransferase in MASLD patients: a randomised controlled trial	Geert Robaeys	Received

SAT-191	Discovery of MI-676, novel direct target of Constitutive Androstane Receptor (CAR) for therapeutic treatment of Metabolism Associated Steatotic Liver Disease (MASLD)	DHARANI SAI SREEKANTH NELLORE	Received

WED-191	Identification of advanced fibrosis in MASLD through breath fingerprinting: clinical trial results	Rifaat Safadi	Received

FRI-191	Efruxifermin improved digital pathology and noninvasive fibrosis measures in participants with MASH and advanced fibrosis or compensated cirrhosis: analysis of the HARMONY and SYMMETRY phase 2b trials	Doreen Chan	Received

THU-191	Assessment of maternal and fetal outcomes of pregnancy in metabolic associated fatty liver disease, a prospective cohort study	Hend Shousha	Received

TOP-192	Acyl-CoA synthetase long-chain family member 4 as a novel prognostic biomarker for poor outcome in drug-induced liver injury	Yu Wang	Received

TOP-193	Serum glycomics at admission predict liver transplantation-free survival in patients with acetaminophen-induced acute liver failure	Lorenz Grossar	Received

TOP-194	A novel mechanism by which the FABP4/CD36 axis exacerbates cholestasis via antagonizing FXR signaling	Yuelin Xiao	Received

WED-195	Dynamics of noninvasive tests (NITs) - LIVERFAST, FIB-4 and vibration-controlled transient elastography (VCTE, Fibroscan), during monitoring therapy with TNR-beta agonist Resmetirom (RT) in patients with MASH- update	Mona Munteanu	Received

THU-195	Phase angle cut-off values can reliably predict malnutrition in non-cirrhotic and cirrhotic MASLD patients: PhAT-LD study	aditi singh	Received

SAT-195	Rifaximin prevents metabolic dysfunction-associated steatohepatitis by suppressing deoxycholic acid-mediated macrophage-hepatocyte dialogue	Mei-Tong Nie	Received

FRI-195	A machine learning model for predicting endpoint achievement in pharmacological trials for metabolic dysfunction-associated liver disease	Farbod Semnani	Received

THU-196	Association of steatotic liver disease with pregnancy outcomes: a systematic review and meta-analysis of 75 million pregnant individuals	Jacqueline Slobin	Received

WED-196	Cell-free chromatin liquid biopsy for non-invasive MASH diagnosis and monitoring	Jenia Gutin	Received

SAT-196	Prime editing enables isogenic modeling of PNPLA3-I148M-associated lipotoxicity in hepatocytes	Haruna Noguchi	Received

FRI-197	Comparative efficacy of non-cirrhotic MASH treatments: an updated network meta-analysis of phase 2-3 candidates	N APOORVA SASIKUMAR	Received

SAT-197	Impact of PFAS on lipid metabolism in MASLD is mediated through steroids and bile acids	Matej Orešic	Received

WED-198	Velacur determined fat fraction as a tool to predict MRI-PDFF changes in patients receiving liver-directed treatment	Caitlin Schneider	Received

THU-198	Development of metabolic dysfunction-associated steatotic liver disease in patients with cryptogenic steatotic liver disease	Won Sohn	Received

FRI-198	Protective potential of minimally processed, plant-derived foods against steatotic liver disease in early adulthood	Yasmina Tashkent	Received

SAT-198	Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD	erika paolini	Received

WED-199	Phenotype-dependent failure of FIB-4 to rule-out advanced fibrosis among patients with MASLD in primary care: four-cohort comparison with LiverPRO	Abdel-Aziz Shaheen	Received

FRI-199	Effect of utreglutide on cardio-metabolic and non-invasive fibrotic biomarkers in participants with metabolic-dysfunction associated steatotic liver disease	Rajamannar Thennati	Received

SAT-200	Humanized immune system mice for preclinical modeling of liver fibrosis and metabolic dysfunction-associated steatohepatitis	Clothilde Philouze	Received

FRI-200	The impact of nutritional intervention on the echographic regression of metabolic dysfunction-associated steatotic liver disease in a cohort of postmenopausal women	Arianna Cocco	Received

FRI-201	Effect of pemvidutide on cardiovascular risk factors in patients with metabolic dysfunction-associated steatohepatitis: 48-week results from the phase 2b, IMPACT trial	Shaheen Tomah	Received

THU-201	Hormonal replacement therapy as a preventive measure in post-menopausal women with metabolic dysfunction–associated steatohepatitis	Norah Terrault	Received

WED-201	aMAP score effectively stratifies HCC risk in the steatotic liver disease population in the UK biobank	Yaru Shi	Received

SAT-201	Single-cell integration of transcriptomics and mtDNA sequencing identifies pan-cellular mosaic mitochondrial heteroplasmy as a hallmark of MASH	Carlos Pirola	Received

FRI-202	Semaglutide improves hepatic and cardiometabolic outcomes in paediatric metabolic dysfunction-associated steatotic liver disease: a prospective observational study	Andrea Tou	Received

THU-202	Association between osteoporosis and the severity of steatotic liver disease	Lea TERRIEN	Received

SAT-203	Deoxycholic acid promotes inflammation-to-cancer transition in metabolic dysfunction-associated steatohepatitis through a multi-omics identified gene signature	Wenying Qi	Received

WED-203	Two-step paediatric MASLD diagnostic approach: primary-care (PC) screening plus clinical fibrosis rule-out to select patients with progressive MASLD	Piotr Socha	Received

THU-204	Phosphatidylethanol reductions are associated with clinically meaningful improvements in blood pressure and lipid profile among patients with steatotic liver disease	Nikolaj Torp	Received

WED-204	DM-LRE score: gradient boosting machine (GBM)-based machine learning model in predicting liver-related events (LREs) in type 2 diabetes mellitus (T2DM)	Terry Cheuk-Fung Yip	Received

FRI-204	FB7033: A novel siRNA dual-targeting Hydroxysteroid 17-beta Dehydrogenase 13 (HSD17ß13) and cell death-inducing DFF45-like effector B (CIDEB) exhibits potential for treatment of metabolic dysfunction-associated steatohepatitis (MASH)	Michael Wang	Received

THU-205	Prognostic impact of chronic kidney disease and proteinuria in metabolic dysfunction–associated steatotic liver disease	Shun-ichi Wakabayashi	Received

SAT-205	JiguCao capsule alleviates metabolic dysfunction-associated steatotic liver disease through modulation of gut-liver axis and toll-like receptor 4 signaling	Wenying Qi	Received

FRI-205	SGLT2 inhibitors and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes	Axel Wester	Received

WED-205	Comprehensive risk assessment for gastrointestinal cancers in steatotic liver disease (MASLD, MetALD, and ALD)	Nobuharu Tamaki	Received

FRI-206	RNA editing of PNPLA3 I148M decreases hepatocyte fat content	Hsiu-Chiung Yang	Received

THU-206	Impact of fibrosis risk on health-related quality of life and activity in patients with metabolic dysfunction–associated steatohepatitis in Germany	Hayley Wallinger	Received

WED-206	Automated image analysis validation for MRI hepatic fat fraction quantification for steatotic liver diseases	Mark Tengowski	Received

TOP-208	Fecal microbiota transplant for alcohol use disorder in patients with cirrhosis: a randomized controlled trial	Srajit Singh	Received

TOP-209	GLP-1 RA use reduces the incidence of alcohol-associated hepatitis and risk of death in type 2 diabetes mellitus and alcohol use disorder in a routine clinical care stetting	Neha Shah	Received

TOP-210	The impact of prior bariatric surgery on patients with compensated and decompensated alcohol-related liver disease: results of an observational multicenter study	Astrid Marot	Received

SAT-211	A novel gamma-aminobutyric acid type A receptor modulator attenuates liver fibrosis with profound anti-obesity action	Elisabeth Rohbeck	Received

THU-211	Impact of small intestinal bacterial overgrowth on disease progression in metabolic dysfunction–associated steatotic liver disease	Ziteng Wang	Received

WED-211	Prognostic value of liver stiffness measurement for liver-related events in metabolic dysfunction-associated liver disease-related compensated advanced chronic liver disease	Kessarin Thanapirom	Received

THU-212	Does size matter? Think again: smartphone-ready reasoning LLMs with RAG match frontier models for MASLD clinical decision support	ISMAEL YEPES	Received

SAT-212	Modulation of interactions between mitochondria and the endoplasmic reticulum by resmetirom in MASLD	Théo ROUSSEAUX	Received

WED-212	Circulating extracellular vesicles and ferritin enable machine learning based detection of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease	Eleni Trifylli	Received

SAT-213	Multimodal analysis bridges liver histological features identified by AI based digital histology tools and -omic signatures in a Japanese MASH cohort	Banishree Saha	Received

THU-213	Global economic burden of metabolic dysfunction–associated steatohepatitis (MASH) in individuals with type 2 diabetes (T2D) across nine countries	Zobair M. Younossi	Received

WED-213	Hepatic antifibrotic response by fibrogenesis markers in patients with MASLD undergoing a 6-month randomized dietary trial	Lorenza Vaira	Received

THU-214	Integrated risk stratification for all-cause and cause-specific mortality in a large MASLD cohort in Taiwan	Ming-Lung Yu	Received

SAT-214	PARP1 rs747657 C>G variant protects against metabolic dysfunction in MASLD	Miriam Longo	Received

WED-214	Validation of clinical care pathways for detecting significant fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD): an individual patient data meta-analysis	Kirsi van Eekhout	Received

THU-215	GCKR rs1260326, dietary factors and incident liver-related events in patients with metabolic dysfunction-associated steatotic liver disease	Ziqi Zhang	Received

SAT-215	PFOA exposure promotes lipid peroxidation–driven inflammatory niche formation in a metabolically vulnerable liver	Wenhua Shao	Received

WED-215	Simplified metabolic dysfunction associated fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis	Laurens Van Kleef	Received

WED-216	Evaluating non-invasive screening strategies for identifying treatment-eligible fibrotic MASH in MASLD patients	Laurens Van Kleef	Received

THU-216	Evaluating gastrointestinal bleeding risks and esophagogastroduodenoscopy requirement in low-risk hepatocellular carcinoma patients undergoing atezolizumab and bevacizumab: interim analysis	Laia Aceituno	Received

WED-217	State-transition models of MASLD progression in economic evaluation: an updated systematic review	Rohan Vijjhalwar	Received

THU-217	The VETC-associated trabecular subtypes in non-cirrhotic HCC is defined by loss of tumor suppressor and downregulation of ribosomal genes	Khushboo Agrawal	Received

FRI-217	Real-world effectiveness of Durvalumab plus Tremelimumab in hepatitis C-associated hepatocellular carcinoma: an Egyptian multicenter cohort study	Mohamed AbdAllah	Received

SAT-218	Trace copper exposure within drinking water standards exacerbates liver injury in metabolic dysfunction	Koichi Tsuneyama	Received

FRI-218	Digital twin–based in-silico randomized trial evaluating immunotherapy plus TARE versus immunotherapy alone in advanced hepatocellular carcinoma	Joseph Ahn	Received

THU-218	Predicting transcatheter arterial chemoembolization response in hepatocellular carcinoma using a two-stage imaging framework with automated liver segmentation and bidirectional temporal difference modeling	Geng-Hao Bai	Received

WED-219	LiverPRO prediction reflects fibrogenic activity in patients with metabolic dysfunction-associated steatohepatitis by identifying patients with elevated PRO-C3	Ying-Wooi Wan	Received

FRI-219	Biological oncological resectability for treatment selection in hepatocellular carcinoma	Kenta Aso	Received

SAT-219	Hepatic 5-HT2B receptor antagonism mediates the anti-steatotic and antifibrotic effects of psilocybin in preclinical MASH models	Anna Signor	Received

THU-219	The IL-7 rs16906115 single nucleotide polymorphism alters the risk for the development of treatment-related AEs in patients with HCC treated with immunotherapy	Lorenz Balcar	Received

WED-220	A distinct aromatic catabolism enterotype of the gut microbiome in metabolic dysfunction associated steatotic liver disease with type 2 diabetes	Jakob Weglage	Received

FRI-220	Changing trends in disease severity and advances in treatments of hepatocellular carcinoma in Germany from 2005 to 2019: a nationwide population-based study	Josune Cabello Calleja	Received

THU-220	Diagnostic and prognostic performance of non-invasive tests for portal hypertension in patients with advanced chronic liver disease and hepatocellular carcinoma – a Baveno cooperation-endorsed European study	Lorenz Balcar	Received

FRI-221	Similar overall survival but distinct response and safety profiles with Atezolizumab-Bevacizumab versus Durvalumab-Tremelimumab in advanced HCC	Claudia Campani	Received

SAT-221	Liver-specific deletion of Gpr146 and Angptl3 reduces plasma lipids and prevents development of diet-induced hepatic steatosis in mice	Umesh Tharehalli	Received

THU-221	Blood- and liver stiffness-based noninvasive tests for clinically significant portal hypertension in patients with compensated advanced chronic liver disease and hepatocellular carcinoma	Lorenz Balcar	Received

WED-221	Understanding the metabolic burden among people with fibrosis and evaluating the implementation of the EASL clinical care pathway in China using the Meinian database	Siyun Wang	Received

TOP-222	Alcohol-related liver disease with latent fibrosis: an indolent phenotype in abstinent patients	David Heitmann	Received

TOP-224	Inhibition of protein kinase C-? as a strategy to overcome steroid resistance in severe alcohol-related hepatitis	Neha Sharma	Received

WED-225	Real-world liver fibrosis screening patterns of adults with type 2 diabetes and cirrhosis: a population-based Canadian cohort	Cindy Wen	Received

FRI-225	Durvalumab–Tremelimumab in advanced hepatocellular carcinoma: real-world data From the LOR-HCC (Lombardy, Italy real-world HCC group)	Lorenzo Canova	Received

SAT-225	A patient-derived hepatocyte organoid model for testing antioxidant strategies in paediatric metabolic dysfunction-associated steatotic liver disease	Francesca Tiano	Received

WED-226	Social determinants of health shape all-cause mortality risk in steatotic liver disease: a machine learning analysis	Cindy Wen	Received

SAT-226	Annexin A1 deficiency exacerbates hepatic metabolic and oxidative dysregulation in streptozotocin-induced diabetic mice	Diego Santos	Received

FRI-226	Multimodal deep learning for predicting early progression in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab	Ciro Celsa	Received

THU-226	Long-term survival and cure fraction in advanced hepatocellular carcinoma under immunotherapy in randomized controlled trials and real-world data	Claudia Campani	Received

SAT-227	Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase inhibitor and resmetirom combination in LDL receptor knockout MASH mice	Wen-Wei Tsai	Received

FRI-227	Multimodal deep learning for therapeutic decision support in hepatocellular carcinoma: integrating clinical data and computed tomography imaging	Ciro Celsa	Received

THU-227	Predicting decompensation in unresectable hepatocellular carcinoma on immunotherapy: the ARTE score	Lorenzo Canova	Received

SAT-228	Sex-specific systemic inflammatory responses to high-fat diet are shaped by hepatic estrogen receptor alpha signalling	Hio Lam Tsou	Received

FRI-228	Dose–response relationship and clinical outcomes after Yttrium-90 transarterial radioembolization for hepatocellular carcinoma: GALAXY-90 study	Kaina Chen	Received

THU-228	Liver and spleen MRI changes as predictors of hepatocellular carcinoma in patients with HCV-related cirrhosis and undefined liver nodules after DAA therapy	Luisa Cavalletto	Received

WED-228	Prevalence of advanced liver fibrosis among first-, second-, and third-degree relatives of patients with MASLD-related advanced fibrosis	ISMAEL YEPES	Received

SAT-229	Effects of farnesoid X receptor activation on the cellular microenvironment of human adipose tissue in metabolic disease	Lena Vosko	Received

FRI-229	Application and evaluation of whole process management model for liver cancer patients undergone Yttrium-90 selective internal radiation therapy (Y-90 SIRT): a retrospective cohort study	Xiaolong Chen	Received

WED-229	Referral burden and second-tier testing in two-step algorithms for detecting significant hepatic fibrosis among Asian community-based type 2 diabetes mellitus	DAE WON JUN	Received

THU-229	A dynamic model incorporating longitudinal alpha-fetoprotein and globulin trajectories to predict early recurrence in early-stage hepatocellular carcinoma	Minghui Zhu	Received

SAT-230	Multi-Omics analyses of fetal hepatoblasts reveal interferon-regulatory factor 9 as a female-biased master modulator of lipotoxicity and antioxidant defense	Jonas Vo	Received

FRI-230	Impact of palliative care on end-of-life healthcare utilization among Asian patients with hepatocellular carcinoma	Matthew Shing Hin Chung	Received

SAT-231	Artificial intelligence for characterisation of inflammation in chronic liver disease	Dylan Windell	Received

FRI-231	Clinical determinants of survival beyond two years in HCC patients receiving non-curative treatment	Burcu Gurbuz	Received

THU-231	Prognostic impact of geriatric nutritional risk index (GNRI) in patients with BCLC stage 0 hepatocellular carcinoma	Li-Chang Chen	Received

WED-231	Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: a multicenter cross-sectional study	Mirko Zoncapè	Received

FRI-232	Imaging-detected immune-related adverse events and clinical outcomes during Atezolizumab–Bevacizumab therapy in unresectable hepatocellular carcinoma: a dual-center study	Subin Heo	Received

THU-232	Diagnostic, screening, and longitudinal performance of des-gamma-carboxy prothrombin as a biomarker for hepatocellular carcinoma	Mateo Chvatal-Medina	Received

WED-232	TP53/ARID1A-driven macrotrabecular and TERT/BAP1-enriched microtrabecular tumors represent two distinct histomorphological subtypes of non-cirrhotic hepatocellular carcinoma	Khushboo Agrawal	Received

SAT-233	Chemical conjugation of Myrcludex B and Triiodothyronine for liver-specific targeting	Dandan Wu	Received

FRI-233	pretreatment neutrophil-to-lymphocyte ratio as a predictive marker for tumor response to Atezolizumab plus Bevacizumab in hepatocellular carcinoma: a multicenter retrospective study	Young Mi Hong	Received

THU-234	Core diagnostic value of DCP and validation of the novel GADAA nomogram for HBV-related hepatocellular carcinoma	zihan liu	Received

WED-234	Identification of novel therapeutic agents using patient-derived organoids in HCC	Reha Akpinar	Received

FRI-234	Transjugular intrahepatic portosystemic shunt as a bridging strategy to hepatocellular carcinoma treatment in patients with refractory ascites or hydrothorax	Camille Imparato	Received

FRI-235	Antiviral therapy and post-resection outcomes in patients with hepatitis B virus-related hepatocellular carcinoma	Hye Won Lee	Received

THU-236	Natural history of indeterminate liver lesions detected by MRI in liver cirrhosis: predicting progression to hepatocellular carcinoma	Thomas Dominicus	Received

WED-236	Baseline tumor and circulating gamma/delta T-Cell signatures and early on-treatment CD8?PD-1? T-Cell expansion predict response to Atezolizumab–Bevacizumab in hepatocellular carcinoma	Manon Allaire	Received

FRI-236	Identification of serum proteomic signatures for predicting clinical outcomes of immunotherapy in advanced hepatocellular carcinoma	Jihoon Kim	Received

WED-237	Spatially resolved multi-omic analysis reveals metabolic niche-dependent regulatory T cell programs in hepatocellular carcinoma	Leonard Bellersheim	Received

FRI-237	First-line therapy in super-older adults with hepatocellular carcinoma: comparative effectiveness of Lenvatinib versus Atezolizumab-Bevacizumab	Masamichi Kimura	Received

THU-237	Hepatocellular carcinoma risk prediction score : a novel artificial intelligence model for hepatocellular carcinoma risk assessment in hepatitis C patients	Eslam Elmasry	Received

SAT-237	Pemafibrate attenuates liver fibrosis and reduces predicted gut lipopolysaccharide biosynthesis and mucin degradation in a metabolic dysfunction-associated steatohepatitis rat model	Yasunori Yamamoto	Received

THU-238	Anticipated patient responses to reviewing abnormal hepatocellular carcinoma imaging results: a descriptive analysis	Dabel Emebo	Received

FRI-238	Conversion surgery after immunotherapy in hepatocellular carcinoma: a French multicentric retrospective study	Shinha-Ashkarr Kouadou	Received

THU-239	Real-world validation of the GAAD algorithm for hepatocellular carcinoma detection across aMAP-defined risk strata in large-scale prospective Chinese cohorts	Rong Fan	Received

FRI-239	Functional convergence towards short chain fatty acid metabolism shapes responsiveness to atezolizumab plus bevacizumab across Western and Eastern populations despite distinct gut microbial composition	Pei-Chang Lee	Received

SAT-239	STING aggravates liver fibrosis in chronic hepatitis B concurrent with metabolic dysfunction-associated steatotic liver disease by modulating gut microbiota and inducing macrophage-derived lysozyme expression	Xiaojing Wang	Received

FRI-240	Clinical utility of tumor morphology for predicting aggressive and hyperaggressive recurrence after curative resection of hepatocellular carcinoma	I-Cheng Lee	Received

WED-240	Liquid biopsy for the detection of hepatocellular carcinoma.	Lauren Brotherton	Received

SAT-240	Development of a novel animal model for acute-on-chronic liver failure in metabolic dysfunction-associated steatotic liver disease: highlighting the critical role of neutrophil	Rui Zhao	Received

THU-240	Remaining chronic hepatitis C treatment gaps impact on the care cascade of HCV relatedhepatocellular carcinoma	Joan Flores	Received

THU-241	Temporal trends of hepatocellular carcinoma and utilization of various abdominal imaging modalities in the United States	Pareen Vora	Received

WED-241	Mechanical cues from fibrotic liver matrix rewire mitochondrial dynamics in hepatocellular carcinoma	Alicia Calé	Received

THU-242	18F-Fluorodeoxyglucose positron emission tomography is a predictive factor of early response to atezolizumab-bevacizumab in patients with hepatocellular carcinoma	Maria Stella Franzè	Received

SAT-242	ZEB2 promotes the progression of MASLD by inducing neutrophil extracellular traps formation	Guangqi Zhu	Received

WED-242	Single-cell RNA sequencing HCC-based atlas reveals CAFs as predictors of immunotherapy resistance	Guillem Cano Segarra	Received

SAT-243	Platelet phenotype and function throughout the spectrum of metabolic dysfunction-associated steatotic liver disease	Mirko Zoncapè	Received

FRI-243	Neoadjuvant radiotherapy combined with lenvatinib and pd-1 blockade in resectable intrahepatic cholangiocarcinoma at high risk of recurrence: a prospective phase II study	Keren Li	Received

WED-244	Generation and characterization of a murine BRAF V600E driven cholangiocarcinoma model	Shreya Chakraborty	Received

SAT-244	Dysregulation of the urea cycle enzymes determines a more severe MASLD phenotype in a DIAMOND preclinical model	Carola Zurita Palomo	Received

FRI-244	Efficacy of second-line therapies and the prognostic value of the crafity score in advanced hepatocellular carcinoma following Atezolizumab plus Bevacizumab failure: a real-world study	Jinpeng Li	Received

THU-245	Anti-HBc positivity is associated with worse tumour features and reduced survival in HBsAg-negative patients with hepatocellular carcinoma	Maria Stella Franzè	Received

WED-245	Differential NK cell residency and immunosuppressive ILC remodeling define subtype-specific tumor-microenvironments in cholangiocarcinoma	Sachin Kumar Singh Chauhan	Received

SAT-245	High prevalence of low muscle strength and low muscle mass in primary biliary cholangitis: a multimodal assessment including muscle ultrasound	Luise Aamann	Received

FRI-245	Radiotherapy with Atezolizumab and Bevacizumab and Survival in Advanced Hepatocellular Carcinoma	Gyungsun Lim	Received

FRI-246	Multi-omics analysis of combined immunotherapy - chemotherapy benefit in advanced intrahepatic cholangiocarcinoma	Xuanchen Liu	Received

THU-246	Machine learning-enhanced serum FTIR spectroscopy analysis for diagnosing hepatocellular carcinoma in cirrhotic patients	Elia Gigante	Received

SAT-246	High burden of depression, sleep disturbance, and anhedonia in primary biliary cholangitis independent of fibrosis stage and prognostic scores	Gupse Adali	Received

SAT-247	Treatment adherence predicts lower risk of disease progression among patients with primary biliary cholangitis in the United States	Diane Ito	Received

WED-247	Multi-ancestry genome-wide association meta-analysis of hepatocellular carcinoma identifies eight novel risk genes including MYC, MAP3K9, DHRS1, and MTTP	Jake Mann	Received

THU-247	Impact of Hepatocellular Carcinoma on circulating reticulated platelets in patients with and without liver cirrhosis	pietro guerra	Received

WED-248	Circulating miRNAs as predictive biomarkers of response to immunotherapy in hepatocellular carcinoma (HCC)	Salvatore Corallo	Received

SAT-248	Recompensation and further decompensation after index decompensation in patients with autoimmune hepatitis: a real-world study	Arnav Aggarwal	Received

FRI-248	The prognostic role of the SMARS score in patients with hepatocellular carcinoma receiving Atezolizumab/Bevacizumab	Aline Mähringer-Kunz	Received

THU-248	Hepatocellular carcinoma imaging using prostate-specific membrane antigen positron emission tomography - The Hepa-SMART trial	Nicholas Hannah	Received

WED-249	From primary tumor to metastasis: stemness dynamics in intrahepatic cholangiocarcinoma	Margherita Correnti	Received

THU-249	Would a non-imaging-based strategy be effective for hepatocellular carcinoma surveillance?	Grishma Hirode	Received

SAT-249	Plasma C4 as a potential biomarker of cholangiocarcinoma in primary sclerosing cholangitis	Ina Andersen	Received

FRI-249	Real-world outcomes of sequential transarterial chemoembolization followed by Atezolizumab–Bevacizumab in patients with unresectable hepatocellular carcinoma	Soe Thiha Maung	Received

SAT-250	Long-term biochemical response is associated with a lower risk of decompensation in autoimmune hepatitis, irrespective of non-selective beta-blocker use	Pinelopi Arvaniti	Received

FRI-250	Integrating locoregional therapies with immune checkpoint inhibitors may improve outcomes in advanced HCC	Mzamo Mbelle	Received

WED-250	Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole	Emilie Crouchet	Received

THU-250	The impact of insulin resistance on hepatic steatosis and outcome for hepatocellular carcinoma patients undergoing surgical resection	CHUN-TING HO	Received

FRI-251	Favourable clinical outcomes with immunotherapy in patients with mismatch repair–deficient/microsatellite instability–high biliary tract cancers: investigation from a multicenter real-world cohort	Katharina Mitzlaff	Received

WED-251	Impact of dual immune checkpoint blockade on the tumor immune microenvironment and determinants of therapeutic response in hepatocellular carcinoma	Kazuma Daiku	Received

THU-251	Cuproptosis related atherosclerosis in Wilson´s disease	Soner Altin	Received

SAT-251	S-adenosyl-L-methionine improves health-related quality of life in patients with primary sclerosing cholangitis and inflammatory bowel disease: a subanalysis of a randomized, placebo-controlled trial	Emil Bik	Received

WED-252	Platelet-induced mitochondrial transfer promotes hepatocellular carcinoma progression	Shuangsuo Dang	Received

FRI-252	First-line Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in Egyptian patients with unresectable hepatocellular carcinoma: a retrospective real-world study	Ehab F. Moustafa	Received

THU-252	Liver stiffness in amyloid light-chain amyloidosis: interest in diagnosis and prognosis	Paul CARRIER	Received

SAT-252	Baseline anti-mitochondrial antibody titre in addition to gamma-glutamyltranspeptidase and alanine-aminotransferase serum levels anticipate future primary biliary cholangitis development	Davide Bitetto	Received

FRI-253	Tumour seeding with percutaneous radiofrequency ablation of primary hepatocellular carcinoma	Stephen Congly	Received

SAT-253	Changes in the clinical presentation of primary biliary cholangitis over the years in a university center in Argentina	Matías Bori	Received

WED-253	Modeling human innate and adaptive immunity in hepatocellular carcinoma: evaluating anti-IL-8 and anti-PD-L1 immunotherapy in humanized mice	Zenzi De Vos	Received

THU-253	Study of the prevalence of hereditary hemochromatosis (HFE) and secondary causes of hiperferritinemia in patients participating in a bloodletting programme	Agustin Castiella	Received

WED-254	UCHL1 inhibition by LDN57444 potentiates sorafenib response in hepatocellular carcinoma: a preclinical study	Kylian Decroix	Received

SAT-254	Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment	Allison Yankey	Received

FRI-254	To better predict hepatic decompensation during immunotherapy for advanced hepatocellular than with Child-Pugh and ALBI: development and validation of a predictive model, an international multicentre study	Massih NINGARHARI	Received

THU-254	Genotypic spectrum and clinical presentation of Wilson disease in a Brazilian cohort	Maria Chiara Chindamo	Received

WED-255	High regeneration-associated stress defines a distinct HCC subgroup with therapeutically exploitable vulnerabilities	Nina Desboeufs	Received

FRI-255	Sub-stratification of Child-Pugh B patients and dynamic evolution of liver function revealed differential benefit from atezolizumab/bevacizumab in unresectable hepatocellular carcinoma	Anne Victoire Odent	Received

THU-255	Dynamic changes in liver stiffness during anti-copper therapy in wilson disease: a longitudinal cohort study	Maria Chiara Chindamo	Received

THU-256	Diagnostic performance of a targeted next-generation sequencing cholestasis-gene panel in adults with unexplained cholestatic liver disease: results from a multicenter Italian cohort study	Daphne DAmato	Received

SAT-256	Biochemical changes and clinical outcomes after obeticholic acid withdrawal in patients with primary biliary cholangitis	Paloma Elma Alañón-Martínez	Received

FRI-256	Durable response is associated with long-term survival even in patients with poor hepatic reserve after Atezolizumab plus Bevacizumab: a multicenter 3-year overall survival cohort with a 6-month landmark analysis	Masatsugu Ohara	Received

WED-256	Loss of secreted and transmembrane protein 1 modulates drug sensitivity and resistance in hepatocellular carcinoma	Cyrollah Disoma	Received

SAT-257	Serum metabolomic signatures for cirrhosis detection and prediction in primary sclerosing cholangitis	Elisa Catanzaro	Received

FRI-257	Serum TGF-ß1 and IDO1 kinetics for the prediction of clinical outcomes among first-line immunotherapy treated patients with hepatocellular carcinoma	Spyridon Pantzios	Received

SAT-258	Distinct disease phenotypes in primary biliary cholangitis according to extrahepatic comorbidities: results from the Italian national PBC registry	Nora Cazzagon	Received

THU-258	Familial intrahepatic cholestasis protein 1 (FIC1) deficiency: surgical biliary diversion improves native liver survival only in patients with relatively low serum bile acid levels in early life	Alise de Groot	Received

WED-258	Hepatic fibrosis–driven tissue factor expression by malignant cholangiocytes is associated with cancer-associated thrombosis and poor survival in intrahepatic cholangiocarcinoma	Luca Fabris	Received

THU-259	Clinical characteristics of alpha-1 antitrypsin deficiency patients and coexistence of metabolic dysfunction-associated steatotic liver disease	Maria Del Barrio	Received

WED-260	Generation and characterisation of a novel Synthetic Notch chimeric antigen receptor (CAR) T cells targeting hepatocellular carcinoma.	Yudi Gao	Received

THU-260	Ileal bile acid transporter (IBAT) inhibitor therapy in adults with hereditary bile salt export pump (BSEP) deficiency: a case series	Carola Dröge	Received

SAT-260	True seronegative autoimmune hepatitis in adults is rare and overestimated	Francesca Colapietro	Received

FRI-260	RTY-406 is a dual-acting ABCB4/MDR3 and ABCB11/BSEP positive functional modulator that demonstrates efficacy in a model of primary sclerosing cholangitis	Eric Bell	Received

FRI-261	RTY-406, a candidate drug for primary sclerosing cholangitis (PSC), a dual-acting ABCB4/MDR3 and ABCB11/BSEP positive functional modulator, demonstrates target modulation in non-human primates	Eric Bell	Received

THU-261	Structured transition care program for chronic liver disease: a 6-Year clinical audit demonstrating superior outcomes	Victoria Ekstrom	Received

THU-262	Baseline fibrosis stage predicts risk of progression in patients with alpha-1 antitrypsin deficiency and a protease inhibitor (Pi)*ZZ/SZ genotype: longitudinal data from the Birmingham AATD registry	Virginia C. Clark	Received

WED-262	Role of the NADPH oxidase 4 in regulating endoplasmic reticulum stress and autophagy in liver tumor cells	Gemma Gonfaus Ortiz	Received

FRI-262	Pathogenic MUC1? cholangiocytes drive fibrogenic crosstalk via the EFNA5–EPHA2 axis in cholestatic liver injury	Aishwarya Bhatnagar	Received

SAT-262	Geographic heterogeneity in primary biliary cholangitis across Latin America: results from ALLATIN cohort	Claudia Couto	Received

SAT-263	Fibrates outperform obeticholic acid in biochemical response at the cost of higher early discontinuation: insights from the Italian PBC registry	Laura Cristoferi	Received

FRI-263	Mosaic X chromosome loss is more frequent in primary biliary cholangitis but does not influence transplant-free survival	Chiara Caime	Received

THU-263	Age-stratified genetic testing for liver disorders improves diagnostic yield and clinical impact in pediatric and adult patients	Angelo Corso Faini	Received

WED-263	Cirrhotic MASLD-HCC exhibits distinct immunosuppressive traits within the tumor microenvironment and is associated with poorer outcomes in patients treated with atezolizumab-bevacizumab	Albert Gris-Oliver	Received

THU-264	Liver disease manifestations in signal transducer and activator of transcription 1 gain-of-function mutation	Sawsan Fathma	Received

SAT-264	Metabolic dysfunction–associated steatotic liver disease drives a high-risk phenotype in autoimmune hepatitis. Results from the COLHAI registry	Elena Gómez-Domínguez	Received

WED-264	A glypican-3 targeted chimeric antigen receptor T cell product secreting programmed cell death ligand 1 and vascular endothelial growth factor blockers shows durable tumor shrinkage in advanced hepatocellular carcinoma	XIAOWEN HE	Received

SAT-265	Primary biliary cholangitis with concurrent metabolic dysfunction-associated steatotic liver disease demonstrates comparable biochemical response to ursodeoxycholic acid: results from the ELLA-PBC cohort	Lily Dara	Received

WED-265	Spatial profiling of the tumour immune microenvironment in hepatocellular carcinoma identifies regulatory T cell–mediated immune exclusion	Nicholas Hannah	Received

FRI-265	Acetylcholine-producing B cells regulate regulatory T-cell function within the bile duct ligation–induced fibrotic liver microenvironment	Nastaran Fazel Modares	Received

THU-265	Quantitative histological evaluation reveals duct paucity in children with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)	Malin Fromme	Received

THU-266	Natural history of liver disease in patients with alpha-1 antitrypsin deficiency and a protease inhibitor (Pi)*ZZ genotype: data from the Alpha-1 liver network in Germany	Hannah Woodley	Received

FRI-266	Identification of molecular targets from the interactome of primary sclerosing cholangitis and their therapeutic modulation	Claudia Fuchs	Received

SAT-266	Cirrhosis progression in primary biliary cholangitis is higher among hispanic patients: results from the ELLA-PBC cohort	Lily Dara	Received

SAT-267	Hepatic hilar lymphadenopathy identifies advanced fibrosis in primary biliary cholangitis	YOUNESS DENDANE	Received

WED-267	Single-Cell RNA sequencing identifies molecular concordance between circulating tumor cells and primary tumor nuclei in hepatocellular carcinoma	Mónica Higuera	Received

FRI-267	Modelling the reactive cholangiocyte phenotype in cholangiopathies using human biliary organoids for evaluation of novel therapeutic compounds	Fabian Heinreichsberger	Received

THU-267	Liver biopsy lesions in Wilson disease: relationship with copper metabolism, clinical and biochemical outcomes, phenotypes and the most frequent mutations. Data from the Spanish AEEH Wilson registry	Luis García-Villarreal	Received

WED-268	Generalist SAM based foundation models outperform medically fine-tuned variants in dynamic liver ultrasound segmentation	Janik Hohmann	Received

FRI-268	T helper cells influence the fate decision of facultative liver stem cells	Ben Higgins	Received

SAT-268	Reassessing the utility of the Ferritin-IgG score in predicting complete biochemical response in patients with autoimmune hepatitis from the ColHai registry: is it truly useful?	Alvaro Diaz-Gonzalez	Received

THU-268	Portal cavernoma may develop during the course of porto-sinusoidal vascular disorder	Mathilde GUERILLOT	Received

SAT-269	Second-line treatment with novel PPAR agonists in patients with primary biliary cholangitis: real-world experience from a european tertiary care center	Miriam M. Düll	Received

WED-269	A serum-based biomarker of type VI collagen degradation (C6M) is associated with increased risk of hepatocellular carcinoma development	Andressa de Zawadzki	Received

FRI-269	Reactive biliary epithelial cells interact with liver macrophages through GAS6-AXL signaling pathway during cholestasis	Tian Lan	Received

THU-269	Haemodynamic alterations associated with hepatic vascular malformations in hereditary haemorrhagic telangiectasia: a cohort study	Pernille Darre Haahr	Received

THU-270	Biochemical response is associated with liver stiffness stability in patients with primary biliary cholangitis treated with seladelpar for up to 3 years in the ongoing open-label ASSURE study	Abigail Dobies	Received

WED-270	From transporter to oncogenic driver: N-linked glycosylation enhances oncogenic capabilities of SLC29A2 in hepatocellular carcinoma	Yu-Hsuan Hsu	Received

SAT-270	Interleukin-17 blockade in primary sclerosing cholangitis: results from the SABR-PSC pilot study	Amera Elzubeir	Received

SAT-271	Efficacy and tolerance of second line treatments for autoimmmune hepatitis: a multicentric french real life FILFOIE study	Domitille Erard	Received

FRI-271	Long-term effects of antibiotics in promoting liver fibrosis during cholestatic liver disease	Cristina Lumbreras Perales	Received

WED-271	Circulating lipid signatures drive mitochondrial stress and inflammatory remodelling in non-cirrhotic MASLD-associated hepatocarcinogenesis	Jian Huang	Received

SAT-272	Spleen stiffness predicts clinical event-free survival in primary biliary cholangitis: a prospective cohort study	Ilkay Ergenc	Received

THU-272	The pharmacokinetic profile of a new trientine tetrahydrochloride formulation supports simpler once-daily dosing for the treatment of wilson disease: results of the triumph-3 study	C.Omar Kamlin	Received

FRI-272	Methyldopa reduces plasma bile acid concentrations in a murine model of estrogen-induced cholestasis	Dina Manna	Received

WED-272	Enhanced detection of hepatocellular carcinoma using combined biomarker panels including alpha-fetoprotein, alpha-fetoprotein-L3, des-gamma-carboxyprothrombin and the galad score	Van Trung Huynh	Received

WED-273	Cathepsin A promotes immune evasion in hepatocellular carcinoma by driving tumor-associated macrophage polarization	Jie Jiang	Received

THU-273	Has the clinical profile of hypoxic hepatitis changed over the past decades?	Edeline Kaze	Received

SAT-273	Clinical outcomes of mycophenolate mofetil as first-line therapy in autoimmune hepatitis: a real-world cohort study	Rut Fernández Bezanilla	Received

FRI-273	Increased miR-27b expression in early primary biliary cholangitis impairs mitophagy via prohibitin-2 suppression	Malgorzata Milkiewicz	Received

FRI-274	Myeloid deletion of SIRT1 exacerbates cholestasis-induced liver disease by promoting inflammation and fibrosis in mice	Mar Moreno-Gonzalez	Received

THU-274	Exploring pregnancy among Wilson disease patients in Europe: results from an exploratory survey to patients from the ERN RARE-LIVER consortium	Paulina Kremser	Received

WED-274	Investigating the immunomodulatory role of the extracellular matrix in hepatocellular carcinoma	Kavitha Kirubendran	Received

SAT-274	Long term prognostic impact of persisting histological activity despite biochemical remission in autoimmune hepatitis (AIH)	Sarah Flatley	Received

WED-275	Longitudinal elevation of IL-10 following atezolizumab plus bevacizumab is associated with favorable response and survival in advanced hepatocellular carcinoma	Jung Hyun Kwon	Received

THU-275	Baseline characteristics of patients enrolled in an international Wilson disease registry: a cross-sectional analysis of study entry data	Farah Lawrence-Wilde	Received

SAT-275	Long-term extrahepatic mortality in autoimmune hepatitis: a cohort study	Sarah Flatley	Received

FRI-275	Disease-specific microbiome signatures distinguish primary sclerosing cholangitis from inflammatory bowel disease	Burcin Özdirik	Received

SAT-276	Association Between Low-Dose Aspirin Initiation and Cancer Risk in Patients With Autoimmune Liver Disease	Paulina Flis	Received

THU-276	Safety of infliximab in sarcoidosis and effect on hepatic involvement – a retrospective cohort study	Elizabeth Low	Received

FRI-276	Modelling biliary epithelial responses to microbial signals using a bile duct on a chip platform	Sarah Peisl	Received

TOP-277	Real-world effectiveness and safety of seladelpar in primary biliary cholangitis: a nationwide electronic health record-based study	Adrielly Martins	Received

TOP-278	Factors associated with the development of primary biliary cholangitis in individuals with antimitochondrial antibodies: a spanish multicenter study	Alvaro Diaz-Gonzalez	Received

TOP-279	Male patients with autoimmune hepatitis have lower rates of treatment response and higher risk of liver-related events: a multicenter nationwide longitudinal study of 2000 patients	Ellina Lytvyak	Received

TOP-280	Long-term safety, tolerability and maintenance of efficacy of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis	Christopher Bowlus	Received

TOP-281	Real world outcomes of primary biliary cholangitis in Latin America	Claudia Couto	Received

THU-282	Spectrum of hepatic nodules and hepatocellular carcinoma in Fontan-associated liver disease: a real-world cohort	Camilla Mancini	Received

WED-282	Visualizing and quantifying brain copper retention in Wilson disease models: a 64Cu PET study	Nicole Antolini	Received

SAT-283	Unmet needs of patients with primary biliary cholangitis in Greece: results from the preliminary analysis of the Hellenic autoimmune liver diseases study group	Nikolaos Gatselis	Received

THU-283	Exploring pregnancy among Wilson disease patients in Europe: results from a health-care providers´ exploratory survey from the ERN RARE-LIVER consortium	Zoe Mariño	Received

WED-283	Loss of STN1 expression due to bi-allelic intronic mutations induces a pro-inflammatory liver sinusoidal endothelial cell phenotype and drives porto-sinusoidal vascular disease development	Lise Bertin	Received

THU-284	Missense variants in the ABCB11 gene and disease severity in patients with bile salt export pump deficiency	Mark Nomden	Received

SAT-284	Outcomes of cirrhotic patients at the presentation of autoimmune hepatitis and the role of biochemical response as a predictor of survival	Elze Maria Gomes Oliveira	Received

FRI-284	A novel therapeutic strategy for cholemic nephropathy: mineralocorticoid receptor antagonists attenuate bile acid–induced renal injury in vivo and in vitro via the rac1–mineralocorticoid receptor pathway	Sigrid Schulte	Received

WED-284	High copper levels induce oxidative stress and inflammatory processes in a cell culture model of Wilson´s disease	Ruth Broering	Received

THU-285	Alpha-1 foundation research registry: highlighting pulmonary manifestations among liver-affected alpha-1 antitrypsin deficiency patients in the United States	Nadine Nuchovich	Received

FRI-285	Thioredoxin reductase 1 regulates the nucleotide binding oligomerization domain containing 2-receptor interacting serine/threonine kinase 2 signaling pathway during cholestatic liver injury	Colin Shearn	Received

WED-286	Exploring the role of the c.41_40dup heterozygous UGT1A1 variant as an alternative polymorphism impacting on young-adult cryptogenic cholestasis phenotype	Fiammetta Di Nardo	Received

THU-286	Immunological landscape of autoimmune hepatitis: clinical insights from a retrospective cohort of 48 patients	dahri ouafae	Received

SAT-286	Burden of recurrent primary sclerosing cholangitis (PSC), re-transplantation, and explant malignancy in a globally representative cohort of patients of >1500 PSC patients undergoing liver transplant	Aliya Gulamhusein	Received

FRI-286	cfChIP-seq liquid biopsy distinguishes autoimmune hepatitis from other liver diseases	Nir Friedman	Received

THU-287	Machine learning–based prediction of immunosuppressive treatment response in autoimmune hepatitis	Azzaoui Oumaima	Received

SAT-287	Efficacy and safety of seladelpar in patients with primary biliary cholangitis and cirrhosis, including those with clinical signs of portal hypertension: interim results from the open-label ASSURE study with up to 4 years of treatment	Allison Yankey	Received

FRI-287	Renal apical sodium-dependent bile acid transporter (ASBT) inhibition increases whole-body bile acid clearance in healthy pigs by enabling renal elimination as quantified by 11C-CSar PET/CT	Michael Srensen	Received

WED-287	Hepatocyte-specific CNNM4 silencing alleviates liver injury in alpha-1 antitrypsin deficiency	Nerea Ferreiro	Received

SAT-288	Increased risk of non-Hodgkin lymphoma in autoimmune hepatitis: a large retrospective cohort study	Rawi Hazzan	Received

WED-288	Utility of mRNA analysis in nasopharyngeal brushings from Wilson disease patients and carriers of ATP7B mutations to detect alterations in gene splicing	Luis García Villarreal	Received

THU-288	Seladelpar vs Elafibranor as second-line treatments for primary biliary cholangitis: asystematic review and meta-analysis	Sahana Parthasarathy	Received

WED-289	Loss-of-function mutations in Wilson disease: frequency and relationship with phenotype and prognosis (Spanish Wilson AEEH registry)	Luis García Villarreal	Received

SAT-289	Long-term risk of inflammatory bowel disease in autoimmune hepatitis: over a 20-year population-based study	Rawi Hazzan	Received

FRI-289	Indoles are colon-dependent circulating microbial metabolites associated with prognosis in primary sclerosing cholangitis	Sara Tjønnfjord	Received

THU-289	Utility of using modified Leipzig score for diagnosis of Wilson´s disease in a resource-limited setting	Yumnah Riaz	Received

WED-290	A determination of ATP7B peptides in dried blood spots from patients with Wilson disease: a feasibility study in a high-prevalence population (Gran Canaria) and potential utility in neonatal screening	Luis García Villarreal	Received

THU-290	Changes in gastroenterology and hepatology practice through primary biliary cholangitis education	S Christy Rohani-Montez	Received

FRI-290	Multi-omics analysis reveals zone-specific hepatocyte antigen presentation and pathogenic CD8+ T cells in autoimmune hepatitis	Han Wang	Received

WED-291	Neutrophil extracellular traps activation in porto-sinusoidal vascular disorder: a novel mechanism linking intestinal permeability to vascular damage	Nicola Pugliese	Received

THU-291	Non-ceruloplasmin bound copper measured by speciation assay: prospective evaluation over 12 months in real world setting of unstable Wilson disease patients	Jamie Heise	Received

TOP-292	Statin use is associated with reduced cholangiocarcinoma risk in primary sclerosing cholangitis: a national EHR cohort study	Miki Scaravaglio	Received

TOP-293	Liver biopsy facilitates efficient and high-quality diagnosis and evaluation of treatment outcomes in primary sclerosing cholangitis: results from the phase 3 NUC-5/PSC trial	Peter Schirmacher	Received

TOP-294	The number needed to treat with bezafibrate as second-line therapy to prevent liver transplantation or death in people with primary biliary cholangitis	Ellen Werner	Received

TOP-295	Centrally-imprinted innate immune tolerance following colitis attenuates cholestatic liver disease: implications for gut-liver axis driven PSC-IBD pathogenesis	Rania Matthys	Received

TOP-296	Liver-specific CNNM4 silencing alleviates fibrosis by restoring bile acids homeostasis in cholestatic preclinical models and human liver slices	Naroa Goikoetxea-Usandizaga	Received

TOP-297	Hepatocyte-intrinsic programs drive vascular pathobiology in Porto-sinusoidal vascular disorder and are modelled in organoids	Hasanka Madubashetha	Received

SAT-298	Diagnosis, treatment and outcomes of primary biliary cholangitis – insight from 801 patients enrolled for 20 years in the Polish registry of two tertiary centres	Maciej Janik	Received

THU-298	Non-ceruloplasmin bound copper measured by speciation assay: response to therapy over 12 months in real world setting of newly diagnosed Wilson disease patients	jamie Heise	Received

WED-299	In vivo determination of the transport capacity of bile salt export pump: a breakthrough for testing novel drugs for progressive familial intrahepatic cholestasis type 2	Willemien Hof	Received

SAT-299	The majority of fatigued primary biliary cholangitis patients do not have clinically significant itch	David E. Jones	Received

THU-299	Genome-wide association study to identify novel genetic variants associated with primary Budd-Chiari syndrome	Shalimar Shalimar	Received

THU-300	Fazirsiran treatment reduces serum biomarkers that predict major adverse liver outcomes in patients with alpha-1 antitrypsin deficiency-associated liver disease	Hannah Woodley	Received

FRI-300	Developing advanced 3D models of cholangiocyte-immune crosstalk	Jeremy Yeoh	Received

WED-300	Using an in vitro bile duct on a chip to study the mechanisms and treatment of biliary atresia	Henry Hoyle	Received

SAT-300	Long-term treatment with elafibranor improves markers of immune response and inflammation in primary biliary cholangitis	Costello Medical	Received

WED-301	Heterozygous variants in NOTCH2 among a cohort of juvenile and adult patients with cholestatic liver disease: Disease modifiers or innocent bystanders?	Marcin Krawczyk	Received

FRI-301	Setting-up a biliary niche-on-a-chip for the study of human liver disease-associated ductular reaction	Guo Yin	Received

THU-301	Novel serum proteomic signatures associated with disease burden in alpha-1 antitrypsin deficiency-associated liver disease	Hannah Woodley	Received

SAT-301	Investigating the burden of illness in primary sclerosing cholangitis (PSC): a multinational study	Jolan Terner-Rosenthal	Received

WED-302	Multimodal definition of the cytokine milieu predicting impaired jaundice clearance in biliary atresia	Matylda Zofia Kuzinska	Received

SAT-302	The mean corpuscular volume (MCV) is a surrogate for therapeutic azathioprine metabolites in patients with autoimmune hepatitis	Guan Sen Kew	Received

FRI-302	Inhibiting cuproptosis mitigates cholangiocyte inflammation in primary biliary cholangitis	Yu-Jie Zhou	Received

THU-302	Prevalence and risk factors of hemochromatosis arthropathy in HFE p.Cys282Tyr homozygotes: a cross-sectional study using adapted EULAR criteria	Daniel Theurl	Received

THU-303	Dimorphic response between the classical and alternative pathways of liver bile acid synthesis after feeding a high in sucrose and fat, choline-deficient, L-amino acid defined diet to Sprague-Dawley rats	Jianing Zhou	Received

WED-303	Multi-omics analysis reveals ECM defects and TGF-ß signaling in biliary atresia	Qiongfen LIN	Received

SAT-303	Lower healthcare resource utilisation and costs associated with alkaline phosphatase normalisation and composite biochemical response among adults prescribed ursodeoxycholic acid for primary biliary cholangitis	Chong Kim	Received

SAT-304	Sustained alkaline phosphatase normalisation and biochemical response are associated with reduced disease progression and clinical outcomes among adults prescribed ursodeoxycholic acid for primary biliary cholangitis	Chong Kim	Received

FRI-304	Evaluation of clinically approved drugs in a Sprague-Dawley rat model of liver fibrosis induced by choline-deficient, L-amino acid defined (CDAA) diet	Jianing Zhou	Received

THU-304	Multidisciplinary care in adult patients with Fontan-associated liver disease	Gabriella Tomaiuolo	Received

WED-304	Variation of management in Wilson´s disease in England: results from the first national audit	James Liu Yin	Received

THU-305	Dysregulation of hepcidin in hemochromatosis: results from a multinational cross-sectional study on serum iron parameters and MRI	Maria Rosina Troppmair	Received

FRI-305	The YAP/TAZ-regulated long non-coding RNA SNHG16 promotes hepatic stellate cell activation	Amira Abdelhamid	Received

WED-305	Exploring causes of excess mortality in the Wilson´s disease psychiatric cohort in the largest psychiatric centre in the UK	James Liu Yin	Received

SAT-305	Metabolic syndrome drives small dense low-density lipoproteins in primary biliary cholangitis: a lipoprint-based analysis	Tomá Koky	Received

SAT-306	Demographic and clinical characteristics of United States real-world patients with primary biliary cholangitis and alkaline phosphatase between 1 and 1.67 vs = 1.67 × upper limit of normal despite ursodeoxycholic acid treatment	Sefa Basci	Received

WED-306	Genetic dysregulation of methionine metabolism in the pathogenesis and progression of biliary atresia	ZUYI MA	Received

FRI-306	Anticoagulation attenuates liver fibrosis via targeting neutrophil extracellular traps and proteasome	Yingjie Ai	Received

THU-306	Prevalence and risk factors of sarcopenia throughout the disease spectrum of symptomatic polycystic liver disease: a retrospective multicentre cohort study	Nele Van Horebeek	Received

WED-307	RNA - based CRISPR/Cas9 - mediated genetic modification of the copper transporter ATP7B in Wilson disease	Moritz Marciniak	Received

SAT-307	Factors associated with second-line treatment initiation among real-world, second-line–eligible patients with primary biliary cholangitis in the United States	Allison Yankey	Received

THU-307	Genotype phenotype correlations and clinical presentation patterns in Wilson disease in a Sardinian cohort	Alberto Civolani	Received

SAT-308	Characteristics and treatment patterns of primary biliary cholangitis: real-world insights from a linked claims–electronic medical records database	Sefa Basci	Received

FRI-308	Lysyl oxidase inhibition disrupts angiogenin directed hepatic stellate cell activation influence by hepatoma cells	Basundhara Das	Received

THU-308	Characteristics of the adolescent population with Alagille syndrome and their liver survival	Dominika Wojdyla	Received

WED-308	New mouse strains recapitulating biliary atresia and Alagille syndrome-associated variants of JAGGED1 reveal a dual role of Jagged1 in liver development and biliatresone-induced injury response	Anna Maria Frontino	Received

TOP-309	Genetic testing reveals hidden genetic diseases in adult patients with idiopathic chronic cholestasis and chronic hepatitis with unknown aetiology	Ignasi Olivas	Received

TOP-310	Two-fold improvement of thrombosis regression rate after implementation of a multidisciplinary treatment protocol for acute superior mesenteric vein thrombosis	Sophie Ciere	Received

TOP-312	Precision gene-edited and functionally enhanced human hepatic organoids establish a novel therapeutic strategy for Wilson disease	Pengfei Yu	Received

FRI-313	Resmetirom ameliorates fibrogenesis in hepatic stellate cells via thyroid hormone receptor alpha-fatty-acid-amide hydrolase 1 signalling pathway	Alba Cabaleiro	Received

SAT-313	Topographical phenotyping of pruritus in chronic liver diseases using standardized body mapping	Miriam M. Düll	Received

THU-313	Expandable non-tumorigenic primary-like human hepatocytes from humanized mouse livers retain hepatic function, enable in vivo engraftment, and support robust HBV infection assays	Lennard Anders	Received

WED-313	Spatially resolved transcriptomics identifies disease-specific hepatic microenvironments in Fontan-associated liver disease	Yukie Nakadai	Received

THU-314	Hepatocyte succinate dehydrogenase/complex II loss drives metabolic rewiring critical for liver homeostasis	David Carneros Trujillo	Received

SAT-314	Genetic predisposition increases the gallstone risk in patients with PSC: single center, prospective analysis	Beata Kruk	Received

FRI-314	Targeting TRIM54: a potential protective strategy against liver injury in cirrhosis	Fan-E Cheng	Received

FRI-315	Effects of combined Atorvastatin and Ambrisentan treatment on hemodynamic alterations and liver fibrosis in a translational rat model of advanced MASLD	M Serra Cusidó	Received

SAT-315	Blood extracellular vesicle proteins predict ursodeoxycholic acid response in primary biliary cholangitis	Ainhoa Lapitz	Received

THU-315	Hepatic CNNM1 mediates metabolic and epigenetic adaptation to inverted feeding in night-shift worker models	Carolina Conter	Received

SAT-316	Efficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels between 1 and 1.67 × upper limit of normal: interim results from the open-label ASSURE study	Abigail Dobies	Received

THU-316	When the clock breaks: H2S as a link between night shift work and metabolic health	Carolina Conter	Received

WED-316	Targeting copper overload in Wilson disease – silencing ion transporters in the liver holds therapeutic potential for copper detoxification	Martha-Julia Sasula	Received

FRI-316	MicroRNA-based predictive staging of liver fibrosis severity in chronic liver disease	Alejandro del Castillo-Cruz	Received

WED-317	Challenges in the care of rare vascular liver diseases: insights from patients, health care providers, and patient organizations	Jane Sattoe	Received

SAT-317	A novel machine learning-based diagnostic tool for distinguishing between primary sclerosing cholangitis and IgG4-related cholangitis: an international asian study in China and Japan	Chenyi Jiang	Received

THU-317	Peptide-decorated DNA nanostructures enable programmable lysosomal interference in liver cells	Petra Elblová	Received

FRI-317	Modulation of collagen-binding integrins as a therapeutic strategy to inhibit liver fibrosis	Fatemeh Derakhshandeh	Received

FRI-318	Potential protective cooperation of interleukin-6-induced miRNA-9 during acute liver injury may underlie reparative and anti-fibrotic responses	Dana Eidelshtein	Received

WED-318	Small molecule approach for increasing biliary phospholipid secretion in a mouse model for MDR3 deficiency (progressive familial intrahepatic cholestasis type 3)	Henkjan Verkade	Received

SAT-318	18F FAPI PET/CT as a non-invasive assessment in autoimmune liver diseases: a prospective pilot study	Zhuwan Lyu	Received

THU-319	Molecular dynamics simulations reveal how hepatitis B virus preS1 haplotypes modulate the protective efficacy of the host sodium taurocholate cotransporting polypeptide S267F variant	Po-Hsien Hsu	Received

SAT-319	Point-of-care liver stiffness measurement predicts liver-related events in autoimmune hepatitis: results from a large nationwide multicenter longitudinal CaNAL study	Ellina Lytvyak	Received

FRI-319	Naringenin attenuates thioacetamide-induced liver fibrosis though epigenomic and transcriptomic reprogramming	Roberto Flores Peña	Received

WED-319	Spatiotemporal profiling reveals the role of the microenvironment in polycystic liver disease progression	Scott Waddell	Received

SAT-320	Impact of metabolic dysfunction-associated steatotic liver disease on treatment response, clinical outcomes and prognosis in primary biliary cholangitis: findings from a large multicenter longitudinal GLOBAL PBC registry	Ellina Lytvyak	Received

WED-320	Multi-ancestry genome-wide association meta-analysis identifies novel susceptibility loci for biliary atresia	Zijing Yang	Received

FRI-320	Identification of Sfrp1 in portal fibroblast and biliary fibrosis development	Wenrui Gao	Received

THU-320	Plectin-dependent hepatocyte mechanics modulates liver fibrogenesis	Markéta Jirousková	Received

FRI-321	UBC13 prevents hepatic stellate cell activation by K63 ubiquitination of HMGB1	SUI GUOYAN	Received

THU-321	Precursor of chemically expanded hepatocytes (pre-cHep) with 1-million-fold expansion potential and liver repopulation capacity	Keisuke Kaji	Received

WED-321	Regulatory T cells polarise to TregTh1 in autoimmune cholangitis, yet cells remain functional, enabling GMP Treg therapy	Ayma Asif	Received

SAT-321	Development and temporal validation of a perioperative prediction model for secondary sclerosing cholangitis in critically ill cardiac surgery patients	Samy Mady	Received

FRI-322	IGFBPs, MMPs, and cytokines as predictors of liver fibrosis: comparative analysis of biomarkers	GABRIELA GUTIERREZ REYES	Received

SAT-322	Patient navigation and patient-reported outcomes assessment in primary biliary cholangitis and primary sclerosing cholangitis reveal quality-of-life differences and early indicators of adverse clinical outcomes: a multi-year registry analysis	Alan Bonder	Received

THU-322	Liver-ETFDH deletion leads to cholestasis and glucose homeostasis disruption	Jose Maria Lanza-Arnaiz	Received

FRI-323	Circulating TSP2, IGFBP7, CD163 and TSP4 as novel, highly predictive serum markers of liver fibrosis in autoimmune hepatitis	Ludwig J. Horst	Received

WED-323	Myeloid progenitor cells are enriched and adopt a pro-inflammatory profile in liver fibrosis	Katharina Bonitz	Received

SAT-323	Impact of imaging surveillance on outcomes after cholangiocarcinoma diagnosis in primary sclerosing cholangitis	Adrielly Martins	Received

FRI-324	Lipometabolic reprogramming via ATGL inhibition improves liver fibrosis and promotes hepatic activated CD8+ tissue-resident memory T cells (TRM) in vivo	Henriette Horstmeier	Received

SAT-324	Latent class analysis identifies three distinct patient phenotypes in primary sclerosing cholangitis: implications for clinical trial access and mental health screening	Adrielly Martins	Received

WED-324	Human liver spatial transcriptomics reveals macrophage-driven antiviral responses distinguishing seronegative fulminant hepatitis from autoimmune hepatitis	Amber Bozward	Received

TOP-325	Time-resolved single-cell profiling of liver fibrosis regression identifies monocyte-derived Kupffer cells as central mediators of resolution	Katharina Bonitz	Received

FRI-329	Constitutive MAS1 G protein-coupled receptor participates in the pathogenesis of liver fibrosis	Sabine Klein	Received

WED-329	Development of ex vivo models to study the response to immunotherapy in hepatocellular carcinoma	Carla Castro Alejos	Received

SAT-329	ACLF metabolic markers can identity or exclude bacterial infections in acutely decompensated cirrhosis	Sania Arif	Received

SAT-330	Systemic inflammation aggravated by translocating environmental bacteria Aquitalea Magnusonii DNA in patients with chronic liver disease	Sania Arif	Received

THU-330	Hepatocyte desmosterol modulation influences the development of colorectal liver metastasis	Ane Nieva-Zuluaga	Received

WED-330	Liver associated invariant T cells are enriched in PSC patients, secrete IFN-? in response to IL-12 and IL-18, and can potentially contribute to Treg plasticity	Scott Davies	Received

FRI-330	The platelet-derived growth factor receptor beta binding vector "Fibrobody®", for clinical targeting of liver fibrosis	Sylvia Klomp	Received

FRI-331	Targeting DNA stress response as a synthetic lethal strategy for activated hepatic stellate cells	Eui Jin Lee	Received

SAT-331	Characterization of the intrahepatic microbiome in patients with HBV-related end-stage liver disease	Jiyang Chen	Received

WED-331	Impact of alcohol consumption on the immune architecture in hepatocellular carcinoma	Margaux Delaporte	Received

FRI-332	Pathological role of argininosuccinate synthase 1 in metabolic dysfunction-associated steatotic liver disease-related liver fibrosis	Ji-Min Li	Received

SAT-332	Antibiotic therapy, not disease severity, shapes the intestinal and oral microbiomes in acutely decompensated cirrhosis	Sren Damsholt	Received

THU-332	Signaling through the insulin receptor induces growth via cell cycle re-entry in hepatocyte spheroids engrafted in the anterior chamber of the eye	Nuria Oliva-Vilarnau	Received

WED-332	Hepatitis B virus specific T cell immunity to guide discontinuation of nucleoside analogue therapy in hepatitis B e antigen negative chronic hepatitis B	Raquel Encijo-Heredia	Received

THU-333	Role of CNNM1 in magnesium homeostasis and hepatocellular dysfunction during aging	Patricia Peña San Felix	Received

SAT-333	An integrated multiomics signature and network analysis differentiating metabolic dysfunction-associated steatotic liver disease and metabolic associated steatohepatitis: a pilot study	Shereen El Sobky	Received

FRI-333	Decellularized liver matrix hydrogels suppress hepatic stellate cell activation via ROS-independent NRF2 activation	Jia Li	Received

THU-334	A human induced pluripotent stem cells-based liver assembloid platform for investigating ischemia/reperfusion injury	Riccardo Perriera	Received

FRI-334	Geniposidic acid suppresses hepatic stellate cell activation by regulating protein kinase B and glycogen synthase kinase 3-beta signaling	Yakun Li	Received

SAT-334	Rifaximin ameliorates liver fibrosis and hepatocarcinogenesis in experimental MASH by inhibiting the gut–liver axis and Epiregulin–IL-8–driven angiogenesis	Kosuke Kaji	Received

THU-335	Hepatic molecular pathways associated with pemafibrate treatment in a rat model of metabolic-associated steatotic liver disease	Yanhao Qiu	Received

FRI-336	PTTG1 silencing via siRNA, effectively downregulates profibrogenic genes in LX2 cells and human precision cut liver slices	Manuel Macías-Herranz	Received

WED-336	Dual TIGIT and PD-1 blockade reverses CD8+ T cell dysfunction in acute-on-chronic liver failure	Yidi Jia	Received

THU-337	Integrating proteomics and metabolomics analysis identifies molecular links associated to liver injury in preclinical model of acute hypoxia stress	Sanju Yadav	Received

FRI-337	Transforming growth factor-ß1 disrupts hepatic zonation and induces fibrotic endothelial remodeling in vivo	Lukas Neckermann	Received

WED-337	Retinoids reprogram TREM2? monocyte-derived macrophages toward a restorative phenotype via redox control to attenuate liver fibrosis	Kyurae Kim	Received

SAT-337	Odoribacter splanchnicus attenuates western diet–induced MASLD by restoring hepatic lipid metabolism	Soon Sun Kim	Received

FRI-338	Fibrosis-staging proteome biomarkers from human cohort evaluated as treatment response biomarkers in rat model	Anouk Oldenburger	Received

SAT-338	The biliary metagenome in malignant cholestasis: analysis of samples obtained during EUS-guided biliary drainage	Marcin Krawczyk	Received

THU-338	MAVS-dependent type I interferon mediated non-viral liver injury and hepatocarcinogenesis upon hepatic autophagy inhibition	Lea Aylin Yücel	Received

FRI-339	Acetyl-CoA carboxylase 2 inhibition in hepatic stellate cells drives their activation and enhances liver fibrosis	Tamara Parracho	Received

WED-340	Hepatocyte senescence controls RORγt+ cell populations in the liver and is sensitive to metabolic zonation	Yuxin Li	Received

FRI-340	Impact of PNPLA3 p.I148M variant on qFibrosis-based collagen morphology in MASLD: analysis from Milan biobank cohort	Giulia Periti	Received

THU-340	Engineered extracellular vesicles derived from mesenchymal stem cells enriched with insulin-like growth factor I restore impaired liver regeneration after partial hepatectomy in fibrotic livers	Mailín Casadei	Received

THU-341	Macrophages drive spatially specific liver regeneration via arginine metabolism reprogramming: the translational potential of arginine supplementation	jinwei chen	Received

FRI-341	Male rats exhibit exacerbated hepatic and metabolic alterations than females in response to a high fat high fructose high cholesterol diet	Yanhao Qiu	Received

SAT-341	Bacteroides intestinalis AM-1 reshapes the gut microbiome and preserves intestinal barrier function to mitigate acetaminophen-induced liver injury	SUSHMITA PANDEY	Received

WED-341	Decoupling of monocyte subset expansion and immune competence in hepatitis B–related acute-on-chronic liver failure	Xiaoqin Liu	Received

TOP-342	Hepatic B cells interact with invariant natural killer T cells via CD40 to stimulate hepatic stellate cells	Jihyo Byun	Received

TOP-343	LSECtin delivered to hAPCs by functionalized nanoparticles ameliorates chronic liver damage in experimental cirrhosis	Oriol Juanola	Received

TOP-344	SIRT4 enhances NK cell cytotoxicity against hepatic stellate cells and reverses liver fibrosis via the AMPKa/p53/NKG2DL axis	Huan Chen	Received

FRI-345	Fibrosis stage-specific human hepatic stellate cell cultures exhibit distinct metabolic and matrix remodelling phenotypes in response to fibrogenic factors	Una Rastovic	Received

THU-345	Cell type-specific role of CD44 in liver regeneration	Tanja Derowski	Received

WED-345	PD-1+ follicular helper T cells as the key discriminator: a combined model with plasmablasts for distinguishing autoimmune hepatitis from drug-induced liver injury	Zikun Ma	Received

SAT-345	Machine learning uncovers functional microbial signatures in cirrhosis patients with type 2 diabetes mellitus	Ingyu Park	Received

FRI-346	Transcriptomic profiling and label-free collagen imaging of hepatic stellate cells cultured as 3D magnetic levitation spheroids	Nataliya Rohr-Udilova	Received

THU-346	Engineering a fibrotic organoid chip revealing ductular reaction driven by matrix-derived forces	Yu Du	Received

WED-346	Single-cell profiling reveals altered natural killer cell composition and transcriptional programs in MASLD-related HCC	STEFANIA MANTOVANI	Received

SAT-346	Fecal metabolic profile differentiates stages of alcohol-related liver disease	Eemeli Puhakka	Received

THU-347	Generation of sinusoidal-like endothelial cells from human induced pluripotent stem cells (hiPSCs) for 3D liver models	CLELIA FERRARO	Received

SAT-347	Incomplete microbial and metabolic recovery during the regression phase of carbon tetrachloride-induced liver fibrosis	Katja Sommer	Received

FRI-347	The non-transcriptional activity of IRF3 induces profibrotic cytoplasmic stress granules	Jared Travers	Received

WED-347	Lessons from single-cell transcriptomics in chronic hepatitis B: refinement without redefinition	Akhilesh Mulay	Received

WED-348	Impaired vaccine-induced adaptive immunity cross-reactive to emerging influenza viruses in chronic liver diseases	Lisa-Marie Müller	Received

FRI-348	Interleukin-33 and Serotonin drive hepatic fibrosis in alveolar echinococcosis via the gut-liver axis	Tuerhongjiang Tuxun	Received

SAT-348	Diet and exercise mitigate MASLD and exert beneficial effects on skeletal muscle via organ crosstalk in diet-induced obese mice	Vanessa Souza-Mello	Received

WED-349	Retinoic acid signaling in hepatic stellate cells orchestrates plasmacytoid dendritic cell recruitment and immune tolerance: implications for cholestatic liver injury	Nobuhiro Nakamoto	Received

SAT-349	Pharmabiotics, phocaeicola dorei, ameliorates liver fibrosis by alleviating macrophage efferocytosis of neutrophils	Sang Jun Yoon	Received

WED-350	Soluble liver antigen (SLA)-specific CD4+ T cells phenotypes in the blood of patients with autoimmune hepatitis (AIH) correlate with the clinical situation	Carina Saggau	Received

FRI-350	ESOR1 links liver fibrosis to hepatocellular carcinoma progression via endothelial EGFR signaling	Jin Wang	Received

THU-350	Interleukin-17a induces hepatocyte conversion into hepatic progenitor-like cells with stem cell characteristics	Pei-Chi Huang	Received

SAT-351	Integrated multi-omics analysis identifies gut microbiota – lipid - metabolite signatures associated with metabolic dysfunction – associated steatotic liver disease in overweight adults	Nataša Veli&269;kovi&263;	Received

THU-351	Hepatic-lobule-mimetic spheroids composed of chemically derived hepatic progenitors and endothelial cells enhance liver regeneration via spatial patterning	Hee Ju Kim	Received

WED-351	Using immunohistochemistry to determine the enclysis of T cells in cholestatic and viral liver diseases	Soumyajit Saha	Received

SAT-352	Loss of crypt-adjacent barrier-supportive macrophages promotes gut barrier failure and organ injury in alcohol-related hepatitis	Joscha Vonderlin	Received

FRI-352	Umbilical cord mesenchymal stem cell-derived extracellular vesicles attenuate hepatic stellate cell activation via mitochondrial modulation	Junyu Wang	Received

THU-352	Surface-modified MSC exosomes with PEGylation and SE-1 antibody conjugation for enhanced circulation and LSEC-targeted therapy in liver fibrosis	MIRA LEE	Received

WED-352	Collectin-11 of the lectin pathway mediates complement-dependent hepatic ischemia-reperfusion injury in mice	Tatsuro Sugaya	Received

FRI-353	The stiffness of liver-derived extracellular matrix hydrogels regulates hepatic stellate cell activation	Junyu Wang	Received

SAT-353	Gut microbiota metabolite butyrate ameliorated acute-on-chronic liver failure by regulating macrophage polarization	Jing Xiao	Received

THU-353	Spatio-temporal omics identifies ZEB1-BMP4 in hepatic stellate cells as a key axis for liver regeneration after acute injury	Jun Li	Received

WED-354	Ugonin J suppresses hepatocyte inflammation via GPX2-mediated redox regulation	Li-Yun Wang	Received

SAT-354	Bile mycobiome diversity classifies fungal peptide signature for early prediction of gallbladder carcinoma	Sanju Yadav	Received

FRI-354	Dynamic changes in type III collagen formation and degradation are associated with fibrotic activity following hepatic injury in rats	Thomas Wiggers	Received

THU-355	Lymphangiocrine signal, Wnt7a is a key driver of cholangiocyte proliferation during liver regeneration	Aarti Sharma	Received

FRI-355	SOX9 drives hepatic stellate cell activation via a PFKFB3-mediated glycolysis-histone lactylation positive feedback loop	Guanglin Xiao	Received

SAT-355	Microbial Streptococcal collagen like-1 protein activates fibrosis via transforming growth factor beta receptor 1 kinase in alcohol-associated liver disease	NEHA sHARMA	Received

WED-355	Targeting the STING pathway as a strategy to suppress hepatitis B virus replication	Mingyuan Zhang	Received

SAT-356	Bifidobacterium pseudolongum-derived inosine mitigates polystyrene nanoplastics-induced hepatic injury by inhibiting the polarization of M1 macrophages	Kaikai Zhang	Received

WED-356	VISTA deficiency exacerbates the development of acute-on-chronic liver failure by promoting Tc1 differentiation	Yao Zhang	Received

TOP-357	Targeting gut microbial nitrogen recycling and intestinal uptake of ammonium attenuates progression of chronic liver disease	yinghong zhu	Received

TOP-358	Exploring biomarkers for immunotherapy benefit in unresectable hepatocellular carcinoma based on microbiome-immunomics	Ningning Zhang	Received

TOP-359	Prospective multicenter evaluation of prototype deep learning algorithms versus liver imaging reporting and data system (LI-RADS) criteria in diagnosing hepatocellular carcinoma on computed tomography	Rex Wan-Hin Hui	Received

TOP-360	Task-agnostic deep learning for hepatocellular carcinoma: a unified pipeline for tumor differentiation grading, microvascular invasion detection and fibrosis staging	Yan Miao	Received

WED-361	Central vagal dysfunction reshapes neutrophil and T cell immunity in hepatocellular carcinoma	Wenxuan Li	Received

FRI-361	Preoperative transarterial radioembolization is comparable to primary liver resection but shows more favorable outcomes than preoperative transarterial chemoembolization in hepatocellular carcinoma beyond the Milan criteria	Jeayeon Park	Received

SAT-361	Bridging the gap in primary sclerosing cholangitis care: results from a patient survey	Adrielly Martins	Received

FRI-362	Prediction of disease control in unresectable hepatocellular carcinoma under Atezolizumab-Bevacizumab with machine and CT deep learning models	Asier Rabasco Meneghetti	Received

SAT-362	Efficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 response study	Sefa Basci	Received

THU-362	mRNA COVID-19 vaccination shortly after PD-1/PD-L1 inhibitor Is associated with better survival in liver cancer: a Mayo Clinic platform study	Yuting Huang	Received

SAT-363	Efficacy and safety of seladelpar in patients with primary biliary cholangitis and risk factors for progression including younger age at diagnosis or higher liver stiffness in the pivotal response study	Sefa Basci	Received

FRI-363	A dynamic prognostic model using alpha-fetoprotein and serial hemogram-based inflammatory biomarkers for unresectable hepatocellular carcinoma treated with first-line immunotherapy	Yujie Ran	Received

THU-363	Serum exosome-related lipids could detect MASLD-associated hepatocellular carcinoma	Jian Huang	Received

SAT-364	Long-term improvements in lipid profiles with elafibranor treatment, and favourable safety with concomitant statin use, in patients with primary biliary cholangitis during the open-label extension of the phase III ELATIVE® trial	Costello Medical	Received

WED-364	Identification of targetable epigenetic-metabolic vulnerabilities in human cholangiocarcinoma	Amaya Lopez-Pascual	Received

FRI-364	Hepatic decompensation is driven by underlying liver disease rather than immunotherapy choice in inresectable hepatocellular carcinoma	Lou-Devy Rouxel	Received

THU-364	Intensive care admission patterns and outcomes in hepatocellular carcinoma patients on systemic therapy	Rex Wan-Hin Hui	Received

FRI-365	Hepatocellular carcinoma stage, treatment patterns, and survival outcomes in a contemporary multicentre international cohort	N APOORVA SASIKUMAR	Received

SAT-365	Real-world survey assessing pruritus in PSC in France, Germany, Italy and the United States: results from a matched patient and their treating physician cohort	Jolan Terner-Rosenthal	Received

THU-365	Oral cholate challenge test stratifies hepatotoxicity risk after liver-directed therapy for hepatocellular carcinoma	Michael McRae	Received

SAT-366	Use of maralixibat for the treatment of cholestatic pruritus in late-onset PFIC	Jolan Terner-Rosenthal	Received

THU-366	Development of a longitudinal predictive model for hepatocellular carcinoma occurrence in patients with chronic hepatitis B	Apichat Kaewdech	Received

WED-366	Tumor–neuron signaling as a functional axis within the cholangiocarcinoma microenvironment	Lorenzo Mainardi	Received

SAT-367	Comparative clinical and immunological features of drug-induced autoimmune-like hepatitis, drug-induced liver injury, and autoimmune hepatitis	Yao Meng	Received

THU-367	Risk and predictors of HCC in a cohort of 1,395 treatment-naïve chronic hepatitis delta patients with F0-F2 fibrosis	Habiba Kamal	Received

FRI-367	Clinical relevance of conversion therapy after atezolizumab plus bevacizumab in hepatocellular carcinoma: a multicenter study	Takuya Sho	Received

WED-368	Genome-wide association of MRC1 with FIB-4 disentangles non-invasive fibrosis assessment from HCC	Francesco Malvestiti	Received

THU-368	Magnetic resonance elastography and cirrhosis outcome risk estimator (CORE) score as independent predictors of hepatocellular carcinoma in chronic hepatitis	Kie Kinjo	Received

FRI-368	Cytokeratin 19 expression stratifies outcomes with hepatic arterial infusion chemotherapy but not atezolizumab plus bevacizumab in advanced hepatocellular carcinoma	Kwon Yong Tak	Received

FRI-369	Recurrence patterns and post-recurrence survival after curative resection for hepatocellular carcinoma: a Milan criteria–based stratification	Chi-Ping Tan	Received

THU-369	Characteristics of hepatocellular carcinoma in the real-world Italian PITER-B/Delta cohort	Loreta A Kondili	Received

WED-369	Transforming growth factor-ß signaling at the SMAD3 linker region promotes cancer cell plasticity and immunosuppression in hepatocellular carcinoma	Wolfgang Mikulits	Received

THU-370	Effectiveness of a structured surveillance program for early detection of hepatocellular carcinoma in contemporary patients with advanced chronic liver disease	Georg Kramer	Received

WED-370	DCLK1-positive tumor cells are associated with immune microenvironment in hepatocellular carcinoma: preliminary insights from a proof-of-concept study	Lorenzo Nevi	Received

SAT-370	Symptom experience in patients with primary biliary cholangitis: pilot survey results	Nekshan Dalal	Received

FRI-370	Prognostic and predictive value of single-nucleotide polymorphism signature in patients with resected hepatocellular carcinoma: a multicentre retrospective study	Xiao-Peng Tian	Received

WED-371	PIVKAHigh VEGF-DHigh advanced hepatocellular carcinoma patients showed Aryl hydrocarbon receptor-dependent metabolic rewiring and immune exhaustion with poor outcomes post stereotactic body radiation therapy	Prabhjyoti Pahwa	Received

FRI-371	CT-derived skeletal muscle mass improves risk stratification in patients undergoing major surgery for perihilar cholangiocarcinoma – a retrospective single center cohort study	Paula Medio	Received

SAT-371	Nebokitug modulates gut–liver inflammatory and tissue-remodeling signatures in PSC patients with coexisting IBD	Tom Snir	Received

THU-371	Clinical benefit of perioperative prophylactic antibiotics in hepatocellular carcinoma (HCC) patients undergoing transcatheter arterial chemoembolization (TACE)	Junying Li	Received

WED-372	Baseline CD69 expressing T cells in peripheral blood associate with response to atezolizumab plus bevacizumab in hepatocellular carcinoma	Min Seo Park	Received

SAT-372	Nebokitug down-regulates core fibrotic and immune pathways defined by single-cell liver profiling	Tom Snir	Received

FRI-372	Percutaneous ablation versus stereotactic body radiotherapy for early-stage hepatocellular carcinoma: a propensity score–matched study	VENTRE Jules	Received

TOP-373	A confidence-aware artificial intelligence pathology model for cholangiocarcinoma diagnosis	Yue Cheng	Received

TOP-375	Prognostic impact of neoplastic portal vein thrombosis and extrahepatic metastases in advanced hepatocellular carcinoma receiving Atezolizumab–Bevacizumab: a multicenter real-world study	Filippo Cattazzo	Received

TOP-376	Hepatocellular carcinoma (HCC) in patients with biopsy proven metabolic dysfunction associated steatotic liver disease (MASLD)	Zobair Younossi	Received

WED-377	EZH2 leads liver sex-dimorphism in HCC development and progression	FRANCESCA GUERRIERI	Received

SAT-377	AI-driven proteomic profiling differentiates composite improvement following treatment with nebokitug in PSC	Tom Snir	Received

THU-377	Shifting aetiology and clinical landscape of hepatocellular carcinoma over four decades: from viral hepatitis to metabolic dysfunction–associated steatotic liver disease in 1,960 patients	Kai Lim	Received

FRI-377	Comparative efficacy and prognostic analysis of different targeted-immunotherapy regimens in advanced hepatocellular carcinoma	Yan Xu	Received

FRI-378	Sequential therapy patterns and prognostic impact of first-line treatment response in unresectable hepatocellular carcinoma patients with failure of Atezolizumab plus Bevacizumab	Jiwon Yang	Received

SAT-378	The italian primary biliary cholangitis registry: insights from a nationwide cohort study	Daphne DAmato	Received

WED-378	Sorpresa-HCC: a multicenter study on the changing epidemiology of HCC in cirrhosis	Tommaso Sarcina	Received

THU-378	Potential limitations of Fib-4 in selecting MASLD patients for HCC surveillance – impact of fibrosis burden on tumour stage and survival in MASLD-related HCC compared with non-MASLD HCC in 1,960 patients over 4 decades	Kai Lim	Received

SAT-379	Alkaline phosphatase and bilirubin levels at one year of fibrate therapy predict long-term outcomes in patients with primary biliary cholangitis receiving second-line treatment	Atsushi Tanaka	Received

THU-379	Development and validation of a machine learning model to prognosticate hepatocellular carcinoma	Ryan YanZhe Lim	Received

WED-379	Oncostatin M modulates tumor-stroma interactions and promotes intrahepatic cholangiocarcinoma progression via JAK/STAT signaling	Nunzia Porro	Received

FRI-379	Comparison of surgical resection, percutaneous ablation, and transarterial chemoembolization for hepatocellular carcinoma patients with recompensated cirrhosis: a multicenter, retrospective, cohort study	Can Zhang	Received

SAT-380	Clinical utility of thiopurine methyltransferase (TPMT) genotype and azathioprine (AZA) metabolites in the management of autoimmune hepatitis (AIH)	Ignasi Olivas	Received

THU-380	Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study	Miriam Longo	Received

WED-380	Single-cell transcriptomic profiling of endothelial-to-mesenchymal transition in MASLD-associated liver carcinogenesis	Victoria Priori	Received

FRI-381	Inhibition of the renin–angiotensin system does not improve the outcomes of hepatocellular carcinoma treated with atezolizumab–bevacizumab	Tommaso Zurli	Received

SAT-381	Impact of metabolic syndrome on clinical outcomes in primary biliary cholangitis: a retrospective cohort study	Jade Pace	Received

THU-381	Combining observation and patient data to predict malignancy progression in LI-RADS 3-4 observations	David Marti-Aguado	Received

SAT-382	Utility of spleen stiffness measurement for the detection of esophageal varices in primary biliary cholangitis (PBC)	Marlene Padilla-Lopez	Received

WED-382	Cabozantinib reshapes the immune landscape of hepatocellular carcinoma through mitochondrial cGAS-STING signaling	Patricia Rider	Received

FRI-382	Neurofilament light chain proteins are a sensitive biomarker of neuronal damage in hepatic encephalopathy	Clelia Asero	Received

THU-382	Performance of HCC risk scores in patients with advanced chronic liver disease: a multicenter cohort study	Mohamed Moussa	Received

FRI-383	Effect of nitazoxanide on organ failures in disease models of alcohol-mediated acute-on-chronic liver failure (ACLF)	Marie Bobowski-Gerard	Received

THU-383	Addition of the GAAD score to imaging improves classification of non-cirrhotic focal liver lesions	Mohamed Moussa	Received

WED-383	Liquid biopsy evaluation of KDM2A and NOTCH3 in hepatocellular carcinoma	Francesca Salani	Received

SAT-383	Beyond fibrosis: clinical relevance of histological inflammatory patterns in autoimmune hepatitis	Maria Carlota Londoño	Received

FRI-384	Differential activity of nitazoxanide vs rifaximin in lipopolysaccharide-induced disease models	Marie Bobowski-Gerard	Received

SAT-384	Statins are underutilized for cardiovascular disease in patients with PBC	Mark Pedersen	Received

THU-384	Post-cholecystectomy syndrome affects ultrasound visualization in non-obese viral-related advanced chronic liver disease ACLD: implications of gallbladder removal for Li-RADS-based hepatocellular carcinoma (HCC) surveillance	Marcello Dallio	Received

WED-384	Transcriptomic reprogramming induced by zinc oxide nanoparticles in experimental hepatocellular carcinoma	Jorge Alejandro Salto Sevilla	Received

THU-385	Cholangiocarcinoma in individuals with chronic liver disease is diagnosed earlier leading to better prognosis	Jone Narbaiza	Received

SAT-385	Identifying primary biliary cholangitis in the general population: a laboratory based look back exercise	Isobel Phillips	Received

WED-385	Galectin-3 inhibition supports HCC growth via pro-tumorigenic liver reprogramming	Paul Schneider	Received

FRI-385	Serum-conditioned nanoplastics trigger hepatocyte injury and inflammation in human liver tissue	Paula Boeira	Received

WED-386	Soluble fibroblast activation protein drives a signal transducer and activator of transcription 3 feedback loop in hepatocellular carcinoma	Deok Hwa Seo	Received

SAT-386	Prevalence and clinical impact of metabolic dysfunction-associated steatotic liver disease in primary biliary cholangitis: a tertiary-center experience	Riccardo Plebani	Received

THU-386	Heterogeneity in hepatocellular carcinoma screening across social determinants of health phenotypes	Lauren Nephew	Received

FRI-386	Monocyte distribution width predicts infection and mortality in acutely decompensated cirrhosis	Robert G Brenig	Received

FRI-387	Apical sodium-dependent bile acid transporter (ASBT) inhibition improves hepatic and extrahepatic manifestations in a mouse model of cirrhosis	Pedro Rodrigues	Received

SAT-387	Meaningful within-patient change on the 5-D itch scale in patients with primary biliary cholangitis experiencing pruritus	Sefa Basci	Received

WED-387	A translational model bridging in vitro and in vivo macrophage phenotypes in orthotopic liver tumours	Blanca Simón-Codina	Received

THU-387	Identify liver tumors from ultrasound images through ensemble learning integrated with the ordered weighted averaging operator	Hsiao-Ching Nien	Received

WED-388	KLF15 acts as a tumor suppressor in cholangiocarcinoma by inhibiting cell proliferation, migration, and mitochondrial energetic activity	Pedro Rodrigues	Received

SAT-388	Primary biliary cholangitis education significantly improves competence in recognising which patients would most likely benefit from second line therapy	S Christy Rohani-Montez	Received

FRI-388	Maladaptive emergency myelopoiesis is already activated in patients with the less severe forms of acutely decompensated cirrhosis, and its amplification drives progression towards severity	Zhujun Cao	Received

TOP-389	Anti-GARP reverts immune suppression and extends overall survival in a MASH-HCC murine model resistant to anti-PDL1+anti-VEGFA therapy	Júlia Huguet i Pradell	Received

TOP-390	Using patient-led genetics to identify new therapeutic targets in metastatic cholangiocarcinoma	Paula Olaizola	Received

THU-393	Comparison of sarcopenia and liver frailty indices for overall survival in hepatocellular carcinoma patients treated with first-line Atezolizumab-Bevacizumab	Asier Rabasco Meneghetti	Received

SAT-393	From real patients to digital twins: synthetic cohorts for evidence generation in UDCA-treated primary biliary cholangitis	Vincenzo Ronca	Received

FRI-393	Germline variants influence cirrhosis and HCC through distinct pathways	Kyong-Mi Chang	Received

WED-393	Prognostic tissue biomarkers for cholangiocarcinoma after tumor resection: from literature review to multicenter international validation	Pedro Rodrigues	Received

WED-394	Coffee-derived compounds enhance chemo and immunotherapy responses in in vitro and in vivo models of hepatocellular carcinoma	Leticia Valente	Received

THU-394	MASLD-related hepatocellular carcinoma in cirrhotic and non-cirrhotic patients: a real-world analysis from the ITA.Li.Ca. cohort	Lucia Ragozzino	Received

FRI-394	Reduced cardiorespiratory fitness and its physiological determinants in patients with cirrhosis: evidence of cirrhosis-induced myopathy	Alexis Couret	Received

SAT-394	Frequency of PFIC-associated genetic variants across different adult cholestatic phenotypes	Maria Chiara Chindamo	Received

WED-395	Extracellular matrix remodeling and gender dimorphism in the progression of primary sclerosing cholangitis to cholangiocarcinoma	Camilla Venturin	Received

THU-395	Attention-based multiple instance learning for classification of focal liver lesions using contrast-enhanced ultrasound	Tobias Paul Seraphin	Received

FRI-395	Recapitulating cirrhosis in vitro using a primary liver microphysiological system and patient plasma profiling	Laura de Jong	Received

SAT-396	Bone mineral density is stable in patients with primary biliary cholangitis receiving up to 3.5 years of elafibranor treatment	Costello Medical	Received

WED-396	Single-cell spatial immune organization determines response to atezolizumab plus bevacizumab in advanced HCC	Anna Vila Escoda	Received

FRI-396	Dyslipidemia is associated with impaired fibrinolysis in patients with cirrhosis	Fynn Elvers	Received

THU-396	Prognostic nutritional index as a predictor for survival in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease	TSAI SHIN-YU	Received

WED-397	Microbial pentadecanoic acid suppresses hepatocellular carcinoma progression by inhibiting NSUN5 methyltransferase activity	Ziyan Wang	Received

SAT-397	Histological and morphometric analyses demonstrate antifibrotic activity of norucholic acid in primary sclerosing cholangitis	Peter Schirmacher	Received

THU-397	Imaging spectrum of giant hepatic hemangioma with diffuse hepatic hemangiomatosis: nine case series	Ki Choon Sim	Received

FRI-397	Increased ceftriaxone exposure in hospitalised patients with decompensated cirrhosis compared to patients without cirrhosis revealed by population pharmacokinetic modelling (TACTILE study)	Solaiman Ezzafzafi	Received

FRI-398	Comparing the intrahepatic effects of carvedilol and simvastatin in experimental liver cirrhosis	Eric Felli	Received

THU-398	Hepatocellular carcinoma in Budd Chiari syndrome: characteristics and risk factors	MARINELA STOIAN	Received

SAT-399	Anti-HK1 and anti-KLHL12 Antibodies: Diagnostic but Not Prognostic in PBC	Nasser Semmo	Received

FRI-399	Neutrophil-derived miR-223 suppresses inflammasome activation and ameliorates pyroptotic cell death in peritoneal macrophages during spontaneous bacterial peritonitis	Mick Frissen	Received

THU-399	Predicting early recurrence of hepatocellular carcinoma after resection: a machine learning model integrating clinical data and LLM-structured pathological features	Tung-Hung Su	Received

FRI-400	IGF1r receptor is involved in the Th17-mediated response in chronic liver disease	Ani Gasparyan	Received

WED-400	Establishing a multi-institutional patient-derived xenograft biobank for precision medicine in cholangiocarcinoma	Lisa Wende	Received

THU-400	Re-evaluating the diagnostic value of alpha-fetoprotein for hepatocellular carcinoma in the direct-acting antiviral era	Yoshinori Takeda	Received

SAT-400	Baseline predictors of treatment failure in autoimmune hepatitis: a multicenter study with external validation	Anna Sessa	Received

SAT-401	Early real-world experiences of Elafibranor in primary biliary cholangitis (PBC)	Charlotte Sewell	Received

WED-401	AREG knockdown triggers Decorin-mediated EGFR activation and paracrine G1 arrest across species	Torsten Wuestefeld	Received

THU-401	Epidemiology and factors affecting survival of intrahepatic cholangiocarcinoma: a population-based study of 12,138 patients	Ker Shiong Tan	Received

FRI-401	Integrated transcriptomic and metabolomic analyses reveal immune and metabolic signatures of overt hepatic encephalopathy	MEIQIAN HU	Received

FRI-402	A peritoneal macrophage-Th1/Th17 axis drives inflammation in spontaneous bacterial peritonitis	Oluwatomi Ibidapoobe	Received

THU-402	Evaluation of the ASAP model for detecting hepatocellular carcinoma in Thai patients with chronic liver disease, including those with negative alpha fetoprotein	Pisit Tangkijvanich	Received

SAT-403	Analysis of structured and unstructured data from a large electronic health record system identifies frequent pruritus and fatigue in patients with PSC	Jolan Terner-Rosenthal	Received

THU-403	Tumor burden score as prognostic factor in newly diagnosed hepatocellular carcinoma	Aki Uutela	Received

WED-403	Whole genome sequences reveal the presence of high structural variants in hepatocellular carcinoma of Fontan-associated liver disease	Taiji Yamazoe	Received

SAT-404	Concomitant metabolic-dysfunction associated steatotic liver disease in primary biliary cholangitis: no adverse liver outcomes but increased cardiovascular risk in a large real-world cohort	Jarell Jie-Rae Tan	Received

THU-404	Predictive value of MRI parameters in the development of hepatocellular carcinoma in liver cirrhosis	Monique van Wijk	Received

TOP-405	Single-cell spatial profiling of cellular architecture in human hepatocellular carcinoma	Claudia Arnedo-Pac	Received

TOP-406	Spatial immune classification reflects CD8 T cell exhaustion states and predicts response to neoadjuvant immunotherapy in hepatocellular carcinoma	Alexandra Emilia Schlaak	Received

TOP-407	Development and validation of a novel pretreatment MRI-based radiomic model to predict progression after thermal ablation in early stage hepatocellular carcinoma using data from two randomised control trials	Mathew Vithayathil	Received

TOP-408	Efficacy and feasibility of neoadjuvant immunotherapy in hepatocellular carcinoma	Sarah Cappuyns	Received

THU-409	Accurate detection of cholangiocarcinoma in primary sclerosing cholangitis by DNA methylation biomarkers in bile and plasma	Hege Marie Vedeld	Received

WED-409	Spatial profiling reveals region-specific immune architectures and checkpoint distribution in extrahepatic cholangiocarcinoma	Dawei Yi	Received

FRI-409	Insulin-like growth factor 1 suppression worsens with cirrhosis severity and mortality, and therapeutic restoration improves outcomes in decompensated cirrhosis: a clinical-experimental study	Parminder Kaur	Received

SAT-409	Management and outcomes of cholangiocarcinoma in PSC: the Toronto experience	Natassia Tan	Received

FRI-410	Circulating bile-acid profiles delineate disease severity and identify a metabolic fingerprint of ACLF	Georgios Konstantis	Received

SAT-410	PRO-C3 shows prognostic and trial-endpoint potential in primary sclerosing cholangitis	Usha Tharmathas	Received

THU-410	Global trends in primary liver cancer between 2000 and 2023	Mathew Vithayathil	Received

SAT-411	Long-term outcomes of autoimmune hepatitis: complications, cancer risk and survival in a large nationwide swedish cohort	Richard Thörn	Received

FRI-411	Systemic markers of fibroblast- and immune cell activity in post-TIPS endotyping within patients with severe clinical evolution	Diana Leeming	Received

FRI-412	Balancing immune dysfunction in ACLF: ASK1 inhibitor SRT-015 mitigates inflammatory responses while enhancing immune antibacterial defenses	Marie Bobowski-Gerard	Received

WED-412	CAND1 as a novel therapeutic target in pediatric hepatoblastoma: linking NEDDylation to tumor progression	Leidy Estefanía Zapata-Pavas	Received

SAT-412	Acute cholangitis in primary sclerosing cholangitis: profile classification of patient-reported symptom burdens predicts recovery from cholangitis episodes	Brian Thorsen	Received

FRI-413	Modulation of the gut microbiome by Yaq-001 ameliorates fecal microbiome transplant (FMT) induced liver injury from cirrhotic specific pathogen-free mice to germ-free mice	Jinxia Liu	Received

WED-413	CRISPR screen identifies GTF2E1 as a regulator of hepatocellular carcinoma immune escape via activating STAT3 to upregulate PD-L1 expression	Yi Zhan	Received

SAT-413	Natural history of primary biliary cholangitis in Alberta: province-wide registry data on treatment uptake, biochemical response, liver transplantation, and survival	Bryce Tkachuk	Received

SAT-414	Secretory immunoglobulin A (sIgA): a new prognostic marker for primary sclerosing cholangitis (PSC)	David Tornai	Received

FRI-414	Dual molecular targeting of Pttg1 and NO delivery restores hemodynamics, halts fibrogenesis and decreases liver steatosis in advanced liver disease	Manuel Macías-Herranz	Received

THU-414	Exploring practices and attitudes towards stopping hepatocellular carcinoma surveillance: a multinational clinician survey with over 500 respondents	Georgia Zeng	Received

SAT-415	Prognostic utility of circulating macrophage activation markers in primary sclerosing cholangitis: gadget or magic?	David Tornai	Received

FRI-415	Bone marrow mitochondrial dysfunction drives pathogenic myelopoiesis and monocyte–macrophage dysfunction in cirrhosis	Manisha Manisha	Received

THU-415	Patient-reported quality of life in porto-sinusoidal vascular disease: insights from a qualitative study and recommendations for clinical research	Anouck Alary	Received

WED-415	Clostridioides difficile mortality in cirrhotic patients matches other bacterial infections in the antimicrobial resistance era	Alexandra Alexopoulou	Received

FRI-416	Treg metabolic dysfunction precedes cirrhosis-associated immune dysfunction: implications for therapeutic intervention	Mzamo Mbelle	Received

THU-416	Sucralfate plus Pantoprazole versus Pantoprazole alone for healing of post–endoscopic variceal ligation ulcers: an open label randomized controlled trial	Vijay Alexander	Received

SAT-416	Metabolic syndrome as a determinant of inadequate biochemical response to ursodeoxycholic acid in primary biliary cholangitis	Christos Triantos	Received

THU-417	Histologic assessment for portal hypertension in porto-sinusoidal vascular disease	Wesam Aleyadeh	Received

SAT-417	Presence of myopathy in patients with primary biliary cholangitis	Yigit Sahin	Received

WED-417	Is 100 the new 250? Ascites fluid PMN >100 has the highest predictive value and odds for 30-day mortality in a national cirrhosis cohort undergoing paracentesis	Jasmohan Bajaj	Received

SAT-418	Enhanced liver fibrosis score improves the predictive value of the Amsterdam-Oxford model in primary sclerosing cholangitis	Jutta van Crevel	Received

FRI-418	Inflammation and viscoelastic haemostasis assessment in a wistar rat model of cirrhosis and peritonitis	Iuliana Nenu	Received

THU-418	Salvage transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: a multicenter study on safety and oncological outcomes	Manon Allaire	Received

WED-418	Dynamic assessment of the AMMON model can guide preventative therapies of patients at risk of liver-related events	Maria Pilar Ballester	Received

THU-419	Spleen stiffness measurement by VCTE stratifies the risk of high-risk varices in patients with vascular liver disease	Lucie ANEMONE	Received

SAT-419	Recurrence rate and clinical outcomes for recurrent primary sclerosing cholangitis after liver transplantation: a systematic review with meta-analysis	Aldo J Montano-Loza	Received

FRI-419	Beyond status markers: profound disruption of vitamin d metabolism in decompensated cirrhosis and its clinical implications	Anika Nier	Received

THU-420	Liver and spleen elastographies accuracy in detecting esophageal varices: comparison of MASLD with mixed etiologies populations	Flavia Fernandes	Received

SAT-420	Serum glycomics are novel biomakers that increase the prognostic value of the GLOBE score in patients with primary biliary cholangitis	Xavier Verhelst	Received

FRI-420	Acute-on-chronic liver failure is associated with impaired function of mitochondria in the liver	Lena Sophia Oeckl	Received

WED-420	Extreme heat exposure is associated with an increased risk of all-cause hospitalization in patients with cirrhosis	Therese Bittermann	Received

FRI-421	GLP-1 agonist lowers portal pressure by modulating hepatic vascular tone in a toxin-induced cirrhotic rat model	Anouk Oldenburger	Received

THU-421	High five-year incidence of portal vein thrombosis after acute variceal bleeding in cirrhosis	Tomàs Balari	Received

WED-421	Food insecurity, frailty, and oral health are key drivers of impaired quality of life in a large US multicenter cohort of adults with compensated cirrhosis	Adam Buckholz	Received

SAT-421	Real-world experience with Elafibranor in patients with primary biliary cholangitis previously treated with Obeticholic acid: an italian multicenter observational study	Alessandro Loglio	Received

TOP-422	Epigenetic dysregulation of the IL1B-driven inflammatory program drives resistance to anti–PD-1 therapy in hepatocellular carcinoma	Wenying Qiao	Received

TOP-423	Therapeutic plasma exchange improves short-term survival in acute on chronic liver failure: a randomised controlled trial	Sagnik Biswas	Received

TOP-424	Continuous terlipressin infusion plus norepinephrine versus norepinephrine alone in acute kidney injury associated with acute-on-chronic liver failure and septic shock: a randomized controlled trial	Jitendra kumar singh	Received

THU-425	Partial splenic embolization (PSE) for the prevention of variceal rebleeding in patients unsuitable for OLTx, TIPS, and endovascular treatment: safety and mortality	Andrea Salomè Velasco Mayorga Velasco Mayorga	Received

FRI-425	Changing epidemiology and clinical presentation of hepatic cirrhosis: data from the Sorpresa study	Tommaso Sarcina	Received

SAT-426	Decline in aspartate- and alanine aminotransferase in relation to clinical outcome in people with primary biliary cholangitis after start of ursodeoxycholic acid	Gemma H.X. Weijsters	Received

THU-426	Efficacy and safety of endoscopic and endovascular interventions for secondary prophylaxis of gastric varices in patients with cirrhosis: systematic review and individual patient data meta-analysis	Sagnik Biswas	Received

WED-426	Effects of GLP-1 receptor agonists on the progression of metabolic chronic liver disease.	Montserrat Camps Fajol	Received

SAT-427	Early thiopurine metabolite monitoring in autoimmune hepatitis improves biochemical response at 6 months and enables early steroid withdrawal in a prospectively managed cohort	Jan Philipp Weltzsch	Received

THU-427	A single tertiary centre audit of adherence to Baveno VII in chronic liver disease: missed opportunities for cost-savings, CO2 emission reductions and improved health resource utilisation?	Benedict Brazier	Received

WED-427	Predictive model of postoperative mortality in patients with cirrhosis. Surgical risk score for patients with cirrhosis (S-RISC)	Lidia Canillas Alavés	Received

FRI-428	Endothelial forkhead box O1 (FoxO1) signalling in acute decompensation and acute-on-chronic liver failure: evidence from in vivo models and in vitro exposure to patient plasma	Fabian Schachteli	Received

SAT-428	Differentiating acute-onset autoimmune hepatitis from drug-induced autoimmune-like hepatitis: a multicenter study and score development	Haoyu Wen	Received

WED-428	Transient hepatic elastography as a composite marker of advanced chronic liver disease severity	Lourianne Cavalcante	Received

THU-428	CVID-associated porto-sinusoidal vascular disorder: is splenomegaly uncoupled from portal hypertension?	Francisco Capinha	Received

FRI-429	Multi-etiology liver proteomic profiling of advanced chronic liver disease stages	Sonia-Emilia Selicean	Received

SAT-429	Biochemical criteria in relation to clinical outcome in people with primary biliary cholangitis using ursodeoxycholic acid	Ellen Werner	Received

THU-429	The evolving role of TIPS: from established indications to real-world practice	Ylenia Capraro	Received

THU-430	Impact of continuing versus discontinuing nonselective beta blockers after transjugular intrahepatic portosystemic shunt on one-year clinical outcomes	Ali Emre Bardak	Received

WED-430	Computed tomography-defined sarcopenic obesity: an emerging risk factor for cardio-cerebrovascular mortality in cirrhosis	Yanhua Chen	Received

FRI-430	Nintedanib improves cardiac rhythm stability and contractility in bile duct ligated-induced cirrhotic cardiomyopathy in cirrhotic rats	Hira Shafique	Received

FRI-431	LSECtin attenuation in cirrhosis correlates with disease severity and inflammation and can be experimentally recovered by IL-10/IL-13 administration	Benedikt Simbrunner	Received

WED-431	Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis	Francesca DArcangelo	Received

THU-431	Oral branched-chain amino acids supplementation in patients with cirrhosis and sarcopenia undergoing TIPS for refractory ascites: a randomized controlled trial	Ciro Celsa	Received

WED-432	A clinical prediction model for severe hepatic encephalopathy and mortality post-transjugular intrahepatic portosystemic shunt in patients with cirrhosis	Stijn de Reus	Received

FRI-432	Characterization of the toll-like receptor ligandome across the clinical spectrum of alcohol-related cirrhosis	Benedikt Simbrunner	Received

SAT-432	Validation of the GLOBE score in a nationwide cohort of people with primary biliary cholangitis	Ellen Werner	Received

THU-432	Validation of albumin-bilirubin-platelet (ALBI-PLT), modified ALBI-PLT, and EVendo score for predicting varices needing treatment (VNT) in patients with hepatocellular carcinoma	Pimsiri Sripongpun	Received

SAT-433	Alkaline phosphatase in relation to clinical outcome according to subgroups of people with primary biliary cholangitis	Ellen Werner	Received

THU-433	Prevalence, dynamics, and clinical impact of sarcopenia in acute and chronic non-cirrhotic non-tumoral portal vein thrombosis	Rares Craciun	Received

SAT-434	Utilization of maralixibat, an ileal bile acid transporter inhibitor, for the treatment of intrahepatic cholestasis of pregnancy: a case series	Jolan Terner-Rosenthal	Received

THU-434	Non-invasive integration of systemic hemodynamics and spleen stiffness across disease stages in cirrhosis	MARTÍN Elizondo	Received

FRI-434	Targeting disrupted immunometabolism-induced mitochondrial bioenergetic failure using YAQ006 and YAQ005 reduces mortality in ACLF	Supachaya Sriphoosanaphan	Received

SAT-435	Early liver stiffness measurement improves the prediction of liver-related events beyond biochemical remission in newly diagnosed autoimmune hepatitis	Yu Jun Wong	Received

WED-435	Sex-stratified prognostic associations of body fat composition and sarcopenia-related parameters in liver cirrhosis	Kei Endo	Received

THU-435	Prevalence and risk factors of esophageal and gastroesophageal varices in myeloproliferative neoplasm patients with portal hypertension in a tertiary government hospital: a 5-year cross-sectional study	Sam Fandood	Received

FRI-435	Ammonia-induced mitochondrial bioenergetic failure is driven through a TLR4-dependent mechanism that specifically targets Complex IV	Supachaya Sriphoosanaphan	Received

WED-436	The efficacy of Rifaximin in preventing liver cirrhosis complications, including spontaneous bacterial peritonitis, encephalopathy, variceal bleeding, and all-cause mortality in adult patients with liver cirrhosis : a meta-analysis	Camille Feliciano	Received

THU-436	Urinary chloride dipstick as a potential biomarker for predicting decompensation in patients with cirrhosis: a prospective multicenter pilot study	Susan Fischer	Received

SAT-436	Challenging the paradigm: IBD status does not independently predict hepatic outcomes in a large, long-term PSC cohort	Yu Jun Wong	Received

FRI-436	Peritoneal remodeling in patients with liver cirrhosis and ascites: a possible pathogenic link to impaired fluid homeostasis and altered peritoneal immunity	Helena Stadler	Received

TOP-437	Immune dysfunction assessed by neutrophil-to-lymphocyte ratio predicts mortality and infection in acute-on-chronic liver failure	Rosa Martin Mateos	Received

TOP-438	Targeting the sEH–EET axis with DPP-4 inhibitor and ARNI ameliorates portal hypertension in experimental cirrhosis	Masafumi Oyama	Received

TOP-439	Oxidized mitochondrial DNA released from injured hepatocytes drives macrophage STING activation in acute-on-chronic liver failure	Qiankun Hu	Received

TOP-440	L-Homoarginine as a novel prognostic biomarker and therapeutic candidate in cirrhotic dilutional hyponatremia: an integrated study from clinical cohort to mechanistic exploration	XUE MEI	Received

THU-441	Diagnostic accuracy of non-invasive detection of clinically significant portal hypertension	Zouhir Gadi	Received

WED-441	Uncontrolled ammonia is associated with increased healthcare resource utilization in hepatic encephalopathy	Jonathan Fischer	Received

FRI-441	Targeting glycolytic rewiring rescues liver sinusoidal endothelial cell mitochondrial bioenergetics and vascular barrier integrity mitigates endotoxin mediated portal hypertension in cirrhosis	Vaibhav Tiwari	Received

SAT-441	One in four adults have already developed cirrhosis at the time of primary biliary cholangitis diagnosis among a national cohort of veterans in the United States	Robert Wong	Received

FRI-442	Stage-dependent central and peripheral dysregulation of platelet biogenesis in experimental cirrhosis	Javier Vaquero	Received

THU-442	Prognostic value of splenic volume in patients with portosinusoidal vascular disease	Ignacio García-Juárez	Received

SAT-442	Real-world efficacy and safety of fibrates in patients with primary biliary cholangitis	Karolina Wronka	Received

WED-442	Distinct disease trajectories and prognosis of further decompensation of cirrhosis	Roberta Gagliardi	Received

FRI-443	Whole blood ex vivo targeted lipidomic profiling as an immunometabolic target screening tool in decompensated liver disease	Joseph Wilson	Received

WED-443	Rectus femoris cross sectional area predicts further decompensation and mortality in patients surviving hospitalization for acute decompensation of cirrhosis	Roberta Gagliardi	Received

SAT-443	Liver transplantation for cholestatic liver diseases: trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades	Zobair Younossi	Received

THU-444	Endoscopic ultrasound–guided portal pressure gradient measurement: prognostic utility and concordance with hepatic venous pressure gradient in a cohort of patients with sinusoidal and presinusoidal forms of portal hypertension	Lucia Giuli	Received

WED-444	Comparative assessment and external validation of ultrasound-derived quadriceps indices against bioelectrical impedance analysis for sarcopenia screening in chronic liver disease	Paolo Gallo	Received

FRI-444	Data-driven biomarker phenotypes refine risk stratification in advanced chronic liver disease	Adrian Wunderbaldinger	Received

FRI-445	Updated natural history of contemporary compensated advanced chronic liver disease patients	Adrian Wunderbaldinger	Received

WED-445	Predictors of clinical course in patients surviving acute decompensation of cirrhosis	Carmine Gambino	Received

THU-445	Predictors and prognostic impact of spontaneous portal vein thrombosis recanalization in cirrhosis: an individual patient data meta-analysis	Antonio Guerrero	Received

SAT-445	Clinical characteristics and predictors of poor biochemical response in patients with primary biliary cholangitis: a single-centre study from Xinjiang, China	Caihua Chang	Received

WED-446	Neutrophil gelatinase-associated Lipocalin as an early biomarker of outcome after TIPS	Sophia Geielbrecht	Received

THU-446	Risk factors for porto-mesenteric venous thrombosis after laparoscopic sleeve gastrectomy: a matched case-control study	Shahd Hamran	Received

WED-447	Baseline characteristics of a prospective, multi-center study on the natural history of compensated cirrhosis: the liver cirrhosis network	David Goldberg	Received

FRI-447	Fenofibrate is associated with improvement in chronic cholangiopathy after liver transplantation: a single-center experience	Fredrik berg	Received

THU-447	Multimodal computed tomography–clinical integration for noninvasive grading of hepatic venous pressure gradient	Seul Ki Han	Received

WED-448	Development of a composite biomarker to predict risk of AKI and mortality following an acute decompensation of cirrhosis	Olivia Greenham	Received

SAT-448	Machine learning identifies soluble VAP-1 as a promising biomarker to discriminate hepatic and extrahepatic precipitants of decompensation in cirrhosis	Majda El Hassani	Received

FRI-448	Donor and recipient pharmacogenetic variation at the POR locus is associated with acute rejection and biliary strictures after liver transplantation	Fredrik berg	Received

THU-448	Diabetes is an independent risk factor for hepatic encephalopathy and death in patients undergoing TIPS placement	Lukas Hartl	Received

WED-449	Real-world management of cirrhotic patients following the HALO program: a retrospective observational study	Tarek Hassanein	Received

SAT-449	Alterations in primary hemostasis in patients with liver cirrhosis and bacterial infection	Alexandra Alexopoulou	Received

FRI-449	Clinical characteristics and outcomes of primary sclerosing cholangitis after liver transplant, with or without inflammatory bowel disease, a national 10 year retrospective study	Afaf Ahmad	Received

THU-449	TIPS facilitates recovery from different types of hepatorenal syndrome and may improve clinical outcomes in patients with HRS-AKI	Lukas Hartl	Received

WED-450	Predictive factors for explantation or mortality after tunneled peritoneal catheters in patients with cirrhosis and refractory ascites	Jérémy Hassoun	Received

SAT-450	Incidence and factors associated with the development of severe chronic kidney disease after liver transplantation in patients with grade 2 and 3 ACLF	Anea Augé	Received

THU-450	Sex and age do not affect the diagnostic and prognostic performance of spleen/liver stiffness-based noninvasive tests for clinically significant portal hypertension: a European multicenter study	Paula Höfinger	Received

WED-451	Post-TIPS decline in von Willebrand factor levels is independently associated with improved survival	Marlene Hintersteininger	Received

THU-451	Sex-specific diagnostic and prognostic performance of blood- and liver stiffness-based noninvasive tests for clinically significant portal hypertension in compensated advanced chronic liver disease	Paula Hoefinger	Received

FRI-451	Outcomes of liver transplantation in patients with sickle cell disease: a systematic review and meta-analysis	Khalid Al Naamani	Received

SAT-451	Validation of consensus liver failure cut offs to predict 30-day mortality in a nationwide inpatient cirrhosis cohort	Jasmohan Bajaj	Received

WED-452	Combined presence of cirrhosis-related hypogonadism and sarcopenia is common and independently linked to impaired survival	Marlene Hintersteininger	Received

SAT-452	Immune failure in ACLF: validation of consensus definitions in two large cohorts of inpatients with cirrhosis	Jasmohan Bajaj	Received

FRI-452	Intrahepatic low shear–induced mitochondrial redox dysfunction in liver sinusoidal endothelial cells drives microvascular dysfunction and contributes to acute portal hypertension	Rajni Yadav	Received

FRI-453	Investigating the impact of carboxylated polystyrene nanoplastics in liver using hepatic cell lines and human precision-cut liver slices	Ashwin Dhanda	Received

THU-453	Long-term outcomes of compensated cirrhosis with mild portal hypertension	Anna Huerta	Received

WED-453	Elevated growth differentiation factor 15 reflects disease-driving mechanisms in cirrhosis and predicts liver disease progression and mortality	Benedikt Hofer	Received

TOP-454	Impact of apixaban on hepatic decompensation in cirrhosis (ApiHep): a randomized controlled trial	Ayush Agarwal	Received

TOP-455	Pre-treatment serum albumin concentration predicts clinical outcomes in patients with cirrhosis receiving long-term albumin	Enrico Pompili	Received

TOP-456	Prognostic impact and predictive factors of cardiac decompensation following TIPS implantation in cirrhosis– data from the multicenter CARTIPS study	Medizinische Hannover	Received

WED-457	MRI-derived splenic indices as novel predictors of liver decompensation	Jasper van Leengoed	Received

THU-457	Real-world effectiveness of Carvedilol vs.Propranolol for primary prophylaxis of variceal bleeding and impact on endoscopic burden	Mohamed Jalloh	Received

FRI-457	Impact of donor hypernatremia on graft function and survival in deceased donor liver transplantation: a systematic review and meta-analysis	Khalid Al Naamani	Received

SAT-457	Beta-blockers for prevention of further decompensation and associated renal outcomes	Brendan Brew	Received

SAT-458	Beneficial impact of consequent non-selective beta-blocker intake on patient outcomes in all stages of chronic liver disease	Josune Cabello Calleja	Received

FRI-458	Post-transplant comorbidities, MASLD development and long-term survival in liver recipients with and without HIV infection	Adriana Cervo	Received

WED-458	Machine learning prediction of covert hepatic encephalopathy in patients with liver cirrhosis based on clinical characteristics	Haoxiang Zhu	Received

THU-458	Quantifying the morbidity and mortality of decompensated liver cirrhosis in Australia	Angus Jeffrey	Received

SAT-459	Impact of cirrhosis on short- and mid-term outcomes of critically ill patients requiring invasive mechanical ventilation	Gemma Cerezal-Gómez	Received

FRI-459	Impact of pre-transplant metabolic syndrome on survival and causes of mortality after liver transplantation: a 20-year cohort study	Carmen Alonso Martin	Received

WED-459	The advanced liver disease MDT: a new model improving palliative care provision for patients with decompensated advanced chronic liver disease	Katharine Hutchison	Received

THU-459	Differential increase in portal pressure across fibrosis stages in steatotic liver disease aetiologies	Oliver Kiehn	Received

THU-460	Prognostic value of ReMELD-Na and MELD 3.0 for predicting transplant-free survival after TIPS for variceal bleeding: a multicenter retrospective study	Markus Kimmann	Received

WED-460	Glucagon-like peptide- 1 receptor agonists improve survival and reduce healthcare utilization in decompensated hepatitis C cirrhosis	Jeeva Jaganathan	Received

FRI-460	Computed tomography–defined sarcopenia as a predictor of mortality in liver transplant candidates: a systematic review and meta-analysis	Sofia Araujo	Received

SAT-460	Clinical benefit of ALSS on 90-day survival in patients with ACLF	Pengfei Yu	Received

THU-461	Comparative risk of acute kidney injury after contrast media exposure in TIPS and CT imaging among patients with decompensated liver cirrhosis: a bicentric retrospective study	Markus Kimmann	Received

SAT-461	Early trajectories of innate immune function predict nosocomial infection in hospitalized patients with cirrhosis	Juan Manuel Diaz	Received

WED-461	Neurofilament light chain in serum predicts overt hepatic encephalopathy in liver cirrhosis	Elise Jonasson	Received

FRI-461	Safety and efficacy of GLP-1 receptor agonists in liver transplant recipients: a multi-national experience	Chiara Becchetti	Received

FRI-462	Impact of multimodal prehabilitation in patients with cirrhosis awaiting liver transplantation: a feasibility trial	Amine Benmassaoud	Received

THU-462	Ultrasound-based monitoring of transjugular intrahepatic portosystemic shunt function: hemodynamic changes and prognostic relevance — Data from a prospective registry of 216 consecutive patients	Matthias Klimanek	Received

WED-462	Neurofilament light chain in cerebrospinal fluid and serum identifies minimal and overt hepatic encephalopathy	Elise Jonasson	Received

WED-463	Treatment with albumin improves circulatory function in patients with cirrhosis and hypovolemic hyponatremia: insights from a randomized controlled trial, the ALBUCAT study	Adrià Juanola	Received

FRI-463	Liver transplantation for HBV-related disease in France: NUC type before LT is associated with patient survival	François Villeret	Received

THU-463	Combining different non-invasive tests stratifies the risk of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD)	Jimmy Che-To Lai	Received

SAT-464	Bilirubin trajectory phenotypes in patients with cirrhosis admitted to intensive care: an externally validated joint latent class mixed model with implications for future definitions of acute-on-chronic liver failure	Thomas Dixon	Received

FRI-464	Liver transplantation for HBV in France: study of antiviral prophylaxis and HBV recurrence in 1,083 patients	François Villeret	Received

WED-464	Comparative prognostic performance of MELD-based and GEMA scores: a real-world cohort study	Furkan Kabukcu	Received

THU-464	ELF score and specifically hyaluronic acid one month after TIPS predict clinical outcomes	LORENZO LANI	Received

FRI-465	Impact of hypothermic oxygenated perfusion on very old liver graft issued from donors after circulatory death (>70 years) livers: insights from a belgian bi-centric experience	Eliano Bonaccorsi Riani	Received

THU-465	Splenic hyperkinetic syndrome: a universal driver of cirrhotic and non-cirrhotic portal hypertension	Natalia Leshchynska	Received

SAT-465	Assessing the effectiveness of an educational intervention to improve BASL bundle compliance and optimise care in the first 24 hours for patients with acute decompensation of cirrhosis in a district general hospital.	Patrick Robinson	Received

SAT-466	Global ROTEM-derived haemostatic profiles predict major non-portal hypertensive bleeding in acute-on-chronic liver failure	Kymentie Ferdinande	Received

FRI-466	Minimal immunosuppression is still too much: oncological and cardiovascular events impact 20-years survival rates of liver recipients	Eliano Bonaccorsi Riani	Received

WED-466	Burden and outcomes of multidrug-resistant spontaneous bacterial peritonitis: experience from a resource-constrained setting	Chitta Ranjan Khatua	Received

THU-466	The differential effects of terlipressin on serum sodium trajectories are mediated by ascites status, treatment indication and baseline sodium	Dorothy Liu	Received

SAT-467	Geographical variation in rifaximin use, gut microbiota composition, and outcomes in european patients with decompensated cirrhosis	Susan Fischer	Received

FRI-467	Secretin therapy during ex-situ normothermic liver machine perfusion: a critical factor for restoration of bile duct physiology and the protective "bicarbonate umbrella"	Roberto Broere	Received

WED-467	Impact of long-term albumin administration on mortality and cirrhosis-related complications: are these data sufficient to change practice?	W. Ray Kim	Received

THU-467	Liver stiffness measurement as an alternative to liver biopsy to rule-out cirrhosis over PSVD in patients with portal hypertension	Ann T Ma	Received

THU-468	Acute variceal bleeding in the UK: contemporary management and outcomes from a nationwide cohort study	Thomas Marjot	Received

SAT-468	Clinical impact of bacterial infections in acutely decompensated cirrhosis: insights from 4.97 million admissions	Yacine Hajji	Received

FRI-468	Clinical outcomes of sequential hypo- and normothermic machine perfusion versus abdominal normothermic regional perfusion for extended criteria donors in liver transplantation: a single center comparison	Roberto Broere	Received

WED-468	Lack of social network and support are predictors of mortality in cirrhosis. Results from an incidence cohort with long-term follow-up	Nina Kimer	Received

TOP-469	Remote patient monitoring reduces liver-related hospital readmissions in patients with acutely decompensated cirrhosis	Alberto Calleri	Received

TOP-470	Longitudinal trajectories of IL-6 and vWF predict clinical outcomes in advanced chronic liver disease independent of liver function	Georg Kramer	Received

TOP-471	The modified hepatic encephalopathy staging tool has significantly greater diagnostic consistency, prognostic performance and clinical impact compared with the West Haven criteria	Annarein Kerbert	Received

TOP-472	Real-world effectiveness of Tolvaptan for hyponatremia in cirrhosis across global regions: a target trial emulation	Kazuya Okushin	Received

SAT-473	Examining the newly proposed consensus organ failure thresholds for acute on chronic liver failure	Jonas Ho	Received

THU-473	EUS-guided direct portal pressure, clinically significant portal hypertension and spleen stiffness: diagnostic and prognostic integration in a prospective cohort	Lucia Salvi	Received

WED-473	Beyond age and disease severity: the pivotal role of intestinal and systemic inflammation as drivers of physical frailty in advanced chronic liver disease	Tomas Koller	Received

FRI-473	The impact of extending preservation time of extended criteria liver grafts through hypothermic oxygenated machine perfusion prior to normothermic machine perfusion on viability assessment and clinical outcomes	Roberto Broere	Received

FRI-474	Incidence risk factors and outcomes of cytomegalovirus infection after liver transplantation	Maximilian Joseph Brol	Received

SAT-474	Exploring rhabdomyolysis in critically ill patients with decompensated cirrhotic - a retrospective analysis of a german transplant centre	Lukas Hofmann	Received

WED-474	Circulating fibronectin reflects disease severity and predicts variceal bleeding in advanced chronic liver disease	Georg Kramer	Received

THU-474	EUS-guided coil and glue injection and beta-blockers versus b-blockers alone for primary prophylaxis of gastric varices in cirrhosis – a multicentre propensity-matched analysis from India	Shubham Mehta	Received

SAT-475	Serological responses COVID-19 vaccination: a potential biomarker to predict liver-related complications in patients with compensated advanced liver disease (cACLD)	CHANGZE HONG	Received

WED-475	Hypoleptinemia in cirrhosis is associated with increased one-year-mortality in women undergoing transjugular intrahepatic portosystemic shunt	Frederike Krus	Received

THU-476	Hepatic bile acid extraction in liver cirrhosis and longitudinal profiles after transjugular intrahepatic portosystemic shunt placement	Maximilian Nepel	Received

FRI-476	Triglyceride-based insulin resistance indices and post-transplantation diabetes mellitus after liver transplantation	Mateo Chvatal-Medina	Received

WED-476	Prevalence, risk factors, and clinical outcomes of micronutrient deficiencies in patients with cirrhosis: a prospective cohort study	&3660;&3660;Narisorn Lakananurak	Received

SAT-476	Comparison of Diagnostic Models and Prognostic Scores of ACLF: Evidence Towards Global Harmonization	MEIQIAN HU	Received

WED-477	Prognosis after TIPS in patients aged =70 years: a multicentre french cohort study	Hélène LARRUE	Received

FRI-477	Triglyceride-rich lipoprotein cholesterol and risk of post-transplant diabetes in liver transplant recipients	Mateo Chvatal-Medina	Received

SAT-477	Prognostic value of minimal hepatic encephalopathy assessment in patients with acute and chronic liver disease	Yu Ri Im	Received

THU-477	Transjugular intrahepatic portosystemic shunt in complicated porto sinusoidal vascular disease: a multicentric retrospective study with propensity score	Eric Nguyen Khac	Received

FRI-478	Synergism of trimethylamine n-oxide and lipoprotein insulin resistance with post-transplantation diabetes after liver transplant	Mateo Chvatal-Medina	Received

SAT-478	Use and effectiveness of lactulose and rifaximin in patients with cirrhosis and hepatic encephalopathy highlight need for new treatments: insights from real-world data	Yacine Hajji	Received

WED-478	Shear wave elastography combined with ALBI score enhances prediction of hepatic decompensation in advanced chronic liver disease	Jaejun Lee	Received

FRI-479	Liver transplant recipients experiencing biliary complications show elevation in quantitative magnetic resonance cholangiopancreatography metrics during monitoring	Anneli Andersson	Received

WED-479	Prevalence of alcohol use among patients with cirrhosis in the United States: a prospective cohort study	Ria Loomba	Received

THU-479	Magnitude of hepatic venous pressure gradient reduction predicts clinical events in portal hypertension: meta-regression analysis of randomized-controlled trials	Irene Pascual Lopez	Received

SAT-480	Beyond MELD: machine learning mortality prediction in cirrhotic patients with sepsis	Jeril Lasington	Received

WED-480	Breaking the habit: evaluating the routine use of spontaneous bacterial peritonitis prophylaxis	Shauna Madigan	Received

FRI-480	From childhood to adulthood: outcomes after pediatric liver transplantation with a median 25-year follow-up	Julia Collot	Received

THU-480	High incidence and clinical relevance of concomitant Hepatopulmonary Syndrome among Patients with Portopulmonary Hypertension	Jendrik Peters	Received

THU-481	Same session validation of a custom-built 22G with the commercial 25G system for EUS-guided portal pressure gradient measurement	Michael Praktiknjo	Received

SAT-481	Machine learning model for non-sodium predictors of ICU mortality drivers in cirrhotic hyponatremia	Jeril Lasington	Received

FRI-481	Impact of recipient aerobic capacity, donor and graft characteristics on survival in patients with cirrhotic liver disease assessed for liver transplantation	Emma Cook	Received

FRI-482	Evolving liver transplant indications and rising pre-transplant metabolic risk burden: a single-center analysis, 2013–2023	Andrew John Cruz	Received

SAT-482	Single-nucleus RNA sequencing identifies a GATA4+ liver sinusoidal endothelial cell subpopulation in acute-on-chronic liver failure	Xiayao Li	Received

FRI-483	Donor-related ethical issues in living donor liver transplantation: a single-center survey from North Macedonia	Elena Curakova Ristovska	Received

SAT-483	The GCS paradox: machine learning shows glasgow coma scale has no prognostic value in hepatic encephalopathy	Lawin Steve Mathew Lasington	Received

THU-483	BAVENO VII criteria and ANTICIPATE models predict first decompensation in a multi-center U.S. cohort of patients with compensated advanced chronic liver disease (cACLD)	Anahita Rabiee*	Received

WED-483	Viscoelastic haemostatic assessment in cirrhosis using ClotPro®: clinical interpretation of manufacturer-derived viscoelastic reference ranges	Maria Buzias	Received

WED-484	The kidney-liver axis decoded: machine learning redefines mortality prediction in cirrhotic patients with acute kidney injury	Lawin Steve Mathew Lasington	Received

FRI-484	Prevalence and factors associated with phosphatidylethanol positivity in candidates for liver transplantation : a proof-of-concept study	Margaux DELHOMME	Received

THU-484	Predictors of multiple endoscopic variceal ligation sessions for obliteration of esophageal varices: a prospective study in a tertiary-level hospital in Bangladesh	Antora Rahut	Received

SAT-484	Incidence and risk factors for acute-on-chronic liver failure in outpatients with cirrhosis - a prospective multicenter cohort study	Angelo Z. Mattos	Received

WED-485	Refining non-acute decompensation to improve risk stratification in advanced chronic liver disease	Martin Sebastian McCoy	Received

THU-485	Spleen stiffness measurement safely avoids endoscopy in obese MASLD and Met-ALD cACLD	Eabha Ring	Received

FRI-485	ACLF-Transplant: a national survey comparing hepatologists´ and intensivists´ views on access to liver transplantation (LT) for ACLF	Vincent Di Martino	Received

TOP-486	Risk reduction in clinically significant portal hypertension with Belapectin in advanced MASH cirrhosis: results from the NAVIGATE trial	Naim Alkhouri	Received

TOP-488	Occurrence of overt hepatic encephalopathy after TIPS in a European prospective cohort of patients with cirrhosis treated by covered TIPS in the 2020s: a EuroTIPS study	Marika Rudler	Received

WED-489	Frailty in patients with advanced chronic liver disease is reduced using BCAA supplementation (Amino L40) combined with community-based structured exercise programme	Matthew McKenna-Barry	Received

SAT-489	Body composition is a predictor of treatment response and survival in hepatorenal syndrome (HRS-AKI)	Sina Oesinghaus	Received

THU-489	Effective prevention of further complications of portal-hypertension is independent of TIPS under-dilation	Davide Roccarina	Received

SAT-490	Acute Kidney Injury Without Chronic Kidney Disease Defines a High-Risk Phenotype in Decompensated Cirrhosis	Kavish Patidar	Received

WED-490	A comparison of thromboelastometry-guided versus standard of care blood product transfusion strategies in patients with liver cirrhosis undergoing dental extractions	Cristina-Maria Muzica	Received

THU-490	Comprehensive transjugular–percutaneous portal hemodynamic assessment (cTP-PHA): safety, feasibility and diagnostic value in patients with undefined or mixed-etiology portal hypertension	Dario Saltini	Received

FRI-491	The effect of Tenofovir on bone mineral density in liver transplant recipients	Esra Nur Durmazer	Received

WED-491	Physician perspectives on palliative care referral and integration in liver cirrhosis: a mixed-methods study	Chung Yau Nah	Received

THU-491	Assessment of non-endoscopic follow-up criteria for esophageal varices using platelet count and albumin levels	SHINYA SATO	Received

SAT-491	Long-term efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange for intermediate-stage HBV-ACLF: a randomized controlled trial	Liang Peng	Received

THU-492	Aging influences encephalopathy risk but not survival after TIPS for acute variceal bleeding: EUROTIPS-Chinese multicenter study	Filippo Schepis	Received

FRI-492	Determinants of early mortality after living donor liver transplantation for acute-on-chronic liver failure	Vijay Dyavadi	Received

SAT-492	Individualised nutrition support improves outcomes in hepatitis B virus-related acute-on-chronic liver failure patients at nutritional risk: a randomised controlled trial	Liang Peng	Received

WED-492	Phase angle as a predictor of mortality in patients with liver cirrhosis	Lenka Nosáková	Received

FRI-493	Outcomes of retransplant for chronic rejection and risk factors for recurrent chronic rejection in liver transplant recipients at a large American academic transplant center	Eric Fox	Received

SAT-493	A phase I clinical trial evaluating the safety and efficacy of the QH-1A combination bio-artificial liver support system incorporating ex-vivo mesenchymal stem cells for the treatment of acute-on-chronic liver failure patients	Liang Peng	Received

THU-493	Prognostic value of SSI-2D-shear wave elastography–derived indices for predicting hepatic decompensation	Christian Sebesta	Received

SAT-494	Elevated plasma aldosterone predicts liver-related mortality in decompensated cirrhosis	Clemens Renhardt	Received

FRI-494	Donor selection and timing in pediatric liver transplantation for genetic liver disorders: a retrospective sibling cohort analysis	Eyad Gadour	Received

THU-494	Prognostic value of grading esophageal varices for decompensation and mortality in compensated and decompensated cirrhosis	Christian Sebesta	Received

THU-495	Endo-TIPSitis in vascular liver diseases- a case series with mid-term follow-up	Ankita Singh	Received

WED-495	Efficacy and safety of low-dose albumin infusion in patients of decompensated cirrhosis with acute kidney injury	Deep Patel	Received

FRI-495	Impact of genetic diagnosis on graft survival and post-transplant complications in pediatric liver transplant recipients: a decade of experience	Eyad Gadour	Received

SAT-496	Statin use in liver cirrhosis is associated with a reduced risk of hepatic decompensation and mortality	N APOORVA SASIKUMAR	Received

FRI-496	Thrombosis vs. Transfusion: The Impact of Prophylaxis in Early Post-Liver Transplant Patients	Tabetha Garver-Mosher	Received

THU-496	Regular human albumin therapy in decompensated cirrhosis: Six-month clinical outcomes from a multicentre Australian cohort	Siddharth Sood	Received

WED-496	Myosteatosis is associated with a higher postoperative incidence of ACLF and mortality in patients with liver cirrhosis, independent of Child-Pugh and VOCAL-Penn scores	Felix Piecha	Received

SAT-497	Optimizing linezolid therapy in acute-on-chronic liver failure through interprofessional therapeutic drug monitoring in the ICU	Stephan Schmid	Received

THU-497	Contribution of myofibroblast activation and sinusoidal capillarization to portal hypertension	Thomas Sorz-Nechay	Received

FRI-497	Local validation of the RETREAT score and simulation of risk-adapted imaging surveillance after liver transplantation for hepatocellular carcinoma	Andrea González Rayo	Received

WED-497	Periprocedural bleeding in patients with cirrhosis: a prospective study	Adonis Protopapas	Received

THU-498	Machine learning-based 8P model achieves high accuracy in predicting portal hypertension severity	Thomas Sorz-Nechay	Received

WED-498	Prevalence and prognostic impact of hyperferritinemia in advanced chronic liver disease	Clemens Renhardt	Received

SAT-498	Machine learning based prediction of early organ failure in acute-on-chronic liver failure	GARIMA SINGHAL	Received

FRI-498	Warming up for success: controlled oxygenated rewarming prior to normothermic liver perfusion	Roberto Broere	Received

SAT-499	Presence of sarcopenia or chronic kidney disease do not influence the level of venous ammonia in stable outpatients with cirrhosis	Rajit Soni	Received

FRI-499	Incidence of early infections in liver transplant recipients at a tertiary care center in Mexico	Alejandro Gutierrez-Castillo	Received

THU-499	Prognostic impact of clinically significant portal hypertension in hepatocellular carcinoma patients with concurrent metabolic dysfunction–associated steatotic liver disease undergoing surgical resection	Chien-Wei Su	Received

WED-499	Closing the coding gap: International classification of diseases (ICD)-10 code K76.82 for hepatic encephalopathy achieves rapid uptake in U.S. real-world practice	Pierbruno Ricci	Received

FRI-500	Liver transplantation for perihilar cholangiocarcinoma: single-centre experience	Tereza Hakova	Received

THU-500	Endoscopic ultrasound guided portal venous pressure predicts hepatic decompensation in patients with suspected portal hypertension: a multicenter study	Lucia Salvi	Received

SAT-500	Fairness-aware machine learning predicts 30-day mortality in vietnamese patients with decompensated cirrhosis	hien tran	Received

FRI-501	First validation of the gender-equity model for liver allocation (sodium and artificial intelligence variants) in an American cohort of patients on the liver transplant waiting list	Austin Halupnik	Received

THU-501	Chronic kidney disease predicts worse ascites control and higher mortality after TIPS: results from the EuroTIPS cohort	Luis Téllez	Received

TOP-502	Longitudinal assessment of body composition and its prognostic impact after TIPS in cirrhosis: a prospective multicenter study (NutriTIPS group)	Simone Di Cola	Received

TOP-503	Medication adherence and liver transplantation survival: a nationwide cohort study	Ilias Kounis	Received

TOP-504	Liver and spleen stiffness measurements by vibration – controlled transient elastography predict liver-related outcomes of patients with porto-sinusoidal vascular disorder	Lucile Moga	Received

FRI-505	Post liver transplant alcohol relapse rate – a single center experience	Jordan Holliday	Received

WED-505	RAAS inhibitors reduces mortality in a real-world multicentre study of liver cirrhosis	N APOORVA SASIKUMAR	Received

THU-505	Decreases in spleen stiffness assessed via vibration-controlled transient elastography at 100Hz upon chronic NSBB treatment do not predict HVPG response: results from a european multicenter study	Paul Thöne	Received

SAT-505	Development and outcome of ACLF in patients with autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis compared to patients with non-autoimmune chronic liver disease: analysis of a multicentric international cohort	Xavier Verhelst	Received

SAT-506	Elevated serum concentrations of Angiopoietin-2 link endothelial dysfunction, vascular destabilization, and poor outcomes across stages of cirrhosis	Lea von Ehren	Received

THU-506	Favourable outcomes in patients with advanced Fontan-associated liver disease following isolated heart transplant	Marius Vögelin	Received

WED-506	Influence of albumin treatment duration on outcome of terlipressin therapy in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI)	Eva Maria Schleicher	Received

WED-507	Dynamic spleen stiffness measurement as a prognostic tool in critically Ill patients with cirrhosis and ACLF	Stephan Schmid	Received

FRI-507	MELD-based prioritization for hepatorenal syndrome and liver transplant waiting list outcomes	SELENE IAVARONE	Received

THU-507	An integrated single-cell and spatial transcriptomic atlas identifies pro-coagulant phenotypic remodeling of liver sinusoidal endothelial cells (LSECs) in porto-sinusoidal vascular disorder (PSVD)	Jinyu Wang	Received

SAT-507	Definition of renal failure with stage =2 acute kidney injury and final serum creatinine =2mg/dL has the best prognostication for mortality in a global cirrhosis cohort	Florence Wong	Received

SAT-508	Exploratory study of early diagnostic markers for hepatitis B-related acute-on-chronic liver failure based on plasma cell-free deoxyribonucleic acid methylation sequencing	Wenxin Zhoudi	Received

WED-508	Systemic inflammation identifies patients with decompensated cirrhosis at high risk for further decompensating events	Christian Sebesta	Received

FRI-508	Continuous glucose monitoring in liver transplant recipients in the intensive care unit: a randomized clinical trial cohort	Richie Alexander Inge Cox	Received

FRI-509	Differences in immunosuppressive strategies for primary sclerosing cholangitis after liver transplantation	August Tronstad Julieb	Received

SAT-509	Timing of diagnostic paracentesis from first physician contact and in-hospital outcomes in cirrhosis with ascites	Alexander Zhu	Received

WED-509	Impact of jaundice on outcomes in patients with cirrhosis and ascites and implications for the definition of further decompensation	Georg Semmler	Received

THU-509	Recompensation of decompensated cirrhosis and long-term resolution of ascites in patients undergoing alfapump placement: experience from the multi-center POSEIDON study	Ethan Weinberg	Received

SAT-510	Reduced thrombin potential is associated with bleeding events and short-term mortality in acute decompensation and acute-on-chronic liver failure	Alexander Zubko	Received

FRI-510	The LiverRisk Score Associated With Postoperative Complications After Liver Transplantation	Shih Hsun Kao	Received

WED-510	Differentiation of minimal and grade 1 hepatic encephalopathy using neurophysiological, neuropsychological, magnetic resonance spectroscopic, and systemic inflammatory parameters	Barjesh Sharma	Received

THU-510	Integrating gut microbiota and clinical parameters to predict beta-blocker response and portal pressure in patients with cirrhosis	Peishan wu	Received

WED-511	Burden and predictors of fatigue among patients with chronic liver disease	Ankita Singh	Received

THU-511	Effects of early placement of transjugular portosystemic shunts in patients with gastric fundal variceal bleeding: a multicenter cohort study	Jie Xue	Received

FRI-511	Sex-based inequities in liver transplant access associated with jaffe creatinine measurement bias: an analysis from the scientific registry of transplant recipients data	Eda Kaya	Received

SAT-512	Potential of reflex testing with the CORE model triggered by liver enzyme abnormalities to improve risk prediction in the general population	Fredrik berg	Received

FRI-512	From retrospective review to guideline creation: establishing CMV management protocols at the Irish national liver transplant centre	Sarah Kenny	Received

THU-512	Controlled expansion stent-grafts in TIPS: a real-world analysis of in vivo diameter change and early hepatic encephalopathy	Zizhen Ye	Received

THU-513	Spleen stiffness-based algorithms for predicting decompensation in treatment-naive HBV-HCC patients	Xiaofeng Zhang	Received

WED-513	Outpatient albumin infusions reduce paracentesis without increasing costs in cirrhosis: a national real-world cost-comparison study	Siddharth Sood	Received

SAT-514	Diagnostic utility of the splenic-to-liver stiffness ratio in porto-sinusoidal vascular disease (PSVD): a multicentric study	Ayush Agarwal	Received

WED-514	Half-dose albumin for the prevention of post-paracentesis circulatory dysfunction (PPCD) in cirrhotic patients with acute decompensation undergoing paracentesis <5 liters: a randomized controlled trial	Pimsiri Sripongpun	Received

FRI-515	Clinical outcomes following TIPS in liver transplant recipients: results from multicentre EuroTIPS registry	Faisal Khan	Received

SAT-515	Mortality prediction using non-invasive fibrosis scores independent of chronic liver disease in patients with COVID-19	Maximilian Joseph Brol	Received

WED-515	Early mortality prediction in cirrhotic patients presenting to the emergency department: the CIRR-SOS score	Leonardo Stella	Received

THU-515	Interventional embolization of spontaneous portosystemic shunts improves survival by reducing further decompensation in selected patients with decompensated cirrhosis: a retrospective matched analysis	Hongbin Zhu	Received

FRI-516	Liver transplant outcomes and clinical burden in patients with alpha-1 antitrypsin deficiency-associated liver disease in Canada	Hannah Woodley	Received

THU-516	Sarcopenia predicts post-TIPS hepatic encephalopathy, and early hepatic encephalopathy predicts mortality: evidence from a multicentric cohort	Amine Zoughlami	Received

SAT-516	The impact of CFTR genotype on liver impairment in patients with cystic fibrosis	Luisa Ranieri	Received

WED-516	A combination of normal inflammation parameters does not rule out infection in patients with acute decompensation	Marija Stojiljkovic	Received

THU-517	Baseline serum metabolomic signatures predict post- liver transplant early complications	Rosmy Babu	Received

WED-517	Prognostic value of morphological imaging features in liver cirrhosis: a cohort study	Signe Swerkersson	Received

SAT-517	Impact of adult population screening for liver cirrhosis using routine blood tests on rate of transient elastography referrals from primary care: a prospective intervention study	Joan Flores	Received

FRI-517	Redefining futility in the machine perfusion era: insights based on the UK-DCD risk score in 362 DCD liver transplantations	Efrayim Küçükerbil	Received

TOP-519	Liver transplantation for portal vein tumor thrombus in the immunotherapy era: outcomes and risk stratification in a multi-institutional study	Rebecca Marino	Received

TOP-520	Rejection-associated transcripts distinguish between different types of rejection after liver transplantation	Alejandro Campos Murguía	Received

FRI-521	Comparative outcome of machine perfusion strategies in liver transplantation: a network meta-analysis	Kshitij Kumar	Received

SAT-521	Feasibility of adult population screening for liver cirrhosis using routine blood tests in Australia: a prospective cohort study	Joan Flores	Received

WED-521	Oral anticoagulant use and clinical outcomes in patients with cirrhosis: a United States national cohort study	Tomohiro Tanaka	Received

WED-522	Rifaximin improves myosteatosis in decompensated cirrhosis - randomized trial	Sunil Taneja	Received

SAT-522	Diagnostic performance of the ELF score for liver fibrosis staging in chronic liver disease: a comparative study with FibroScan, serum markers, and liver biopsy	Tatsuya Fujino	Received

WED-523	A multicentre multistate modelling on the natural history of liver decompensation: longitudinal analysis of 1,450 patients	Margaret Teng	Received

THU-523	Recurrence of primary biliary cholangitis after liver transplantation: predictors and graft and patient outcomes	Paúl Francisco Domínguez Cardoso	Received

SAT-523	Genetic determinants of clinical phenotypes in pediatric liver transplant recipients with inherited liver diseases	Eyad Gadour	Received

SAT-524	Percutaneous liver biopsy in Spain: current clinical practice and safety in the era of non-invasive tests	Mariano Gómez-Rubio	Received

WED-524	Active smoking is linked to persisting systemic inflammation and higher mortality after TIPS	Tammo Tergast	Received

FRI-524	Basiliximab preserves renal function after liver transplantation without increasing rejection or graft loss	Dorothy Liu	Received

THU-525	Decellularized bile duct scaffolds facilitate autologous regeneration in a rat model of bile duct defect	Yusuke Hanabata	Received

FRI-525	Time-adjusted analysis of cumulative immunosuppression and hepatocellular carcinoma recurrence risk after liver transplantation	Dorothy Liu	Received

SAT-525	Do large language models think like hepatologists? A multi-dimensional real-world study	Amaryllis Görz	Received

WED-525	Predictors and outcome of overt hepatic encephalopathy after elective TIPS in cirrhosis: data from a multicenter randomized controlled study	Apolline Leproux	Received

WED-526	Intestinal abundance of Enterococcus is linked to a higher risk of infection post transjugular intrahepatic portosystemic shunt (TIPS-) insertion: first results from the TIPINF study	Anja Tiede	Received

FRI-526	Multidisciplinary follow-up after liver transplantation: diagnostic yield and impact on cancer and cardiovascular outcomes	Erica Nicola Lynch	Received

FRI-527	The coexistence of sarcopenia and myosteatosis is associated with adverse clinical outcomes following liver transplantation	Ellina Lytvyak	Received

WED-527	Effect of PPI exposure and discontinuation on infection outcomes in cirrhosis	Arianna Toscano	Received

THU-527	Social nurse interventions may reduce mortality in patients with acute decompensated liver cirrhosis	Palle Bager	Received

SAT-527	Reevaluating liver enzyme reference ranges in chronic kidney disease: a population-based study	Rawi Hazzan	Received

WED-528	UCH-L1 and GFAP as novel biomarkers for early detection of hepatic encephalopathy	Pere Vaquer-Grimalt	Received

THU-528	Knowledge of filipino adults on metabolic dysfunction–associated steatotic liver disease (masld) and its relationship with sociodemographic factors, nutritional status, physical activity, food security, and diet quality: a cross-sectional study	Melvin Bernardino	Received

SAT-528	CT-derived spleen volume combined with routine labs accurately differentiates PSVD from cirrhosis across global cohorts	Subin Heo	Received

FRI-528	Outcomes of everolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma with or without steroid induction	Bianca Magro	Received

WED-529	Severity at diagnosis and progression in chronic liver disease by aetiology: a nationwide cohort study of 146,654 individuals in Sweden, 2002–2022	Juan Vaz	Received

THU-529	Glypican 3-targeted antigen-specific fluorescent imaging enhances real-time intraoperative tumor identification in hepatocellular carcinoma: a translational study	Shuhei Kanda	Received

FRI-529	Who drops out? Preoperative prediction of hepatic hypertrophy techniques failure from the IGROWtoH registry	cecilia maina	Received

SAT-529	Malnutrition beyond BMI in chronic liver disease: a prospective study of nutritional risk, sarcopenia, and food insecurity	Benjamin Kaschube	Received

FRI-530	Medical management of patients undergoing elective, liver-related invasive procedures - a novel collaboration model between hepatologists and hepato-biliary surgeons	Chiara Mangini	Received

WED-530	Machine learning and generative artificial intelligence models outperform established prognostic scoring systems in predicting acute decompensation in patients with chronic liver disease	Mathew Vithayathil	Received

SAT-530	A machine learning approach to non-invasively predict hepatic decompensation in compensated advanced chronic liver disease: the CIRI model	Georg Kramer	Received

THU-531	Simvastatin attenuates post-hepatectomy hemodynamic liver injury in fibrotic livers through KLF2-eNOS signaling	Fumiaki Munekage	Received

WED-531	Optimal glycaemic targets to prevent major adverse cardiovascular events and risk of hypoglycaemia in patients with type 2 diabetes and cirrhosis	Mary Yue Wang	Received

SAT-531	Association between small intestinal bacterial overgrowth and chronic liver disease in patients with functional gastrointestinal disorders: a cross-sectional study in southern Vietnam	Ngan Le Thanh Quynh	Received

SAT-532	Direct prothrombin concentration as replacement for INR improves accuracy of MELD in 90-day mortality prediction in patients with acute decompensation of cirrhosis	Markus Maagaard	Received

WED-532	Exploratory analysis of neurofilament light chain across steatotic liver disease suggests utility in hepatic encephalopathy but not in obesity-related cognitive dysfunction	Charlotte Wernberg	Received

FRI-532	Obesity as a key risk factor for de novo malignancies in liver transplant recipients: a 23-year cohort study	Natalia Marcos Carrasco	Received

THU-533	Mitochondrial transfer from S100A4+ macrophages triggers hepatocyte GSTP1 lactylation and PANoptosis in ischemic liver injury	Mengxue Sun	Received

FRI-533	Impact of tumor biology versus imaging on post-transplant outcomes in hepatocellular carcinoma (HCC)	Natalia Marcos Carrasco	Received

TOP-534	Hepatic chimerism and partial immune tolerance in an allogeneic mouse liver transplant model	Keiko Iwaisako	Received

TOP-535	Barriers and facilitators in alcohol-related care pathways: findings from a qualitative interview study	Lea Ladegaard Grnkjr	Received

TOP-536	Conceptual development of an advanced practice nurse role for patients living with liver cirrhosis in a Swiss health care system	Jasmin Herzog	Received

SAT-537	Nurse-led clinics improve hepatocellular carcinoma surveillance rates and survival in patients with cirrhosis	Mohammad Malik	Received

WED-537	Targeted albumin therapy for recompensation in decompensated HBV-related cirrhosis: baseline characteristics of a multicenter randomized trial	Wanting Yang	Received

FRI-537	Predicting packed red blood cell requirements in patients undergoing orthotopic liver transplant – foundation work for a quality improvement project	Anna Matusiewicz	Received

THU-538	Relationship between patient activation and e-health literacy levels and associated factors in patients with liver cirrhosis: a cross-sectional study	Ferya Celik	Received

SAT-538	Quantification of hepatic steatosis: a prospective multicenter head-to-head comparison of histopathology, digital pathology and MRI-PDFF	David Marti-Aguado	Received

WED-538	Prefrailty and frailty predict hospitalization in patients with cirrhosis	ISMAEL YEPES	Received

FRI-538	Cross-modality validation of 90% pathological response as a predictor of long-term survival in early-stage HCC	Mzamo Mbelle	Received

FRI-539	Long-term outcomes of endoscopic therapy for post-transplant biliary anastomotic strictures: a single center experience	Shubham Mehta	Received

WED-539	Health literacy is independently associated with frailty in cirrhosis	ISMAEL YEPES	Received

THU-539	Elafibranor tolerability and response in patients with primary biliary cholangitis previously treated with bezafibrate: a real-world single-centre experience	Fatema Jessa	Received

FRI-540	Donor PNPLA3 rs738409 genotype is a risk factor of long-term graft survival after liver transplantation	Irena Mikova	Received

SAT-540	Review of palliative care involvement in advanced liver disease	David O Sullivan	Received

THU-540	Early UK experience with elafibranor in primary biliary cholangitis: a multicentre pharmacist-led review	Arron Jones	Received

WED-540	Ammonia is an inconsistent marker of clinical outcomes in people with cirrhosis and hepatic encephalopathy: evidence from ten pooled systematic reviews and meta-analyses	Harry Zacharias	Received

WED-541	Clinical application of extensively drug-resistant organism (XDRO) colonization screening in patients with acute decompensation of cirrhosis (AD) in low and high prevalence countries	Nicola Zeni	Received

THU-541	Exploring issues and challenges experienced by patients with ascites in a view to develop an innovative abdominal belt for early detection of ascites	Ajee K L	Received

FRI-541	Validation of the RETREAT score for predicting hepatocellular carcinoma recurrence after liver transplantation: evidence from an Italian multicenter cohort	VERONICA PAON	Received

SAT-541	External validation of the VOCAL-Penn score for extrahepatic surgical risk assessment in cirrhosis in Asian and European populations	Ana Ostojic	Received

THU-542	Clinical efficacy of 3 dose Hepatitis B vaccine on protective seroconversion among patients with cirrhosis of liver	Ajee K L	Received

SAT-542	Evaluating artificial intelligence for the diagnosis of drug-induced liver injury in clinical practice	Anna Pocurull	Received

FRI-542	Quantifying the impact of liver graft dysfunction on kidney outcomes after liver transplantation: a retrospective multicenter longitudinal cohort study using the L-GrAFT risk score	Yu Nie	Received

WED-542	Portosystemic ammonia gradient (PAG) predicts risk of overt hepatic encephalopathy occurrence in patients after TIPS	Feng Zhang	Received

FRI-543	Rejection rates after liver transplantation are not increased with hormonal contraceptive use	Helen Oberweis-Manion	Received

THU-543	Cost-effectiveness of screening for hepatitis C virus infection among people who use drugs in South Korea	Hye-Lin Kim	Received

SAT-543	The use of non-invasive tests to detect and direct management of cirrhosis does not reduce the incidence or delay the onset of first severe decompensation events or improve survival: first report of the ELUCIDATE trial	William Rosenberg	Received

WED-543	Assessing synthetic and cholestatic function for decompensation and mortality in compensated cirrhosis: a multi-centre cohort study	Shengyang David Zhang	Received

THU-544	Care competency skills and degree of distress among informal caregivers of patients with chronic liver disease	Suja Kumari S	Received

FRI-544	Outcomes of patients covertly/overtly consuming alcohol in the transplant assessment/waitlist period: a single centre experience	HELEN ODONOVAN	Received

WED-544	Metabolic dysfunction increases the risk of liver-related events in virologically suppressed HBV-Related compensated cirrhosis	Ling Zhou	Received

WED-545	Perioperative mortality, morbidity and sex-specific outcomes in cirrhotic patients undergoing non-hepatic surgeries: a multi-centered cohort study propensity score analysis	Julie Zhu	Received

THU-545	Binge drinking as a key driver of steatotic liver disease: prevalence, predictors, and population impact in a large screening cohort	Ea Kyed	Received

SAT-545	Lifetime survival and penetrance in HFE p.C282Y/p.H63D compound heterozygous and p.H63D homozygous individuals – a liver clinic cohort study	Wolfgang Straka	Received

THU-546	LivR Well 2.0 - Nourishing a hungry liver: interim results	Sophie Page	Received

SAT-547	Linkage of effective cirrhosis management may be critical for the realization of any benefits associated with early detection of cirrhosis: explanatory analyses from the ELUCIDATE randomised trial	Sudeep Tanwar	Received

WED-547	FibroScan® insights: lifestyle change and liver health in primary biliary cholangitis	Louise Campbell	Received

FRI-547	Accuracy, feasibility, and nursing workload of continuous glucose monitoring in liver transplant recipients in the intensive care unit	Marc Pañero Moreno	Received

THU-548	Prevalence and risk factors of liver steatosis, fibrosis, and at-risk mash in mexican patients with recently diagnosed type 2 diabetes mellitus	Astrid Ruiz Margain	Received

SAT-548	Development and validation of a non-invasive model for predicting advanced liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease and dysglycemia	Xuejie Zhang	Received

THU-549	Patient characteristics and treatment outcomes associated with the retreatment of Hepatitis C in patients previously treated with direct-acting antivirals	Shannyn Sheehan	Received

SAT-549	Prognostic value of handgrip strength in 1,294 japanese patients with liver cirrhosis: a large-scale multicenter cohort study from the NHO network	Hiroshi Yatsuhashi	Received

WED-549	Feedback meetings as a method to involve patients with alcohol-related liver cirrhosis and their relatives	Marie Christiansen	Received

TOP-550	Coagulopathy and lactate dehydrogenase predict fetal loss in liver dysfunction during pregnancy	Reshma Reshma	Received

TOP-551	Intrahepatic cccDNA Activity in HBsAg-Negative HBV Carriers and Its Association with HCC Risk	Yanfei Feng	Received

TOP-552	Alcohol use at the time of transient elastography does not affect liver stiffness measurement	Jordi Gratacós-Ginès	Received

SAT-553	A blood based diagnostic for the identification and risk stratification of fibrosis and cirrhosis based on adverse outcomes	Nicole Zhang	Received

WED-553	Setting the standard – development of quality standards for liver nurses	Michelle Clayton	Received

THU-553	Early health-related quality of life decline and hypoalbuminaemia predict outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab	Masako Shomura	Received

FRI-553	Development and external validation of the MEAF ALT/AST continuous model: a universal tool for assessing early allograft dysfunction in liver transplantation	Carmen Payá Llorente	Received

FRI-554	Dynamic liver stiffness predicts recurrent cirrhosis and mortality after liver transplantation: a longitudinal joint modelling study	Nargiz Nuruzade	Received

WED-554	Wilson disease patient support programme in Ireland - the impact one year on	Anna Gorham	Received

THU-554	Joint consultations during transition: perspectives of young adults with rare liver diseases	Janne Suykens	Received

WED-555	Liver cancer screening in patients with cirrhosis and the role of allied health professionals: real-world experience of a community-based liver center	Anna Marie Hefner	Received

THU-555	Real-world nutritional management and outcomes in alcohol-associated hepatitis: a comparison of adherence to guidelines and short-term mortality between two centers	Erica Wajntraub Bakszt	Received

FRI-555	Etiology-specific patterns of long-term cognitive recovery after liver transplantation: insights from a cross-organ comparison	Joanna Raszeja-Wyszomirska	Received

FRI-556	Risk factors for T-cell mediate rejections after liver transplantation	Florian Rennebaum	Received

SAT-556	Long-term outcomes of patients with hepatitis D recurrence after liver transplantation	Özgür Aktas	Received

WED-556	Real-world biochemical response to elafibranor in PBC across second-line treatment subgroups: A United Kingdom regional centre experience.	Rachael Kamiri-Ngugi	Received

THU-556	A review of terlipressin use in hepatorenal syndrome-acute kidney injury across 18 hospitals in the United Kingdom: Can we "CONFIRM" a change in practice?	(Leslie) Chun Man Wong	Received

SAT-557	Subgenotype discrepancies in hepatitis delta virus highlight the need for a unified phylogenetic classification	Federico Garcia	Received

WED-557	Physical activity for the management of paediatric metabolic dysfunction-associated steatotic liver disease: an international multidisciplinary consensus	Shelley Keating	Received

FRI-557	Optimising liver transplant candidates through prehabilitation and rehabilitation: preliminary 6-month findings	Jesus Rivera Esteban	Received

THU-557	Hepatitis C in detainees entering Barcelona prisons: an opportunity to detect the infection in groups with limited access to the health system	Elena Yela	Received

SAT-558	EVOLVE-HBV study: characteristics and treatment eligibility of adults living with hepatitis B virus infection in rural KwaZulu-Natal, South Africa	Motswedi Anderson	Received

WED-558	Developing an evidence-based decision-support tool for culturally sensitive communication in hepatitis D care	Patrizia Künzler-Heule	Received

THU-558	Small interfering RNA targeting all hepatitis B virus transcripts rapidly decreases the levels of hepatitis D virus in serum but not in the liver of HBV/HDV coinfected humanized mice	Johannes Bächer	Received

FRI-558	Excluding ascites from the GEMA-Na score does not impact outcome predictions in liver transplant candidates	Manuel Luis Rodriguez Peralvarez	Received

THU-559	HDV propagates by hijacking a non-canonical, lysosome-derived exosomal pathway independent of HBV	Enkhtuul Batbold	Received

WED-559	A nurse-led tissue adhesive pathway to eliminate persistent post-paracentesis leakage: advancing hepatology nursing practice, patient comfort and value-based care	Mei Lin	Received

SAT-559	Performances of Baveno VII and aasld 2024 criteria for detecting high risk varices in untreated patients with HDV cirrhosis	Maria Paola Anolli	Received

SAT-560	Prevalence and clinical relevance of cardiometabolic factors in european patients with HDV-related liver disease (methdv study) - a save-d and d-shield pooled analysis	Maria Paola Anolli	Received

FRI-560	Post-transplant statin therapy improves long-term survival and lipid trajectories after liver transplantation	Sanjaya Satapathy	Received

THU-560	Combination immunotherapy can promote clinical cure in a model of chronic hepatitis B	Nicholas Carey	Received

WED-560	Improvement of patient satisfaction via implementation of a specialist nurse for patients with hepatocellular carcinoma – second interim analysis of the HCC care nurse pilot study	Larissa Pajancic	Received

SAT-561	Long-term risk and predictors for hepatocellular carcinoma and other liver-related outcomes in a large African-born cohort with chronic hepatitis B, living in Sweden	Katarina Johansson Arhem	Received

WED-561	Improvement in liver stiffness following lifestyle intervention- real-world hepatology cohort	Amy Parry	Received

THU-561	Cellular NEDD4 family ubiquitin ligase AIP4 ubiquitinates HGS to facilitate HBV naked capsid egress	Yidan Chen	Received

FRI-561	Hepatic iron overload in explants: associations with underlying liver disease indication and disease severity	Roxanna Sharifi	Received

WED-562	Patient reported outcomes of a nurse-led community-based post-discharge liver care program	Kristen Peake	Received

SAT-562	End-of-treatment biomarkers and HBV genotype predict severe biochemical flares after nucleos(t)ide analogue cessation: individual patient level meta-analysis of five prospective studies within the PROSTOP consortium	Fleur Ballet	Received

THU-562	Study on the immunomodulatory effects and mechanisms of the traditional chinese medicine formula Tiaoganbuxuyidu against HBV in mice	Fan-E Cheng	Received

WED-563	An audit to assess preventable emergency department presentations in patients with abdominal ascites secondary to cirrhosis	Kristen Peake	Received

SAT-563	Longitudinal HBsAg trajectories might predict virological outcomes in patients with chronic hepatitis B infection	Sara Battistella	Received

THU-563	Mathematical modeling of HBV infection and HEPLISAV-B treatment in rAAV-HBV mouse model	Harel Dahari	Received

WED-564	Areas for improved efficiency for patients with cirrhosis having elective abdominal paracentesis	Kristen Peake	Received

FRI-564	Cystatin C is associated with worse survival in patients with cirrhosis awaiting liver transplantation	Miguel Sogbe	Received

THU-564	Understanding early hepatitis B virus kinetics in primary human hepatocytes using an agent-based modeling approach	Harel Dahari	Received

SAT-564	Management of chronic hepatitis B in people with human immunodeficiency virus infection in Europe: real-world evidence from Spain and Germany	PABLO RYAN	Received

TOP-565	The evolving role of quantitative serum hepatitis B surface antigen (qHBsAg) measurement in chronic hepatitis B (CHB) management: comparison of EASL guidelines with an international expert consensus	Dipika Morgan	Received

TOP-566	Hepatitis B core–related antigen predicts immune-active transition in HBeAg-negative indeterminate chronic hepatitis B	Hsing-Yu Yeh	Received

TOP-567	AASLD–EASL zone ALT associated with higher risk of HCC and liver-related mortality inchronic hepatitis B patients	Tai-Chung Tseng	Received

TOP-568	HBV preS1 haplotypes mediate the protective effect of NTCP S267F variant against liver cirrhosis in chronic hepatitis B	Hsiang-Hsuan Chuang	Received

FRI-569	Using artificial intelligence-based models and radiomics in mri to predict hepatocellular carcinoma after liver transplant	Emma Stevenson	Received

WED-569	Patient-reported symptom burden and health care utilization in outpatients with advanced chronic liver disease – the prospective ATOMIC study	Martina Reiberger	Received

SAT-569	Variation in hepatitis B virus replication across Africa: analysis of the multicenter hepatitis B in Africa collaborative network (HEPSANET) cohort study	Kalisha Bheemraj	Received

THU-569	The mechanism of HSP90AB1 binding to hepatitis B surface antigen driving the progression of HBV-related hepatocellular carcinoma through chaperone-mediated autophagy	Shuangsuo Dang	Received

FRI-570	Risk factors and temporal evolution of allograft steatosis following liver transplantation	Yinan Su	Received

THU-570	ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development	Yannick Debing	Received

FRI-571	Beyond survival: long-term growth outcomes in pediatric liver transplant patients with over 20 years of follow-up	Michela Triolo	Received

WED-571	Impact of sedentary behaviour on metabolic profiles: insights from a romanian cohort of patients with metabolic dysfunction-associated liver disease (MASLD)	Elena Rezi	Received

SAT-571	Low pre-treatment concentrations of HBV cccDNA transcriptional activity markers – HBcrAg and pre-genomic RNA - can predict response to therapy with pegylated interferon, but not to bulevirtide monotherapy in chronic hepatitis D patients	Ivana Carey	Received

THU-571	Temporal transcriptional dynamics in HBV-specific CD8 T cells during long-term NUC therapy in HBeAg- chronic hepatitis B	Sara Doselli	Received

FRI-572	Favourable real-life outcomes of stereotactic body radiotherapy and magnetic resonance-guided radiotherapy for hepatocellular carcinoma in liver transplant candidates	José URSIC BEDOYA	Received

THU-572	Differential interferon responses in HDV infection reveal USP18-driven IFN-a resistance and novel ISG candidates	Claudie Eber	Received

WED-572	Development of a care pathway for patients with liver cirrhosis	Laurence Seynhaeve	Received

SAT-572	Durability of functional cure in chronic hepatitis B: a systematic review and meta-analysis	Yuxing Chen	Received

FRI-573	Early barriers to liver transplantation: referral failures in patients admitted for decompensated cirrhosis	José URSIC BEDOYA	Received

THU-573	Characterization of viral integrations in cancer driver genes in non-tumor tissues of HBV-associated HCC via RAISING-sequencing	Kento Fukano	Received

SAT-573	Seroprevalence and clinical characteristics of hepatitis d virus infection in korean patients with chronic hepatitis B and HBV-related hepatocellular carcinoma	Gwang Hyeon Choi	Received

THU-574	Monoclonal anti-HBs antibody, tobevibart, induces myeloid expansion and activation through phago-lysosomal processes	Adam Gehring	Received

FRI-574	Comparison of four meld-based scores and assessment of gender equity in waiting list outcomes in patients awaiting liver transplantation in The Netherlands	Minneke Coenraad	Received

WED-574	Hepatitis C electronic patient record flags: an opportunity to remove inaccuracies and re-engage lost to follow-up patients	SAMUEL UVEGES	Received

SAT-574	Antiviral therapy based on the EASL guideline 2025 reduces the risk of hepatocellular carcinoma: a multinational study	Ho Soo Chun	Received

SAT-575	Epidemiology of hepatitis delta virus in Belgium: a prospective cross-sectional cohort study	Marie Coessens	Received

FRI-575	Natural history and post-transplant outcomes in patients transplanted for autoimmune liver diseases: a comparative analysis of PBC, autoimmune hepatitis and overlap syndromes	Elena Velasco Martinez	Received

THU-575	Immunometabolic stress drives persistent bystander activation of innate-like CD8? T cells and hepatocyte HBV transcription despite antiviral therapy	Upkar Gill	Received

WED-576	Safety of bulevirtide 10 mg is consistent across demographic and clinical subgroups: results from an integrated analysis	Soo Aleman	Received

FRI-576	Non-A1-to-O liver transplantation: should recipient anti-A antibody titers be assessed?	Taylor Viggiano	Received

THU-576	Drug-mediated transcriptional readthrough of HBV RNAs triggers antiviral effects in infected hepatocytes	Guillaume GIRAUD	Received

SAT-576	Hepatitis B virus genotype distribution and viral load patterns in African immigrants to Canada	Curtis Cooper	Received

SAT-577	HLA genetic markers identify HDV patients at risk of persistent viremia and advanced fibrosis	Maria Francesca Cortese	Received

THU-577	Spatially clustered capsid substitutions distinguish human-tropic from zoonotic hepatitis E viruses	André Gömer	Received

WED-577	Up to 24 months durability of functional cure in response to bepirovirsen plus Peg-IFN sequential therapy in B-Together responders: results from the B-Sure study	Alex Walker	Received

SAT-578	A systematic literature review of quantitative HBsAg distribution, HBsAg/HBeAg loss and clinical outcomes in HIV/HBV co-infected population	Amber Garrick	Received

WED-578	Transcriptomic profiling reveals distinct immune signatures in chronic hepatitis B and identifies blood transcriptional modules associated with hepatitis B e antigen loss following therapeutic vaccination with GS-2829 and GS-6779	Mario Cortese	Received

WED-579	Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study	Gregory Suess	Received

SAT-579	Predictors of HBsAg loss, including baseline quantitative HBsAg, in adults with chronic hepatitis B: a regional cohort study in China	Amber Garrick	Received

SAT-580	Prolonged HDV RNA positivity and significant risk of HDV RNA re-ocurrence in hepatitis delta patients who underwent liver transplantation	Esmee Fath el Bab	Received

WED-580	Baseline and on-treatment characteristics of HBeAg-positive patients and correlates of HBeAg loss following GS-2829 and GS-6779 therapeutic vaccination in virally suppressed patients with chronic hepatitis B	Rachel Wen-Juei Jeng	Received

FRI-581	Liver transplantation (LT) for malignant and benign liver tumors in the United States and Europe: a 20-year perspective	Zobair Younossi	Received

SAT-581	Scaling up ProLINK nationwide in Spain, early results of an implementation strategy for hepatitis C and hepatitis B and delta virus search and linkage to care	Federico Garcia	Received

WED-581	SOLSTICE Week 48 Subgroup Analysis: Impact of BMI on ALT Normalization After Successful Viral Control in Participants With Chronic Hepatitis Delta Virus Infection Treated With Tobevibart Plus Elebsiran	Alina Jucov	Received

TOP-582	Bulevirtide monotherapy prevents liver decompensation in patients with hdv-related cirrhosis: a case control study with propensity score weighted analysis	Elisabetta Degasperi	Received

TOP-583	Controlled bulevirtide discontinuation in chronic hepatitis D: The D-SOLVE BUL-STOP trial	Julia Kahlhöfer	Received

TOP-584	Virological breakthroughs during long-term Bulevirtide monotherapy in patients with CHD: integrated analysis from the multicenter real-life save-d and d-shield studies	Elisabetta Degasperi	Received

WED-585	Functional analysis of clinically observed SNPs in the bepirovirsen binding site reveals reduced HBV fitness via impaired HBx/HBV polymerase activity in vitro	Alexander Koenig	Received

SAT-585	Hepatitis delta in Spain: prevalence and clinical, demographic and virological characterization from a nationwide prospective cohort	Federico García	Received

FRI-585	Performances of the page-b and amap scores to predict hepatocellular carcinoma in patients with compensated delta cirrhosis treated long-term with bulevirtide monotherapy (save-d study)	Maria Paola Anolli	Received

THU-585	Bulevirtide treatment reduces bystander activation of CD8+ T cells in chronic hepatitis D virus infection	Reem Hoblos	Received

SAT-586	Enhanced HBcAg immunoassay enables detection of clinically relevant low-level HBV viremia for treatment eligibility	Rene Geissler	Received

FRI-586	The effectiveness and safety of bulevirtide monotherapy are similar in chronic hepatitis delta patients with and without cirrosis: results from the prospective multicenter d-shield study	Maria Paola Anolli	Received

SAT-587	Distinct patterns of HBsAg isoform reflect viral activity and characterize disease stage in the setting of chronic HDV infection	Ilaria Grossi	Received

THU-587	The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities	Jin Hong	Received

FRI-587	Bulevirtide monotherapy is safe and well tolerated in chronic hepatitis delta: an integrated safety analysis of bulevirtide clincial trials at week 96	Tarik Asselah	Received

WED-587	Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: results from the B-Sure study	Alex Walker	Received

WED-588	Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy	Lung-Yi Loey Mak	Received

FRI-588	Real-world effectiveness of antiviral therapy for chronic HBV infection in Africa: HEPSANET analysis	Kalisha Bheemraj	Received

THU-588	Acute hepatitis E virus infection in asymptomatic blood donors is characterized by constrained intra-host diversity and temporal mutational signatures	Saskia Janshoff	Received

WED-589	Turkish real-world effectiveness and safety of bulevirtide in chronic hepatitis delta: a multicentric experience with long-term follow up	Muge Ozari Gulnar	Received

THU-589	Seroprevalence and viral biomarker characterization of hepatitis D infection in treatment naive-infected blood donors with hepatitis B in Cameroon	Rodrigue Kamga Wouambo	Received

FRI-589	Bulevirtide effectiveness in hepatitis delta infection across geographic origins and genotypes: real-world data from Portugal	Mariana Cardoso	Received

SAT-589	High diagnostic value of transient elastography for the diagnosis of advanced fibrosis and cirrhosis in patients with hepatitis D virus infection	Anna Hahn	Received

THU-590	Development of a novel TLR-7 agonist SA-5 as a therapeutic option for chronic hepatitis B: a multimodal biomarker scoring for safety and efficacy in the first-in-human study	TATSUYA KANTO	Received

FRI-590	Modeling HBsAg during liver transplantation reveals insights into the role of HBIG and mechanisms of HBsAg clearance	Harel Dahari	Received

SAT-590	Reflex anti-HDV testing among HBsAg-positive patients: diagnostic yield and screening impact in a retrospective cohort study	Rawi Hazzan	Received

SAT-591	Correlation of bile acid dynamics with bulevirtide response and disease severity in patients with hepatitis D	Marlene Hintersteininger	Received

FRI-591	Peginterferon alfa-2b–based therapy achieves higher HBsAg Loss in high-risk chronic hepatitis B patients: a prospective multicenter cohort study	Shuangsuo Dang	Received

THU-592	Nucleoside analog 4´-Fluorouridine inhibits hepatitis E virus infection in vitro and demonstrates high potency in vivo	Mara Klöhn	Received

WED-592	Multitargeting ASO-based constructs as a new promising silencing strategy in HBV infection in vitro	Arnau Puig Lopez	Received

FRI-592	Progressive decline of HBcrAg levels in patients with chronic hepatitis Delta long-term treated with Bulevirtide monotherapy	Elisabetta Degasperi	Received

SAT-592	Low HBsAg and HBV DNA levels lead to stable state of sustained control among chronic hepatitis B patients: results from the SIGNAL study	Grishma Hirode	Received

WED-593	Integrated efficacy analysis of bulevirtide 10 mg from studies MYR204 and MYR301 at weeks 48 and 96 across subgroups	Pietro Lampertico	Received

THU-593	Replication assessment of chimeric HEV-3 subtypes demonstrate enhanced replication fitness of HEV-3f isolates	Alina Kohl	Received

FRI-593	Therapeutic drug monitoring of Bulevirtide plasma levels in chronic hepatitis Delta patients	Elisabetta Degasperi	Received

SAT-593	Impact of cardiometabolic risk factors control in patients with chronic hepatitis B treated with nucleos(t)ide analogues	Karen Cheuk-Ying Ho	Received

THU-594	Detailed molecular profiling of intrahepatic and serum viral markers in HBeAg-positive chronic hepatitis B patients without clinical cirrhosis	Jung Hyun Kwon	Received

FRI-594	Safety and efficacy of long-term tenofovir alafenamide treatment in patients aged 60 years and older with chronic hepatitis B: experience from two phase 3 clinical trials	Scott K. Fung	Received

WED-594	Lonafarnib/ritonavir with or without peginterferon achieves rapid, durable responses in a chronic hepatitis D: extended analyses from the phase 3 D-LIVR trial	Robert Taylor	Received

SAT-594	Human leukocyte antigen DQB1 variants and seroclearance of hepatitis B markers in the REVEAL cohort	Claire Hsu	Received

SAT-595	Association of HDV RNA levels with liver disease progression in a large cohort of treatment-naïve Asian patients with chronic hepatitis D	Habiba Kamal Khodir	Received

THU-595	Reduced apoptosis in HBV/HDV-expressing hepatocytes due to HDV-specific modulation of EphA signaling	Pia Lembeck	Received

FRI-595	Validation of a sequencing-based HBV genotyping assay with serological backup for DNA-suppressed patients	Sanne Gils	Received

WED-595	Antiviral effect and safety of terbinafine in chronic hepatitis B: results of a phase 1b study	Diederick van Doorn	Received

SAT-596	Serum gamma glutamyl transferase (GGT) levels is superior to alanine aminotransferase (ALT) to predict long-term liver-related complications and mortality in patients with chronic hepatitis D (CHD)	Habiba Kamal Khodir	Received

WED-596	Suppressing HBsAg by hepatitis B immunoglobulins does not lead to functional cure and has no impact on NK cell, T cell and B cell phenotypes in patients with chronic hepatitis B	Julia Kahlhöfer	Received

FRI-596	Effects of retreatment on HBsAg loss following Nucleos(t)ide analogue withdrawal: a multicenter cohort study accounting for time-varying confounding	Yao-Chun Hsu	Received

WED-597	Safety, pharmacokinetics, pharmacodynamics, and antiviral activity of cavrotolimod, alone and in combination with low-dose nivolumab, for the treatment of chronic hepatitis B	Dheepika Weerasinghe	Received

THU-597	CX-5461 exerts pangenotypic anti-hepatitis E virus effect in preclinical models	Yuebao Li	Received

FRI-597	Impact of baseline hepatic steatosis on Peg-IFN-a therapy efficacy in chronic hepatitis B: a cohort study	Haoxiang Zhu	Received

TOP-598	Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear On-NA responders: results from the B-Sure study	Alex Walker	Received

TOP-599	Personalised risk-based HCC surveillance in HCV-related advanced fibrosis/cirrhosis after SVR: real-world evidence of cost effectiveness	Gamal shiha	Received

TOP-600	Sex-specific patterns of cardiometabolic and renal complications by ethnicity among people with hepatitis C in British Columbia, Canada: a population-based study	Dahn Jeong	Received

WED-601	Intermittent versus continuous interferon-alpha 2b plus tenofovir alafenamide therapy results in fewer adverse events with similar HBsAg reduction in treatment-naïve HBeAg-negative CHB patients: a multiregional randomized controlled trial in China	Haoxiang Zhu	Received

FRI-601	Real-world 12-month outcomes of Bulevirtide therapy in chronic hepatitis D: interim results from a prospective romanian cohort	Speranta Iacob	Received

WED-602	Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level	Man-Fung Yuen	Received

FRI-602	Impact of the NTCP rs17556915 polymorphism on disease severity and bulevirtide treatment response in chronic hepatitis D: a multicentre real-world study	Yu Ri Im	Received

SAT-602	Real-world experience of 25 years of Lamivudine therapy: highlighting favorable long-term outcomes in chronic hepatitis B	Jaejun Lee	Received

WED-603	Lonafarnib as finite treatment for chronic hepatitis D: Long-term effect on hard endpoints	Cihan Yurdaydin	Received

FRI-603	Liver-related mortality and transplantation risk associated with self-discontinuation of nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B	Rachel Wen-Juei Jeng	Received

SAT-603	High-sensitivity HBsAg next assay predicts HBsAg seroreversion in chronic hepatitis B patients following functional cure	Fahong Li	Received

SAT-604	Prevalence and Impact of Hepatic Steatosis on Clinical Outcomes in a U.S. Multi-Ethnic Cohort of Chronic Hepatitis B	Jonathan Lim	Received

THU-604	Mapping HBV and HDV infection in human liver tissues uncovers recovery phenotype upon clearance	Maelle Locatelli	Received

WED-604	Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on risk of liver and non-liver outcomes in patients with viral hepatitis and type 2 diabetes	Xinrong Zhang	Received

SAT-605	End-of-treatment HBV RNA, HBsAb, and HBcAb levels predict durability of Peg-IFN induced HBsAg loss in CHB patients	Yuqi Liu	Received

FRI-605	Impact of bulevirtide treatment on patient-reported outcomes among patients with hepatitis delta in Europe	Chong Kim	Received

WED-605	From cure to complexity: post-SVR liver and metabolic trajectories in diabetic patients	Clelia Asero	Received

THU-606	Antisense oligonucleotide-based strategy to target hepatitis delta virus infections	Julie LUCIFORA	Received

FRI-606	Pipecolic acid–associated amino acid remodeling predicts functional cure in nucleoside analogue–experienced chronic hepatitis B treated with pegylated interferon alpha plus programmed cell death protein 1 blockade	Yaping Li	Received

SAT-606	Probability of functional cure after nucleos(t)ide analogue withdrawal in chronic hepatitis B: the impact of malignancy and chemotherapy exposure	Yen-Chun Liu	Received

SAT-607	Clinical performance of the Cobas HDV assay for hepatitis D virus RNA detection and quantification for the diagnosis and treatment monitoring of patient with chronic hepatitis D	Emma Court	Received

FRI-607	End-of-treatment HBsAg level predicts functional cure and clinical relapse but not severe flare risk after Nucleos(t)ide analogue cessation in chronic hepatitis B	Hsin-Che Lin	Received

THU-607	Hepatitis B surface antigen directly alters Dendritic cell-mediated natural killer cell responses	Zuzana Macek Jilkova	Received

WED-608	High efficacy of direct-acting antivirals and significant fibrosis regression in childhood cancer survivors with chronic hepatitis C: a prospective study	Aliya Balabek	Received

THU-608	Uncovering the role of AGO binding as a potential innate immune evasion strategy during hepatitis E virus infection	Rui Marques da Costa	Received

FRI-608	Real-life adherence to bulevirtide monotherapy in chronic hepatitis D: a behavioral survey across Italian centers	Alessandro Loglio	Received

SAT-608	Genetic diversification in hepatitis Delta antigen and ribozyme correlates with altered virological and biochemical markers and may inform novel therapeutic targets	Alessia Magnapera	Received

THU-609	Antiviral Activity of Cyclophilin Inhibitors against hepatitis Delta Infection in vitro	Rola MATAR	Received

SAT-609	Comparing health-related quality of life for chronic hepatitis B patients with and without treatment cessation: findings from the prospective multicentre COIN-B trial	Axelle Vanderlinden	Received

WED-609	Navigating hepatitis C (HCV) treatment decision-making during pregnancy: a qualitative study	Tamara Barnett	Received

FRI-609	Novel HBV biomarkers predict HBsAg seroclearance in patients with chronic hepatitis B infection after cessation of long term nucleos(t)ide analogue	Lung-Yi Loey Mak	Received

THU-610	Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition	David McGowan	Received

SAT-610	The longitudinal impact of anti-HBe on qHBsAg decline in chronic hepatitis B	Andrew Mendlowitz	Received

FRI-610	NTCP variants do not impact Bulevirtide antiviral activity or HDV treatment response	Savrina Manhas	Received

WED-610	Cumulative metformin exposure and risk of hepatocellular carcinoma after hepatitis C cure in a multicentre cohort	Henar Calvo Sánchez	Received

WED-611	Multidisciplinary program for on-site screening and treatment of hepatitis C in patients with severe mental illness attended in mental health centers: the MENTAL-C study	Nuria Cañete Hidalgo	Received

SAT-611	Integrating double reflex hepatitis D virus testing to reduce diagnostic gaps and streamline clinical pathways	Almuthana Mohamed	Received

THU-611	Functional characterization of urine-associated hepatitis E virus mutations: effect on kidney infection and antiviral efficacy	Patrick Behrendt	Received

FRI-611	National registry of patients with hepatitis D treated with bulevirtide: real-world clinical practice data in Spain	Adriana Palom	Received

SAT-612	Hepatitis B virus outcomes in people with HIV after cessation of tenofovir-containing antiretroviral therapy: a systematic review and meta-analysis	Amir Mohareb	Received

WED-612	Serum laminin-2 monomer as a noninvasive marker for predicting hepatocellular carcinoma after direct-acting antiviral-induced cure of hepatitis C virus infection	Yu Ping Chang	Received

THU-612	Differential roles of HBc depending on its translation from spliced or unspliced HBV RNA	Dang Hoan Nguyen	Received

FRI-612	Early miRNA signatures predict virological control and response to Bulevirtide in chronic hepatitis D	Javier Pérez Garreta	Received

WED-613	Serum Golgi protein 73 as a noninvasive marker of hepatic fibrosis in chronic hepatitis C virus infection	Yun-Chu Chen	Received

SAT-613	Significant gaps in the cascade of care contribute to poor liver cancer outcomes among people with hepatitis B: a retrospective-prospective longitudinal cohort study	Dina Moussa	Received

FRI-613	Long-term efficacy and safety of tenofovir disoproxil fumarate in chronic hepatitis B: real-world experience from a North African center	Boukhraiss Rajaa	Received

TOP-614	Hepatitis elimination and liver care in south-east Austria (HEAL-S) - HCV cohort	Lavra Rebol	Received

TOP-615	Evaluation of HEV Burden and Urine Antigen Diagnostic Utility in the DZIF Transplant Cohort	Nora Proske	Received

FRI-617	Peginterferon alpha-2b and nucleos(t)ide analogs combination therapy for chronic hepatitis B patients with high HBsAg level at the end of treatment (52 weeks) from ongoing CREATED excellent study	Feng Ren	Received

SAT-617	Development of a new model for identifying HBV-related pre-ACLF patients among those with progressive total hyperbilirubinemia	Yuhang Nie	Received

WED-617	Hepatic and extrahepatic malignancies in hepatitis C virus-infected patients with cirrhosis treated with direct-acting antivirals in long-term observation	Krystyna Dobrowolska	Received

THU-618	Distinct hepatic transcriptional programmes in chronic hepatitis B are reshaped by metabolic dysfunction	Eva Parisi	Received

FRI-618	Characteristics of circulating immune cells in pediatric patients with chronic hepatitis B undergoing antiviral therapy	Feng Ren	Received

WED-618	Evaluation of clinical performance and utility of the combined HCV antigen-antibody assay (HCV Duo)	Tatsuya Fujino	Received

SAT-618	Global gaps in hepatitis B (HBV) and D (HDV) care: results from a worldwide survey of clinical practice	George Papatheodoridis	Received

SAT-619	High burden of active HDV infection and broad genetic diversity of HDV in Cameroon: insights from molecular diagnostics and whole-genome sequencing	Lorenzo Piermatteo	Received

WED-619	Survival benefits of SVR across different BCLC stages in HCV patients: results from the England national HCV registry	MARIA FERNANDA GUERRA VELOZ	Received

THU-619	Plasma THC is inversely associated with insulin resistance before and after HCV cure in people with HIV–HCV coinfection (ANRS CO13 HEPAVIH and ELICSIR study)	Camelia Protopopescu	Received

THU-620	Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer	Heleen Roose	Received

WED-620	Obesity as a population-wide risk factor for liver disease progression: results from the German Hepatitis C-Registry (DHC-R) and the UK Biobank	Yvonne Serfert	Received

FRI-620	Clinical outcomes of Bulevirtide treatment in patients with chronic hepatitis Delta in a tertiary center from Bucharest, Romania	Anca Saran	Received

FRI-621	Bile acid profile modifications in patients with chronic hepatitis D receiving bulevirtide therapy	Christiane Stern	Received

WED-621	The oral cholate challenge test detects early hepatic improvement with ledipasvir/sofosbuvir in liver transplant recipients and patients with advanced cirrhosis	Michael McRae	Received

THU-621	Verification and validation data of the CE-IVD marked AltoStar® HDV RT-PCR Kit 1.5 for monitoring HDV RNA viral load in plasma and serum samples	Karin ROTTENGATTER	Received

FRI-622	Impact of antiviral selection on survival outcomes in hepatitis B-related acute on chronic liver failure: a comparative study of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate from the multicentre APASL ACLF research consortium	Sunil Taneja	Received

THU-622	A novel human liver chimeric mouse model to study Hepatitis B virus DNA integration	Melina Schäfer	Received

SAT-622	Predictors of loss to follow-up in hepatitis B care in Ethiopia: a prospective multicenter cohort study	Lasse Rossvoll	Received

WED-623	Persistence of cryoglobulinemia after SVR in asymptomatic HCV patients identifies a population at risk for immune and lymphoproliferative disorders	Loreta A Kondili	Received

FRI-623	High HBsAg loss with peginterferon alfa-2b retreatment in chronic hepatitis B patients with low HBsAg levels after initial therapy	Guiqiang Wang	Received

SAT-623	Quantitative HBsAg identifies individuals unlikely to achieve spontaneous functional cure of chronic hepatitis B	Juan carlos Ruiz cobo	Received

THU-623	Arrayed human and porcine ISG screens identify hepatitis E virus host restriction factors	Sarah Schlienkamp	Received

THU-624	Characterization of isogenic hepatitis B virus variants transcriptomically links the basal core promoter mutation to a subset of hepatitis B-associated hepatocellular carcinoma	Leon Louis Seifert	Received

WED-624	Association of a liver steatosis–related polygenic risk score with hepatocellular carcinoma risk after hepatitis C virus eradication	Yu-Sheng Lin	Received

SAT-624	Comorbid hepatic steatosis among people with HBV monoinfection and HBV/HIV coinfection in the hepatitis B in Africa collaborative network (HEPSANET): prevalence, predictors, and association with fibrosis	Edford Sinkala	Received

FRI-624	Factors associated with lack of alanine aminotransferase normalisation in patients with chronic hepatitis B virus after 8 years of tenofovir-based treatment	Grace Lai-Hung Wong	Received

THU-625	Clustered regularly interspaced short palindromic repeats associated protein 9 guide RNA circular templates reduce hepatitis B virus replication via covalently closed circular DNA degradation	Deok Hwa Seo	Received

SAT-625	Surveillance threshold and risk stratification of hepatocellular carcinoma by prediction model in Asian patients receiving antiviral treatment for chronic hepatitis B: a nationwide population-based cohort study	Won Sohn	Received

FRI-625	Characterisation of HDV RNA, HBsAg and ALT kinetics in patients treated with bulevirtide and pegylated interferon for 96 weeks in the SEE-D trial	Emmanuel Zavalis	Received

WED-625	The association of liver stiffness measurement with liver-related complications in chronic hepatitis C infection: a retrospective study in Thailand	Pemika Manassevee	Received

FRI-626	Effect of peginterferon alfa-2b with or without nucleos(t)ide analogues on long-term outcomes in chronic hepatitis B: preliminary 48-week results from the multicenter, prospective VISION study in China	Qing-Lei Zeng	Received

THU-626	The homeobox family suppresses hepatitis B virus via a key non-Immunosuppressive pathway during the active phases of chronic hepatitis B	Zhongliang Shen	Received

WED-626	Hepatocellular carcinoma surveillance among chronic hepatitis C patients after successful sustained virologic response: a systematic review and meta-analysis of economic evaluation studies	Soe Thiha Maung	Received

SAT-626	HBcrAg as a multifaceted biomarker in chronic hepatitis B: Implications for immune activity and HCC prediction	Myeong Jun Song	Received

SAT-627	Are hepatitis B vaccination programmes in Africa visible to healthcare workers?	Catherine Wendy Spearman	Received

FRI-627	Redefining the Achievable Population for HBsAg Seroclearance: A Nationwide Real-world Cohort Stratified by Baseline Quantitative HBsAg	Qiran Zhang	Received

WED-627	Micro-elimination of HCV in state-infected cohort – 40 years´ experience	David O Sullivan	Received

THU-627	Hepatocellular carcinoma is a viral reservoir during hepatitis C treatment with direct-acting antivirals	Mario Jorge Silva	Received

WED-628	Improving machine learning prediction of hepatitis C virus infection by incorporating social determinants of health from clinical notes via natural language processing and contextual-level data	Haesuk Park	Received

SAT-628	Long-term risk of hepatocellular carcinoma in strictly defined immune tolerant patients with chronic hepatitis B - Results from the global RADICAL consortium	Lisa van Velsen	Received

FRI-628	Younger age and abnormal baseline ALT levels predict superior responses to peginterferon alpha-2b therapy in children with chronic HBV infection	Hongfei Zhang	Received

THU-628	The miR-4461–FGA regulatory axis characterises hepatitis B virus infection and HBV-related hepatocarcinogenesis	Masaya Sugiyama	Received

SAT-629	Prospective evaluation of ethnicity and HBV genotype in predicting off-treatment outcomes after nucleos(t)ide analogue cessation: results from the multicentre COIN-B trial	Axelle Vanderlinden	Received

THU-629	AZD6750, a CD8a-guided IL-2 molecule, enhances hepatitis B virus-specific CD8+ T-cell activation and function	Phillip Swanson	Received

WED-629	Prevalence of advanced liver fibrosis and cirrhosis among patients with hepatitis C in a UK prison	Jennifer Plunkett	Received

TOP-630	The interferon-inducible protein C19ORF66 suppresses HBV reverse transcription through incorporating into viral nucleocapsid	Wanying Liang	Received

TOP-631	Discovery and preclinical profiles of a first-in-class potent hepatitis E virus inhibitor AT-587	Qi Huang	Received

TOP-632	DDX5 and DDX17 RNA helicases regulate HBV RNA splicing	Guillaume GIRAUD	Received

WED-633	The dynamic of fibrosis scores (FibroTest, APRI and FIB-4) over a 10 year period in HCV cirrhotic patients after sustained virological response with direct-acting antivirals therapy	Anca Saran	Received

SAT-633	The impact of longitudinal hepatitis B virus genotypic diversity and viral dynamics on hepatocellular carcinoma risk in chronic hepatitis B	Ding-Lian Wang	Received

FRI-633	Treatment with direct-acting antivirals in HCV-infected patients after liver transplantation	Micha&322; Brzd&281;k	Received

THU-633	The impact of single-nucleotide variants of hepatitis B virus and antiviral on liver cancer in gray zone patients	Wei Teng	Received

FRI-634	Sustained virologic response rates following incomplete direct-acting antiviral therapy for hepatitis C: a real world study	Kevin Leyden	Received

SAT-634	Long-term clinical outcomes in chronic hepatitis B patients with nucleos(t)ide analogue treatment who achieved HBsAg <100 IU/mL	Jian Wang	Received

THU-634	Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments	Barbara Testoni	Received

WED-634	HCV screening and prevalence among children with neonatal abstinence syndrome and their mothers - underserved at-risk populations in the era of HCV elimination	Caroline Schwarz	Received

THU-635	Mitochondrial-ER remodeling differentiates HCC-adjacent and HCC-free HBV-infected liver tissues	Kousho Wakae	Received

FRI-635	Proton-pump inhibitor Omeprazole did not affect the plasma pharmacokinetics of Bemnifosbuvir and Ruzasvir fixed-dose combination in healthy participants	Xiao-Jian Zhou	Received

FRI-636	Bemnifosbuvir and ruzasvir administered as a fixed-dose-combination have low potential to inhibit P-gp, BCRP or OATP1B1/3 mediated transport	Xiao-Jian Zhou	Received

SAT-636	Hepatitis B surface antigen isoforms and HBV RNA for the management of nucleos(t)ide analogue discontinuation: an ancillary study of the STOP-NUC trial	Florian van Bömmel	Received

WED-636	Intrahepatic cholestasis of pregnancy and preterm birth in pregnant individuals with chronic hepatitis C: findings from ostrich, a multicenter north american cohort	Catherine Chappell	Received

WED-637	Preterm birth in pregnant individuals with chronic hepatitis C: findings from OSTRICH, a multicenter North American cohort	Catherine Chappell	Received

THU-637	Aacquisition of four amino acid substitutions promotes robust replication of hepatitis C virus genotype 1b in cell culture	Noriyuki Watanabe	Received

SAT-637	Integrated model nurse clinic reduces adverse pregnancy outcomes of pregnant women with chronic hepatitis B	Grace Wong	Received

FRI-638	FIB-4 fails to identify significant liver fibrosis in people with HIV: evidence from a large multinational screening study	Felice Cinque	Received

WED-638	Combined use of aMAP risk score and M2BPGi for stratifying hepatocellular carcinoma risk after SVR following direct-acting antiviral therapy	Tomoyuki Suehiro	Received

WED-639	Hepatic recompensation after sustained virologic response in patients with hepatitis C virus–related decompensated cirrhosis: a Japanese multicenter study	Yuki Tahata	Received

WED-640	Driving HCV elimination through dedicated hospital-based teams and pathways. A retrospective and prospective study in southern Italy	Pietro Torre	Received

THU-640	The impact of nucleos(t)ide analogues anti-hepatitis B virus therapy on PD-1 expression levels in peripheral blood T cells of patients	Liu Yang	Received

SAT-640	HBV screening in rheumatology: a significant gap in HBV DNA testing for HBsAg-negative, anti-HBc-positive patients	Senlin You	Received

FRI-640	Autoimmune hepatitis triggered by acute hepatitis A infection	Ignacio García-Juárez	Received

FRI-641	Viral capsid constitution and neutralizing antibodies predict chronification of hepatitis E virus infection	Jonathan Garn	Received

SAT-641	Comparative kinetics of quantitative hepatitis B surface antigen decline in HBV genotypes B and C under standard of care and novel therapy	ning yu	Received

WED-641	Evaluation of ALBI and FIB-4 scores to predict hepatocellular carcinoma in patients with chronic hepatitis C and sustained virological response to direct-acting antivirals	Cristiane A. Villela-Nogueira	Received

SAT-642	Comparison of the proportion of chronic hepatitis B patients with indeterminate phase based on the 2025 EASL and the 2025 AASLD guidelines	Shaoqiu Zhang	Received

WED-642	Trends in hepatocellular carcinoma and mortality following hepatitis C virus infection in sweden: progress toward the WHO elimination goals	Anna Wadman	Received

SAT-643	Gut microbiome functional profiles associated with fibrosis outcomes in chronic hepatitis B	Zhe ZHANG	Received

WED-643	COVID-19 pandemic had minimal impact on the effort spent on the enhancement programme of treatment coverage for all adult patients with chronic hepatitis C virus (HCV) infection	Grace Wong	Received

THU-644	Investigation of Plasma Exosomal let-7a-5p in Modulating Th17 Cell Differentiation Associated with Functional Cure	Meng Zhao	Received

SAT-644	Risk factors for abnormal ALT in postpartum women with chronic hepatitis B : a systematic review and meta-analysis	Chengxuan Yao	Received

FRI-644	Porcine-derived pancreatic enzyme replacement therapy as a cause of hepatitis E virus infection	Yonghao Liang	Received

WED-644	Impact of sustained virological response on the prognosis of patients with HCV-related cirrhosis: a large-scale multicenter cohort study from the pre-and post-DAA eras	Hiroshi Yatsuhashi	Received

TOP-646	Intratumoral persistence of hepatitis delta virus is associated with a PD-1–high, Th1-deficient immune-inflamed microenvironment in hepatocellular carcinoma	Orgil Jargalsaikhan	Received

EASL Congress 2026

27-30 May, Barcelona

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 27/05/2026 TO 30/05/2026

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.EASL2026.2026



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions